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Abstract 
 
The cannabinoid CB1 receptor is a G protein-coupled receptor (GPCR) which is 
important in the regulation of neuronal function, predominately via coupling to 
heterotrimeric Gi/o proteins. The receptor has also been shown to interact with a 
variety of other intracellular signalling mediators, including other G proteins, 
VHYHUDO PHPEHUV RI WKH PLWRJHQ DFWLYDWHG NLQDVH 0$3 VXSHUIDPLO\ DQG ȕ-
arrestins. The CB1 receptor is recognised by an array of structurally distinct 
endogenous and exogenous ligands and a growing body of evidence indicates that 
ligands acting at GPCRs are able to differently activate specific signalling 
pathways, a phenomenon known as functional selectivity or biased agonism. This 
is important in future drug development as it may be possible to produce drugs 
which selectively activate signalling pathways linked to therapeutic benefits, while 
minimising activation of those associated with unwanted side effects. The main 
aim of this thesis, therefore, was to investigate ligand-selective functional 
selectivity at the cannabinoid CB1 receptor both endogenously and exogenously 
expressed in a variety of cell lines. 
 
Chinese hamster ovary (CHO) and human embryonic kidney (HEK 293) cells 
stably transfected with the human recombinant CB1 receptor and untransfected 
murine Neuro 2a (N2a) cells, were exposed to a number of cannabinoid receptor 
DJRQLVWVLQFOXGLQJWKHHQGRJHQRXVDJRQLVWDQDQGDPLGHWKHSK\WRFDQQDELQRLGǻ9-
THC, and several synthetic ligands. Ligand affinity was determined using 
competition radioligand binding assays. Regulation of several CB1 receptor-
coupled intracellular signalling mediators was investigated; G protein activation 
was measured using the [35S]-*73Ȗ6 ELQGLQJ DVVD\ SKRVSKRU\ODWLRQ RI
extracellular signal-regulated kinases (ERK), c-Jun N-terminal kinases (JNK) and 
p38 MAP kinases was measured using the immunocytochemical In-cell Western 
WHFKQLTXH 0RGXODWLRQ RI F$03 DFFXPXODWLRQ DQG ȕ-arrestin recruitment were 
measured using DiscoveRx detection assay kits. Using concentration-response 
data, agonist bias was analysed using equimolar comparison plots, and by 
comparison of intrinsic relative activities for all agonists, calculated relative to the 
high potency cannabinoid receptor agonist HU-210 for the transfected cells or 
WIN 55,212-2 for the Neuro 2a cells. 
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7KH 33$5Į DJRQLVW IHQRILEUDWH ZDV LGHQWLILHG DV D SUHYLRXVO\ XQUHFRJQL]HG
cannabinoid receptor agonist, exhibiting modest selectivity for the CB2 receptor 
subtype (~25-fold). In addition to its functioning as an orthosteric agonist, 
fenofibrate, at high concentrations, appeared to act as a negative allosteric 
modulator at the CB1 receptor expressed in CHO cells, identified by radioligand 
binding assays, and non-competitive inhibition of the orthosteric agonist CP 
55,940 in the [35S]-*73Ȗ6ELQGLQJDVVD\ 
 
All three cell lines showed CB1- and Gi/o protein-dependent activation of ERK and 
inhibition of forskolin-stimulated cAMP accumulation: however, the magnitude of 
these responses differed between the three cell lines, with the responses in the 
Neuro 2a cells being markedly smaller than in the recombinant cell lines. The 
synthetic agonists WIN 55,212-2 and ACEA both exhibited bias towards ERK 
activation, in comparison to inhibition of cAMP accumulation, in both the CHO 
and HEK cell lines. HU- ǻ9-THC, methanandamide and fenofibrate all 
exhibited bias towards ERK activation in the Neuro 2a cells, but only the HU-210 
bias was quantified, as the other three agonists did not couple to cAMP formation 
or inhibition in this cell line. In addition, time-course experiments revealed further 
novel patterns of agonist bias in ERK signalling, with CP 55,940 alone producing 
a second phase sustained ERK response in CHO cells, while higher concentrations 
of WIN 55-212-2 produced a CB1-receptor-dependent reversal of ERK 
phosphorylation in HEK cells at 20 min, but not 5 min, agonist stimulation. 
Additional cell-dependent responses were observed with HEK cells alone, 
exhibiting Gi/o protein-independent ERK activation and increase in cAMP levels. 
Despite reports in the literature to the contrary, none of the cell lines tested 
showed receptor-mediated activation of JNK or p38 MAP kinase. 
 
In conclusion, this thesis has demonstrated functional selectivity at the 
cannabinoid type 1 receptor in a number of cell lines, expressing both native and 
transfected recombinant receptors. These findings contribute to our increasing 
understand of the complexity of GPCR signalling, and potentially allow for the 
development of more targeted drugs able to selectively engage with beneficial 
signal transduction pathways. 
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Chapter 1 
 
General Introduction  
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1.1. Cannabinoid Receptors 
The cannabinoid receptor family is a member RI WKH µUKRGRSVLQ-OLNH¶*SURWHLQ-
coupled receptor class; specifically it is a member of subgroup A13, which 
includes other lipid signalling receptors including the lysophosphatidic acid and 
sphingosine-1-phosphate receptors, and the melanocortin/ACTH receptor family 
(Joost & Methner, 2002). The general structure of cannabinoid receptors is similar 
to that of other GPCRs with an extracellular N-terminal domain followed by seven 
WUDQVPHPEUDQH Į-helical domains connected sequentially by three intracellular 
and three extracellular loops, finally ending with an intracellular C-terminal 
domain (Figure 1.1) (Howlett et al., 2002). 
 
Currently, two distinct cannabinoid receptors have been identified ± CB1 and CB2. 
The CB1 receptor gene was initially identified in rat (Matsuda et al., 1990), human 
(Gerard et al., 1990) and mouse (Chakrabarti et al., 1995a); however, orthologues 
of the gene encoding the receptor have now been identified in most mammalian, 
and several non-mammalian species (Murphy et al., 2001). The human CB1 
receptor protein comprises 472 residues, and exhibits 97 ± 99% sequence 
homology with the rat and mouse protein. The coding sequence for the CB1 
receptor comprises a single exon; however, at least one splice variant of the 
human type 1 receptor (CB1A) has been reported, though it is yet unclear if this is 
normally expressed in any significant amount (Shire et al., 1995). The CB1 
receptor is predominantly found in the CNS, being the most highly expressed 
GPCR in the brain (Tsou et al., 1998). Its main CNS function appears to be the 
inhibition of neuronal activity, mediated by receptors present at pre-synaptic sites, 
and activated by endogenous cannabinoid ligands synthesised at the post synaptic 
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site. Peripheral receptor expression is present in a number of tissues including 
thyroid and adrenal glands, liver, gastrointestinal tract and reproductive organs 
(Pagotto et al., 2006).  
 
The CB2 receptor was initially identified in the leukemic HL-60 cell line (Munro 
et al., 1993). There is only 48% sequence homology between the two receptor 
types, which increases to 68% when comparing only the transmembrane regions 
(Cabral & Griffin-Thomas, 2009). The CB2 receptor is not as evolutionarily 
conserved as the CB1 receptor, with 81% sequence homology between the human 
and rat receptors (Cabral & Griffin-Thomas, 2009). The CB2 receptor is also much 
shorter than the CB1 receptor, comprising 360 residues, although, like the CB1 
receptor, the CB2 receptor gene contains a single exon (Shire et al., 1995). Despite 
this lack of homology, both receptor subtypes share a common pool of high 
affinity ligands with varying CB1/CB2 selectivity (see section 1.4.). The CB2 
receptor is predominantly expressed in immune tissues with mRNA and protein 
present in spleen, tonsils, thymus and several haematopoietic cell types including 
lymphocytes and macrophages (Galiegue et al., 1995). The role of the receptor in 
these tissues is probably largely immunosupressive, though this is still debated. 
CB2 receptors are also present in the CNS, where they are primarily found in 
microglia (Carlisle et al., 2002), and in the gastrointestinal tract where they may 
regulate motility (Izzo, 2004), and GI inflammation (Wright et al., 2008). While 
there are some reports of neuronal CB2 receptor expression, these findings remain 
controversial, with many groups unable to detect CB2 receptor in neuronal tissue 
(Onaivi et al., 2008). 
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Figure 1.1 Two-dimensional snake plot diagram of the human cannabinoid type 1 
receptor. Residues forming the ligand binding site are highlighted in blue, while 
*5. SKRVSKRU\ODWLRQ VLWHV LPSRUWDQW WR UHFHSWRU GHVHQVLWLVDWLRQ DQG ȕ-arrestin 
recruitment are highlighted in green.  
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There is mounting evidence for the existence of non CB1/CB2 cannabinoid 
GPCRs. GPR55 was initially isolated as an orphan receptor (Sawzdargo et al., 
1999) and subsequently characterised as a putative cannabinoid receptor by in 
silico comparison of the orthosteric ligand binding site with that of the established 
cannabinoid receptors (Baker et al., 2006), though overall sequence homology 
with CB1 (13.5 %) and CB2 (14.4 %) is low (Pertwee et al., 2010). GPR55 has 
been shown to couple to a range of cannabinoid ligands, although at present, 
lysophosphatidylinositol and its 2-arachidonoyl derivative are suspected to be the 
endogenous receptor ligands. The receptor is predominantly present in the brain, 
where it is widely expressed, with peripheral expression limited to the ileum. At 
present, the physiological function of GPR55 is unclear; however recent research 
has highlighted its importance in driving some cancer cell proliferation and 
migration, making it a potential oncological therapeutic target and biomarker. 
Other putative cannabinoid GPCRs include the N-arachidonoyl glycine (NAGly) 
receptor GPR18 (Gantz et al., 1997) and GPR119 (Pertwee et al., 2010).  
 
The most prominent non-GPCR cannabinoid targets are the transient receptor 
potential cation channel subfamily V member 1 (TRPV1) and the peroxisome 
proliferator-activated receptors (PPARs). TRPV1 is a non-selective cation 
channel, predominantly expressed in peripheral sensory neurons which is activated 
by noxious stimulus, including heat (>43°C) and low pH. It is also activated by 
FDSVDLFLQWKHSK\WRFRPSRXQGUHVSRQVLEOHIRUWKHµKHDW¶sensation from ingesting 
chilli peppers. The endogenous cannabinoid ligands anandamide (Ross, 2003) and 
N-arachidonoyl dopamine (Huang et al., 2002a) have been thoroughly 
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characterised as TRPV1 agonists, with N-arachidonoyl dopamine, in particular, 
promoted as the putative endogenous TRPV1 ligand. 
 
PPARs are members of the nuclear receptor superfamily and function as ligand-
activated transcription factors, recognising a range of endogenous fatty acids and 
their derivatives, and are generally involved in metabolism and cellular 
differentiation (Michalik et al., 2006). To date, three receptor isoforms have been 
LGHQWLILHG Į ȕį DQG Ȗ DOWKRXJK DW SUHVHQW RQO\ 33$5Į DQG 33$5Ȗ DUH
therapeutic targets - 33$5Į LV WKH WDUJHW IRU WKH ILEUDWH FODVV RI
anWLK\SHUOLSLGDHPLF DJHQWV ZKLOH 33$5Ȗ LV activated by the thiazolidinediones, 
used in the treatment of type 2 diabetes. All PPAR subtypes are expressed in the 
liver, with other major receptor populations present in adipose tissue and skeletal 
muscle. Their main function is as regulators of lipid metabolism; e.g. activation of 
33$5Į OHDGV WR XSUHJXODWLRQ RI JHQHV LQYROYHG LQ WKH XSWDNH DQG XWLOLVDWLRQ RI
free fatty acids (Rakhshandehroo et al., 2010). Many cannabinoid ligands, 
including anandamide, WIN 55,212-DQGǻ9-THC have been reported as PPAR 
agonists in vitro (Pertwee et al., 2010). 
 
1.2. Cannabinoid Signalling Pathways 
In keeping with the complex pattern of cell and tissue responses to cannabinoid 
receptor activation, cannabinoid receptors, particularly CB1, have been shown to 
interact with a number of intracellular signalling pathways (Figure 1.2). 
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1.2.1. Heterotrimeric G proteins 
A large body of research has shown both receptor subtypes to couple 
predominantly to Gi/o (Howlett et al., 2002), whose activation functionally inhibits 
the enzyme adenylyl cylcase (AC) and thus, production of the intracellular second 
messenger cAMP, which is involved in the activation of a number of intracellular 
effectors including cAMP-dependent kinase (PKA). Adding further complexity to 
the signalling pattern of cannabinoid receptors, CB1 has been shown to couple to 
other G proteins. Coupling to Gs proteins has been shown in CB1-transfected CHO 
cells (Felder et al., 1998) and cultured rat striatal neurons (Glass & Felder, 1997), 
in which cAMP accumulation was observed upon stimulation with the CB1 /CB2 
receptor agonist HU-210 and blocked by the selective CB1 receptor antagonist 
rimonabant (SR141716A). However, these experiments were performed in the 
presence of pertussis toxin (PTX) and forskolin, which artificially increases cAMP 
levels by directly activating adenylyl cyclase. Other work has shown CB1 
receptor-mediated cAMP accumulation in transfected CHO cells without the 
inclusion of PTX and forskolin, though only at high agonist concentration 
(Maneuf & Brotchie, 1997). CB1-mediated activation of the Gq signalling pathway 
has also been shown (Lauckner et al., 2005). Stimulation of CB1-transfected HEK-
293 cells and cultured mouse hippocampal neurons with the CB1/CB2 receptor 
agonist WIN 55,212-2 increased intracellular calcium levels. This response was 
PTX-insensitive, but was blocked by transfected dominant negative GTĮ, which 
interferes with normal Gq activation. 
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1.2.2. Mitogen-activated protein kinases 
Both receptor subtypes have also been shown to couple positively to members of 
the mitogen-activated protein (MAP) kinase family of serine/threonine protein 
kinases which regulate a variety of cellular responses, including gene expression, 
growth, cellular transformation and apoptosis (Pearson et al., 2001). Extracellular 
signal-regulated (ERK) MAP kinases are important in the regulation of several 
cellular processes, including proliferation, division, differentiation and survival 
(for review see Shaul & Seger, 2007), while c-Jun N-terminal kinases (JNKs) and 
p38 kinases typically modulate cellular function in response to stressful stimuli, 
including UV radiation, reactive oxygen species (ROS), heat, osmotic shock and 
cytokines (Pearson et al., 2001). CB1 receptor-mediated activation of ERK has 
been shown in U373MG human astrocytoma (Bouaboula et al., 1995), transfected 
CHO cells (Galve-Roperh et al., 2002) and Neuro 2a and N1E-115, both murine 
neuroblastoma cell lines (Graham et al., 2006; Bosier et al., 2008), and via CB2 
receptor in HL-60 cells (Kobayashi et al., 2001), with responses which were PTX-
sensitive, suggesting the involvement of Gi/o proteins. The mechanism by which 
cannabinoid receptors activate MAP kinases has not been fully elucidated, but a 
number of pathways have been suggested, including direct actions via activation 
of phosphoinositol 3-kinase (PI3K) (Galve-Roperh et al., 2002) and release of the 
lipid second messenger ceramide, with subsequent activation of Raf, an upstream 
mediator of the ERK signalling cascade (Sanchez et al., 1998), indirect actions 
through its effects on cAMP accumulation (Melck et al., 1999), and at least one 
report of modulation via Gq proteins (Asimaki et al., 2011). In addition, GPCR-
dependent (5.DFWLYDWLRQFDQEHPHGLDWHGYLDȕ-arrestin (see 1.3.1), which brings 
various components of the ERK signalling pathway into close proximity, by acting 
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as a protein scaffold (DeWire et al., 2007). Sprague-Dawley rats treated with the 
non-VHOHFWLYHFDQQDELQRLGDJRQLVW&3VKRZHGHQKDQFHGOHYHOVRIȕ-arrestin 
and ERK1/2 (Franklin et al., 2013), while ERK activation in CB1 receptor 
transfected HEK cells by the CB1-selective allosteric modulator ORG27569 was 
QHDUO\DEROLVKHGE\ UHGXFHGH[SUHVVLRQRIȕ-arrestin 1 using siRNA (Ahn et al., 
2013). Functionally, CB1 receptor-mediated ERK activation is believed to play a 
role in synaptic plasticity and neuroprotection, as disruption of CB1 signalling in 
hippocampal slices results in synaptic degradation. 
 
Activation of both JNK and p38 kinases has been demonstrated in CB1-transfected 
CHO cells (Rueda et al., 2000) and in human primary coronary artery endothelial 
cells (Rajesh et al., 2010). In addition JNK activation, has been observed in Neuro 
2a (He et al., 2005) and N1E-115 cells (Bosier et al., 2008), in which p38 
activation could not be detected. The activation of these two MAP kinases appears 
then, to some degree, to be cell/tissue type selective. 
 
1.2.3. Modulation of ion channel function 
Cannabinoid CB1 receptors are able to regulate the activity of a number of calcium 
and potassium channels in a positive or negative manner, depending on the 
channel type. This functionality is thought to contribute significantly to the 
inhibition of neurotransmitter release from pre-synaptic sites. CB1 receptors 
couple positively to voltage-gated rapidly inactivating A-type (Deadwyler et al., 
1995) and negatively to non-voltage-gated D-type K+ channels (Mu et al., 1999) 
in a PTX-dependent manner as observed in hippocampal neurons. These effects 
were shown to be mediated by a reduction in cAMP/PKA activity (Hampson et 
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al., 1995; Mu et al., 1999). CB1 receptors have been shown to couple positively to 
inwardly rectifying Kir channels in a PTX-dependent manner in a number of 
systems, including transfected AtT20 (Mackie et al., 1995) and HEK 293 cells 
(Vasquez et al., 2003) and in mouse nucleus accumbens (Robbe et al., 2001). 
 
N-type Ca2+ channels are inhibited by CB1 receptor activation in NG108-15 cells 
in a PTX-sensitive, cAMP pathway-independent manner (Mackie & Hille, 1992). 
This negative coupling to N-type channels has also been observed in rat superior 
cervical ganglion neurons (Pan et al., 1996) and striatal neurons (Huang et al., 
2001). P/Q-type Ca2+ channels have also been shown to be negatively regulated 
via CB1 receptors in a number of systems (Mackie et al., 1995). In contrast to 
CB1, CB2 receptors have not been shown, as yet, to regulate ion channels. 
 
1.2.4. Calcium ion flux 
Activation of cannabinoid receptors can lead to increased free intracellular 
calcium concentration, [Ca2+]i, via release from internal stores. The classical 
pathway for the increase of cytoplasmic [Ca2+] is via phospholipase C (PLC), 
which cleaves phosphoinositol 4,5-bisphosphate, producing the second 
messengers diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). DAG 
promotes activation of protein kinase C (PKC), while IP3 causes release of Ca2+ 
from intracellular stores via activation of IP3 receptors present on endoplasmic 
reticulum. Agonist stimulation of neuroblastoma/glioma hybrid NG108-15 cells 
produced an increase in [Ca2+]i, which was blocked by PTX and rimonabant 
(Sugiura et al., 1996). This response was subsequently shown to be blocked by the 
phospholipase C inhibitor U73122 (Sugiura et al., 1997). CB1 receptor promotion 
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of intracellular Ca2+ responses has also been reported in rat cerebellar granule 
neurons where it was also blocked by PTX, rimonabant, U73122 and the IP3 
receptor antagonist xestospongin C (Netzeband et al., 1999). The data indicate that 
CB1 receptors are able to couple to the PLC signalling pathway via Gi/o proteins. 
CB2 receptors have also been shown to couple to this pathway in calf pulmonary 
endothelial cells (Zoratti et al., 2003). Other pathways coupling CB1 receptors to 
the intracellular Ca2+ response have been described, including calcium release 
from internal stores via an IP3-independent, arachidonic acid-dependent pathway 
(Begg et al., 2001; Demuth et al., 2005), and activation of Gq proteins (Lauckner 
et al., 2005). 
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Figure 1.2 Cannabinoid post-receptor signalling. The CB1 receptor couples predominantly to Gi/o proteins, which inhibit the function of adenylyl 
cyclase, resulting in inhibition of the function of the cAMP-dependent kinase, PKA. Gi/o protein-dependent modulation of various potassium and 
calcium ion channels allows the CB1 receptor to regulate neuronal excitability and neurotransmitter release, in line with the endogenous 
FDQQDELQRLGOLJDQGV¶UROHDVUHWURJUDGHQHXURWUDQVPLWWHUVLQKLELWLQJSUH-synaptic neuronal activity. However, in certain cases, the CB1 receptor 
has also been shown to couple to other G proteins, including Gs, which, in contrast to Gi/o, activates AC, and Gq protein, which activates 
phospholipase C (PLC), resulting in release of calcium ions from intracellular stores and activation of protein kinase C . Cannabinoid receptors 
couple positively to several members of the mitogen-activated protein kinase superfamily, including ERK, JNK and p38. In particular, 
cannabinoid activation of ERK has been demonstrated via several distinct pathways, including via Gi/o and Gq SURWHLQVDQGYLDȕ-arrestin, which 
is typically recruited to activated receptor as part of the processes of desensitisation and clathrin-dependent internalisation, but also promotes 
receptor signalling by acting as a scaffold protein for the recruitment of other signalling pathway mediators. Activated effector protein kinases 
including PKA and ERK modulate an array of transcription factors, thus altering gene expression. 
Dashed lines represent incompletely defined signalling cascades. 
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1.3. Modulation of Cannabinoid Receptor Signalling 
1.3.1. Receptor Regulation 
Persistent ligand binding to GPCRs can produce a series of adaptations in receptor 
functionality and expression. GPCR desensitisation is characterised by attenuation 
of receptor-mediated effector activity, typically via phosphorylation of 
intracellular domains which prevent receptor interaction with signalling pathway 
effectors, such as G proteins, and promotes interaction with modulators of receptor 
desensitisation such as arrestin proteins (see below). Subsequently, GPCR 
internalisation may occur where receptors are sequestered to intracellular vesicles 
by endocytosis. Once internalised, receptors may be either recycled to the cell 
membrane or degraded in lysosomes via hydrolytic enzymes. Downregulation is a 
reduction in the receptor population as a result of receptor internalisation and 
degradation and/or a reduction in receptor gene expression.  
 
Desensitisation and downregulation of CB1 receptor has been reported in a number 
of endogenous and exogenous systems. Reduction in [356@*73Ȗ6ELQGLQJDQG/or 
Bmax (receptor density) values, determined by measuring radioligand binding, have 
been observed upon chronic stimulation with ǻ9-THC (Sim et al., 1996; Breivogel 
et al., 1999), anandamide (Rubino et al., 2000), CP 55,940 (Rubino et al., 1997) 
and WIN 55,212-2 (Sim-Selley & Martin, 2002) in several distinct brain regions, 
and cultured cell lines. Furthermore, immunocytochemical staining demonstrates a 
reduction in the membrane receptor density upon stimulation with cannabinoid 
agonists (Hsieh et al., 1999). Interestingly, the pattern of desensitisation and 
downregulation is tissue-dependent, which can be explained by the tissue-
dependent expression of various effectors. 
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Receptor phosphorylation is promoted by a number of effectors, including the 
second messenger-dependent kinases PKA and PKC, and GPCR-regulating 
kinases or GRKs, which have higher affinity for active receptor conformations. 
Arrestins are proteins which bind to phosphorylated receptors, causing further 
reduction in receptor-signalling pathway coupling and promotion of receptor 
internalisation by facilitating binding with clathrin and the clathrin adaptor 
molecule AP2, which are important components of clathrin-mediated endocytosis. 
,QWHUHVWLQJO\ȕ-arrestins are also known to mediate GPCR signalling, particularly 
ERK activation, by acting as scaffolding proteins, as stated in section 1.2.2 
(Lefkowitz & Whalen, 2004). 
 
There is evidence to suggest that *5.DQGȕ-arrestin proteins play a role in CB1 
receptor regulation. Co-H[SUHVVLRQRI*5.DQGȕ-arrestin 2 in Xenopus oocytes 
expressing rat CB1 receptors significantly enhanced receptor desensitisation upon 
acute stimulation with WIN 55,212-2 (Jin et al., 1999) and prolonged (18-24 hr) 
perfusion of rat hippocampal neurons with WIN 55,212-2 resulted in 
desensitisation of the agonist-mediated inhibition of [Ca2+]i flux via voltage-gated 
calcium ion channels (Kouznetsova et al., 2002). Receptor desensitisation was 
SUHYHQWHGE\GRPLQDQWQHJDWLYHPXWDQWVRI*5.DQGȕ-arrestin 2, which block 
the function of their endogenous protein counterparts. Chronic treatment with the 
major phytocannabinoid tetrahydrocannabinol (ǻ9-THC) in mice increased levels 
of GRK DQGDQGȕ-arrestin 1 and 2, but not GRK 5 and 6 (Rubino et al., 2006). 
This upregulation was present in hippocampus and prefrontal cortex, but absent in 
striatum and cerebellum of Ras-GRF1-null mice, providing further evidence of 
tissue-dependant receptor regulation. 
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The intracellular C-terminal tail of the CB1 receptor appears to be important in 
GRK/arrestin-mediated CB1 desensitisation. Mutation of putative phosphorylation 
sites at residues 460-463 prevented receptor internalisation in transfected AtT20 
cells (Hsieh et al., 1999). Subsequent research by the same group showed that 
mutation of phosphorylation sites at residues 426 and 430 attenuated 
desensitisation (Jin et al., 1999), but had no effect on receptor internalisation. 
Together, the data indicate that pathways regulating desensitisation and 
internalisation involve distinct receptor domains, and that GRK/arrestin activity is 
not required for internalisation of CB1 receptors. 
  
Despite the evidence linking GRK/arrestin activity to CB1 desensitisation, little 
evidence for direct interaction of these proteins currently exists, with no reports of 
CB1 co-immunoprecipitation with GRK or arrrestins, and a recent study using 
bioluminescence resonance energy transfer (BRET) to measure protein proximity 
finding only ZHDNLQWHUDFWLRQEHWZHHQWKHUHFHSWRUDQGȕ-arrestin 2 (Vrecl et al., 
2009). The DiscoveRx PathHunter® ȕ-arrestin receptor activation assays XWLOLVHȕ-
arrestin recruitment to the receptor to give a measure of receptor activation with 
published examples of its use at the CB2, GPR55 and GPR18 receptors present in 
the literature (McGuinness et al., 2009; Yin et al., 2009). Cells are transfected 
with modified UHFHSWRUDQGȕ-arrestin, each tagged with complementary fragments 
RI D ȕ-galactosidase enzyme. Arrestin recruitment to the receptor forces the 
complementation of the two fragments to give a functioning enzyme which can be 
detected by the addition of substrate. Such assays have demonstrated that the 
FDQQDELQRLGUHFHSWRUVGRLQWHUDFWZLWKȕ-arrestin, albeit in an artificial system. 
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1.3.2. Receptor-Receptor Interaction 
It is now well established that GPCRs are able to interact with each other to form 
multimeric complexes; indeed, it is generally believed that the majority of receptor 
activity involves such complexes. Receptor-receptor interactions may be either 
homomeric, involving receptors of the same type, or heteromeric, involving 
different receptor types. A CB1 C-terminal polyclonal antibody exclusively 
labelled a high molecular weight form of the CB1 receptor, consistent with 
homodimerized receptors in Sprague-Dawley rat brain (Wager-Miller et al., 
2002), which has been shown to be present in rat hippocampus (Hajos et al., 2000; 
Wager-Miller et al., 2002) and amygdala (Katona et al., 2001) in vivo. The 
physiological role of CB1 receptor homomers has yet to be identified. 
 
CB1 receptors have been shown to form heterodimers with a number of class A 
GPCRs. CB1 and dopamine D2 receptors have been co-immunoprecipitated from 
transfected HEK-293 cells (Kearn et al., 2005) while BRET techniques have 
provided more direct evidence of receptor heterodimerisation (Navarro et al., 
2008). BRET analysis in live cells has also revealed direct CB1 interactions with 
į-ț-, and µ-opioid receptors (Rios et al., 2006). Other studies show CB receptor 
interactions with adenosine A2A (Carriba et al., 2007) and orexin OX1 receptors 
(Ellis et al., 2006).  
 
One functional role of these receptor heterodimers appears to be modulation of 
receptor-coupled signalling responses. Dual activation of CB1 receptors and 
dopamine D2 receptors in cultured rat striatal neurons resulted in switching of CB1 
signalling from inhibition of adenylyl cyclase to PTX-insensitive AC stimulation 
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(Glass & Felder, 1997). Unstimulated D2 receptor dimerization was also shown to 
have a similar effect on CB1 receptor-mediated signalling in transfected HEK 293 
cells (Jarrahian et al., 2004). Stimulation of µ-opioid receptors resulted in a 
significant decrease in CB receptor-mediated G protein activation and ERK1/2 
phosphorylation in endogenously and exogenously expressing cell lines 
respectively, indicating a functional role for opioid/cannabinoid dimers (Rios et 
al., 2006).  
 
Many questions have yet to be answered regarding CB1 receptor-receptor 
interactions, including the elucidation of which other GPCRs can form 
heterodimers with CB1, which CB1 receptor domains are important for 
dimerisation and what is the full functional role of these heterodimers and CB1 
homomers (Mackie, 2005). 
 
1.3.3. Other Receptor-Interacting Proteins 
A number of other proteins are known to interact with GPCRs and cannabinoid 
receptors in particular. The GPCR-associated sorting protein GASP1 is a large 
protein shown to facilitate downregulation of certain GPCRs VXFK DV į-opioid 
(Whistler et al., 2002) and dopamine D2 receptors (Bartlett et al., 2005). GASP1 
interacts with the intracellular tail domain of the receptor and promotes receptor 
trafficking to lysosomes for proteolytic degradation (Bartlett et al., 2005). The 
dominant-negative C-terminal GASP1 fragment, cGASP reduced CB1 receptor 
localisation to lysosomes, reduced receptor degradation and enhanced receptor 
recycling to the cell surface when co-expressed in HEK 293 cells. GASP1 
interacted with a fusion protein containing the CB1R C-terminal tail (Martini et 
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al., 2007), and endogenous GASP1 co-immunoprecipitated with CB1R from 
transfected cells and rat brain tissue (Martini et al., 2007; Tappe-Theodor et al., 
2007). Interestingly, mutations at the putative phosphorylation sites 460 and 464 
did not interfere with co-immunoprecipitation of the receptor with GASP1, 
suggesting that these motifs do not play a role in CB1/GASP1 interaction (Tappe-
Theodor et al., 2007). cGASP1 also decreased levels of receptor downregulation 
in cultured neurons (Tappe-Theodor et al., 2007). cGASP1 had no effect on the 
rate or degree of receptor internalisation. In vivo administration of cGASP1 via a 
viral vector prevented analgesic tolerance to WIN 55,212-2 in rats (Tappe-
Theodor et al., 2007). Together, this research strongly indicates that GASP1 plays 
an important role in receptor downregulation by facilitating receptor localisation 
to lysosomes and subsequent receptor degradation. 
 
A family of novel cannabinoid receptor-interacting proteins (CRIP) comprising 
two splice variants, CRIP1a and CRIP1b have been identified (Niehaus et al., 
2007). These proteins interact with the C-terminal domain of the CB1 receptor at 
sites distinct from the phosphorylation sites involved in desensitisation and 
internalisation. CRIP1a orthologues are present in a number of vertebrates. CRIP1a 
was shown to decrease constitutive inhibition of voltage-gated calcium channels in 
superior cervical ganglion neurons transfected with CB1, while having no effect on 
agonist-induced inhibition, suggesting a role in regulating constitutive receptor 
activity. CRIP1b, thus far, has only been identified in primates, with an, as yet, 
unknown function. 
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1.4. Cannabinoid Ligands 
1.4.1. Endogenous Cannabinoids 
The endogenous cannabinoid receptor ligands or endocannabinoids are 
eicosanoids, with the two most studied endocannabinoids to date being N-
arachidonoyl ethanolamine (anandamide or AEA; Figure 1.3) and 2-arachidonoyl 
glycerol (2-AG). Other, putative endocannabinoids include 2-arachidonyl glyceryl 
ether (noladin ether) (Hanus et al., 2001), N-arachidonoyl dopamine (NADA) 
(Huang et al., 2002b) and O-arachidonoyl ethanolamine (virodhamine) (Porter et 
al., 2002). Anandamide was the first endocannabinoid to be isolated and identified 
and its name derives IURPWKH6DQVNULWZRUGµananda¶PHDQLQJµEOLVV¶ (Devane et 
al., 1992). A number of pathways for the biosynthesis of AEA from the 
precursor N-arachidonoyl phosphatidylethanolamine (NArPE) have been 
proposed, with the enzyme NAPE-PLD being the most widely accepted (Sagar et 
al., 2009). Others include the PLC-3731DQGĮȕKHQ]\PDWLFSDWKZD\VZKLFK
together with the NAPE-PLC pathway may combine to form an integrated system 
in which one pathway compensates if another is downregulated (Liu et al., 2008). 
Biosynthesis of the acyl glycerol 2-AG from the immediate precursor 
diacylglycerol (DAG) is less well characterised but is believed to involve 
postsynaptically located DAG lipases and, potentially, a phospholipase A1 and 
phospholipase C complementary pathway (Sagar et al., 2009). Endocannabinoid 
synthesis in the CNS occurs mainly at post-synaptic neuronal sites in a transient or 
µRQ-GHPDQG¶ PDQQHU DQG WKH\ DUH EHOLHYHG WR DFW DV UHWURJUDGH VLJQDOOLQJ
molecules inhibiting pre-synaptic neuronal activity. Endocannabinoids are thus 
dHVFULEHG DV µQRQ-FODVVLFDO¶ QHXURWUDQVPLWWHUV LQ Fontrast to classical 
neurotransmitters which are pre-synthesised and stored in vesicles. 
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Endocannabinoids are hydrolysed post-synaptically by hydrolase pathways with 
fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) being 
the most prominent metabolic routes for AEA and 2-AG respectively (Sagar et al., 
2009). The oxidative enzyme cyclooxygenase type-2 (COX-2) also metabolises 
these two endocannabinoids. 
 
In terms of its pharmacology, anandamide is a CB1/CB2 ligand with moderate 
nanomolar affinity (Table 1.1). The inclusion of a non-specific amidase inhibitor, 
such as phenylmethylsulfonylfluoride (PMSF) is usually a pre-requisite when 
using anandamide, and indeed most endocannabinoids, in assays involving intact 
tissue preparations, to prevent degradation of the endocannabinoid by endogenous 
hydrolase activity. Interestingly, anandamide appears to act as a partial agonist in 
a number of in vitro functional assays and shows modest (~5-fold; Table 1.1) CB1 
receptor selectivity. Anandamide has also been conclusively shown to act as an 
agonist at TRPV1 (see 1.1), a non-selective cation channel involved in neuronal 
detection of noxious physical and chemical stimuli.  
 
2-AG, like anandamide, exhibits marginal CB1 selectivity (~3-fold; Table 1.1) 
with a reported affinity in the low micromolar range; significantly lower than that 
reported for anandamide. However, unlike anandamide, 2-AG appears to be a full 
agonist at the CB1 receptor, or at least has higher activity than anandamide, with a 
number of functional studies reporting quantitatively similar results to those found 
with other more prominent full agonists, including R-(+)-WIN 55,212-2 (Howlett 
et al., 2002).  
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Noladin ether, an ether of 2-AG, has affinity for both receptor types, but the data 
available thus far indicate that it is significantly (140-fold; Table 1.1) CB1 
receptor-selective. Virodhamine is reported as an endogenous in vivo CB1 
antagonist, while acting as a full agonist at the CB2 receptor (Porter et al., 2002). 
N-arachidonoyl dopamine (NADA) was initially synthesised as part of a larger 
series of N-acyl dopamines (Bisogno et al., 2000), but was later identified as an 
endogenous molecule in rat and bovine neuronal tissue (Huang et al., 2002b). 
NADA appears to be CB1 receptor-selective, but still has micromolar affinity for 
CB2 receptors expressed in rat spleen tissue. NADA was reported as being 45-fold 
more potent than anandamide in eliciting intracellular Ca2+ increase in 
neuroblastoma cells, but still produced a sub-maximal response compared to HU-
210. NADA appears to be a TRPV1 agonist, with potency significantly greater 
than that reported for anandamide. This has led some to the conclusion NADA is a 
putative endogenous TRPV1 ligand, or endovanilloid (Huang et al., 2002b). 
 
The endocannabinoids can be seen as part of a larger group of well established 
cannabinoid receptor agoniVWV RI ZKLFK WKH µFODVVLFDO¶ µQRQ-FODVVLFDO¶ and 
aminoalkylindole cannabinoids are the other prominent members. Each group is 
comprised of lipophillic compounds which bind to CB1 and CB2 receptors with 
high affinity but have distinct chemical structures (Figure 1.3). 
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Table 1.1 
Ki values for cannabinoid ligands determined via in vitro displacement of 
radioligand, in nM (adapted from Howlett et al. 2002) 
Ligand CB1 Ki value CB2 Ki value 
Anandamide 61a, b 
89a 
543 
71.7a, b 
252b 
1930a, c 
371a 
1940 
279a, b 
581 
2-ararchidonoyl glycerol 472b 
53.8d 
1400 
145d 
Noladin Ether 21.2b >3000 
R-(+)-methanandamide 17.9a, b 
20a, b 
868a, c 
815c 
ACEA 1.4a, b >2000a, b 
ǻ9-THC 53.3 
39.5b 
40.7 
80.3b 
35.3b 
75.3 
40 
36.4 
32.2 
3.9b 
HU-210 0.0608 
0.1b 
0.73 
0.524 
0.17 
0.22 
CP 55,940 5 
3.72 
1.37b 
0.58 
0.50a, b 
1.8 
2.55 
1.37b 
0.69 
2.80a, b 
R-(+)-WIN 55,212-2 9.94b 
4.4a, b 
1.89 
62.3 
123 
16.2b 
1.2a, b 
0.28 
3.3 
4.1 
Rimonabant  
(SR 141716A) 
11.8 
11.8 
12.3 
5.6 
1.98b 
13,200 
973 
702 
>1000 
>1000b 
a
 with phenylmethylsulfonyl fluoride 
b
 binding to rat receptor 
c
 binding to mouse receptor 
d
 species unspecified. All other data from experiments using human receptor 
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1.4.2. Classical Cannabinoids 
Classical cannabinoid agonists contain ABC-tricyclic dibenzopyran rings and are 
either naturally occurring phytocannabinoids in the Cannabis sativa plant or are 
synthetic derivatives of natural compounds. The most prominent 
SK\WRFDQQDELQRLG LV WKH DUFKHW\SDO FDQQDELQRLG ǻ9-WHWUDK\GURFDQQDELQRO ǻ9-
THC; Figure 1.3), which was the first cannabinoid agonist identified and is the 
main psychoactive constituent RI FDQQDELV ǻ9-THC exhibits nanomolar affinity 
for cannabinoid receptors, with similar affinity for both CB1 and CB2 receptors 
(Table 1.1) /LNH DQDQGDPLGH ǻ9-THC acts as a partial agonist at the CB1 
receptor, with an apparent intrinsic efficacy significantly lower than that of 
reported full agonists such as CP 55,940 and R-(+)-WIN55,212-2 (Howlett et al., 
2002)7KHLQWULQVLFDFWLYLW\RIǻ9-THC at CB2 receptors is even lower than at the 
CB1 UHFHSWRUZLWKDQXPEHURIIXQFWLRQDODFWLYLW\H[SHULPHQWVVKRZLQJǻ9-THC 
WR DFW DV DQ DQWDJRQLVW 2WKHU SURPLQHQW SK\WRFDQQDELQRLG DJRQLVWV LQFOXGH ǻ8-
THC, which exhibits similar potency and efficacy for the two CB receptor types as 
ǻ9-7+&DQG WKHZHDNDJRQLVWFDQQDELQRODǻ9-THC metabolite (Howlett et al., 
2002). 
 
One of the most widely employed synthetic phytocannabinoid analogues is 11-
hydroy-ǻ9-THC-dimethylheptyl (HU-210) (Figure 1.3) /LNH ǻ9-THC, HU-210 
has similar affinity for both CB1 and CB2 receptors, but has a significantly (~100 - 
 IROG KLJKHU DIILQLW\ IRU WKH UHFHSWRUV WKDQ ǻ9-THC. Also, XQOLNH ǻ9-THC, 
HU-210 is a full CB receptor agonist, with intrinsic activity comparable to other 
full agonists. Most phytocannabinoids and first-generation synthetic analogues, 
such as HU-210 are non-selective for the two CB receptor types; however, more 
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recently developed compounds such as HU-308, JWN-051 and L-759633, exhibit 
CB2 receptor selectivity. 
 
1.4.3. Non-Classical Cannabinoids 
Non-classical cannabinoids lack the dihydropyran ring structure, instead being bi- 
or tri-cyclic analogues. The best known compound from this group is the bicyclic 
CP 55,940 (2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-
methyloctan-2-yl)phenol; Figure 1.3), which is routinely used as a reference 
agonist or radiolabelled tracer in CB receptor binding assays. It is not selective for 
either CB receptor type with affinity within the nanomolar range, but it is reported 
as having lower affinity than HU-210 (Table 1.1). CP 55,940 has a similar 
potency and intrinsic activity at CB receptors as HU-210 as reported in a number 
of various functional assays (Howlett et al., 2002). Another prominent bicyclic 
cannabinoid agonist is CP 47,497, the first non-classical analogue produced, 
which has high affinity and potency at both receptor types and acts as a full 
agonist. The tricyclic analogue CP 55,244 is reported to have a higher potency for 
CB receptors than HU-210, and several studies show it to have a higher intrinsic 
activity than most other current cannabinoid agonists. 
 
1.4.4. Aminoalkylindoles 
$PLQRDON\OLQGROHVDUHFDQQDELQRLGDJRQLVWVVWUXFWXUDOO\XQUHODWHGWRǻ9-THC and 
the other classical and non-classical agonists and are derived from the non-
steroidal anti-inflammatory drug-like compound pravadoline. The most prominent 
compound within this group is R-(+)-WIN 55,212-2, which exhibits high affinity 
for both receptor types and modest (~8-fold; Table 1.1) CB2 receptor selectivity 
38 
 
(Figure 1.3). Like HU-210 and CP 55,940, WIN 55,212-2 is commonly used in 
functional receptor assays as a reference agonist. More recently synthesised 
aminoalkylindole compounds include JWH-015 and L-768242, exhibit greater 
CB2 receptor selectivity (Howlett et al., 2002). 
 
1.4.5. Diarylpyrazoles 
The main family of cannabinoid receptor inverse agonists and antagonists are the 
diarylpyrazole series. SR 141716A, now known officially as rimonabant, is a high 
affinity CB1 receptor-selective ligand (Table 1.1; Figure 1.3). It was one of the 
first compounds from this group identified and is commonly used in in vitro and in 
vivo experiments to antagonise responses mediated by cannabinoid agonists. Next-
generation analogues of SR141718A have been developed which have increased 
CB1 receptor selectivity, with AM 251 being a good example. Unlike the other 
groups of cannabinoid ligands, a number of diarylpyrazoles exhibit high CB2 
receptor selectivity, including SR144528. 
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Figure 1.3 Structures of cannabinoid receptor ligands. An example from each of 
the main groups of ligands is present. 
 
1.4.6. In vivo effects of cannabinoid ligands 
Due to the abundance of CB1 receptors in the CNS, and the important role the  
cannabinoid system plays in the modulation of neuronal excitability and 
modulation of neurotransmitter release, cannabinoid agonists exert well 
characterised psychotropic effects when administered in vivo. Some 
therapeutically beneficial effects include analgesia, antiemetic effects, appetite 
stimulation, and decreased GI motility, while potentially unwanted side effects 
include sedation, euphoria, dysphoria and effects of cognition and memory (for 
review see Howlett et al., 2002). The standard animal model for characterising the 
effects of cannabinoid ligands at the CB1 receptor in vivo is the tetrad test, which 
measures effects on antinociception, catalepsy, hypoactivity and hypothermia in 
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rodents, with a general correlation between ligand binding affinity at the CB1 
receptors, and the potencies in the four behavioural assays. 
 
CB1 receptor antagonists/inverse agonists, both block the psychotropic effect of 
pre-administered cannabinoid agonist, and exert opposing effects to those of the 
agonists, including suppression of appetite and improvements to short term 
memory, when administered alone. Rimonabant was developed as an anorectic, 
anti-obesity drug and was approved for sale in the European Union in 2006; 
however it was shortly after removed from the market, due to increased incidents 
of depression and suicidal thoughts in patients. 
 
1.4.7. Other cannabinoid ligands 
More recently, a family of novel, endogenous peptide cannabinoid receptor 
ligands has been reported (Gomes et al., 2010). Enzyme-substrate capture analysis 
of proteosome-generated peptide fragments led to the identification of a nine-
residue peptide (PVNFKFLSH) derived from the haemoglobin-Į FKDLQ ZKLFK
caused hypotension in anesthetised rats, leading to the name hemopressin (Rioli et 
al., 2003) (Figure 1.4). Hemopressin and the C-terminally truncated fragments 
PVNFKF and PVNFKFL were subsequently shown to exhibit orally active 
antihyperalgesic activity in a rat model of experimental pain induced by 
carrageenan and bradykinin (Dale et al., 2005). Furthermore, this effect was not 
mediated via opioid receptors as the response was insensitive to the opioid 
receptor antagonist naloxone. A number of in vitro assays have shown 
hemopressin to be a highly CB1-selective inverse agonist, effectively blocking 
HU-210-induced functional responses (Heimann et al., 2007). A subsequent study 
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using an affinity purification approach in mouse brain identified two N-terminally 
extended peptide fragments - RVD-hemopressin-Į and VD-hemopressin-Įderived 
IURP WKH KDHPRJORELQ Į-chain and VD-hemopressin-ȕ derived fURP WKH ȕ-chain 
(Gomes et al., 2009). All three peptide fragments exhibit nanomolar affinity for 
CB receptors present in mouse cerebellum and were shown to be potent CB 
receptor agonists with RVD-+SĮ DQG 9'-+SĮ EHLQJ &%1 receptor-selective, 
while VD-+Sȕ exhibited similar activity at both receptor subtypes. Several 
attempts to replicate these initial finding were unsuccessful, and it was postulated 
that the ligands form peptide aggregates in aqueous solution, precluding them 
from the receptor binding site. Most recently it was shown that RVD-+SĮDQGD
range of further N-terminally extended peptides (termed Pepcans) acted as 
negative allosteric modulators of the CB1 receptor, which may explain the atypical 
pharmacology previously reported (Bauer et al., 2012). 
 
 
 
Figure 1.4 Structure and amino acid sequence of hemopressin peptide. 
 
Yangonin, one of six major kavalactones present in the kava plant (Piper 
methysticum) was shown to possess significant affinity for the CB1 receptor in 
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[3H]-CP 55,940 competition binding assays, which may account for some of the 
intoxicating effects of kava ingestion (Ligresti et al., 2012). 
 
1.4.8. Cannabinoid Allosteric Modulators 
GPCRs are able to interact with compounds teUPHGµDOORVWHULFPRGXODWRUV¶ZKLFK
are proposed to interact with binding sites on the receptor which are 
topographically distinct from the binding site of the endogenous ligand, termed the 
orthosteric binding site, allowing them to alter the binding and functional 
properties of orthosteric agonists (Christopoulos & Kenakin, 2002). The first 
allosteric modulators at cannabinoid receptors to be reported were a series of 
novel compounds developed by Organon - Org 27569 (5-chloro-3-ethyl-1H-
indole-2-carboxylic acid [2-(4-piperidin-1-yl-phenyl)-ethyl]-amide), Org 27759 
(3-ethyl-5-fluoro-1H-indole-2-carboxylic acid [2-94-dimethylamino-phenyl)-
ethyl]-amide) and Org 29647 (5-chloro-3-ethyl-1H-indole-2-carboxylic acid (1-
benzyl-pyrrolidin-3-yl)-amide, 2-enedioicacid salt); Figure 1.5) (Price et al., 
2005). Using radioligand binding assays, the compounds were shown to interact 
non-competitively at CB1 receptors, including partial displacement of [3H]-
rimonabant and facilitation of [3H]-CP 55,940 binding in mouse brain membranes. 
The compounds appear to negatively modulate agonist-induced responses, which 
is in contrast to their positive facilitation of agonist binding, which goes against 
the standard notion of agonist efficacy being positively coupled to occupancy. 
Stimulation of mouse vans deferens with WIN 55,212-2 produced an inhibition of 
electrically-evoked tissue contraction and this inhibition was attenuated by all 
three compounds in a concentration-dependent manner, with no significant change 
in WIN 55,212-2 potency (Price et al., 2005). The compounds were also shown to 
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reduce [356@*73Ȗ6ELQGLQJ significantly in CP 55,940 and anandamide-stimulated 
mouse brain (Price et al., 2005).  
 
 
 
 
Figure 1.5 Structure of Organon compounds Org 27569, Org 29647 and Org 
27759 (adapted from Price et al. 2005). 
 
A second series of novel synthetic molecules, typified by the compound 
PSNCBAM-1 (4-chlorophenyl)-3-[3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl]urea); 
Figure 1.6) were also shown to be negative allosteric modulators (Horswill et al., 
2007). As with the Organon compounds, PSNCBAM-1 partially displaced [3H]-
rimonabant and facilitated [3H]CP 55,940 binding, this time in HEK293-hCB1 cell 
membranes. PSNCBAM-1 appears to act as a negative modulator, producing a 
robust concentration-dependent decrease in the intrinsic activity of CP 55,940-
stimulated [356@*73Ȗ6ELQGLQJLQ+(.-hCB1 membranes, with no significant 
effect on potency. PSNCBAM-1 also reversed the CP 55,940- and anandamide-
induced decrease in cAMP accumulation in HEK293-hCB1 cells stimulated with 
forskolin. These results are consistent with PSNCBAM-1 acting as an allosteric 
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modulator, and are similar to the results seen for the Organon compounds. This is 
not surprising as they share common structural features, suggesting their pattern of 
receptor binding and alteration of receptor conformation may be similar. More 
recent studies of PSNCBAM-1 (Wang et al., 2011), confirmed its activity as a 
non-competitive antagonist of CP 55,940- and WIN 55,212-2-stimulated 
[356@*73Ȗ6ELQGLQJ LQFHUHEHOODUPHPEUDQHV IURP&%/PLFH ,QWHUHVWLQJO\, 
however, PSNCBAM-1 exhibited agonist-selective potency, with a significantly 
higher potency for the CP 55,940-bound receptor than the WIN 55,212-2-bound 
receptor in cerebellar and HEK293-hCB1 membranes. This suggests that CP 
55,940 and WIN 55,212-2 induce distinct receptor conformations and highlights 
the potential of allosteric modulators as tools for analysing the molecular 
mechanisms behind ligand-induced differential signalling (see below). 
 
 
 
 
 
Figure 1.6 Structure of PSNCBAM-1 (adapted from Horswill et al, 2007). 
 
A study by Navarro et al. (2009) suggested that a number of dopamine transporter 
inhibitors including the 3-phenyltropane RTI-371 (3b-(4-methylphenyl)-2b-[3-(4-
chlorophenyl)isoxazol-5-yl]tropane) and the benzotropane JHW-007 (N-butyl-3a-
[bis(4-fluorophenyl)methoxy]tropane) may exhibit allosteric modulation of CB1 
receptors (Navarro et al., 2009).  CP 55,940-stimulated calcium mobilisation in 
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RD-HGA16 cells (CHO cell line over-expressing the promiscuous G protein GĮ) 
transfected with hCB1 was enhanced by a number of DAT inhibitors, suggesting a 
positive allosteric effect. However, some of the compounds were also shown to be 
non-competitive antagonists of µ-opioid receptors, which, along with their actions 
as DAT inhibitors, complicates their pharmacological profile. 
 
1.5. Functional Selectivity 
1.5.1. Concept and Background 
Classical pharmacological theory holds that a GPCR exists in one of two distinct 
structural conformations - an active conformational state (R*) which couples to 
and activates downstream effectors, and an inactive state (R) which does not. 
Under basal conditions, a receptor population is comprised of receptors in both 
states, resulting in a constitutive level of effector activation. Agonists are ligands 
which preferentially bind to the active receptor conformation. This increases the 
ratio of the receptor population in the active state which in turn increases the level 
of receptor-mediated effector activation. Inverse agonists bind preferentially to the 
inactive receptor conformation causing a decrease in the ratio of active to inactive 
receptors and, therefore, a decrease in the constitutive activity. Antagonists exhibit 
no preference for either receptor conformation, do not change the active to 
inactive ratio and so have no appreciable effect on receptor-coupled effectors 
(Kenakin, 2001).  
 
In this model, the GPCR can be sHHQDVDQµRQRII¶VZLWFKIRUZKLFK all agonists 
produce the same pattern of receptor activation in a concept known as intrinsic 
efficacy. The observation that some agonists produce sub-maximal functional 
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responses, described as partial agonism, is explained as lower (but still significant) 
increases in the ratio of receptor in the active conformation, relative to full 
agonists. 
 
While this theory has been well established for decades, it is too simplistic to 
explain the complex pattern of pharmacology seen with a number of GPCRs. 
Functional selectivity (also known as agonist-directed trafficking or ligand±
induced differential signalling) can be defined as the ability of a ligand to 
differently activate specific signalling pathways and can be expressed as 
differences in ligand potency and/or intrinsic activity in relation to a functional 
effect (e.g. activation of a particular second messenger) compared to one or more 
others (Urban et al., 2007; Hudson et al., 2010).  
 
This extended theory posits that GPCRs, like other proteins, can adopt multiple 
distinct structural conformations, importantly, more than one active 
conformational state (i.e. R*1, R*2, R*3, R*n etc). Most GPCRs, including the 
cannabinoid receptors, orthosterically bind a number of structurally distinct 
endogenous and exogenous ligands. Each ligand may preferentially bind to a 
subset of active receptor conformations and each active receptor conformation 
may interact with a distinct set of downstream effectors resulting in ligand-
dependent receptor signalling. 
 
This phenomenon has been reported with increasing prevalence in the last decade 
for a number of GPCRs including adrenergic, muscarinic, dopamine and serotonin 
receptors (Urban et al., 2007). For example, the 5-HT2 receptor subgroup 
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independently couples, under the influence of different agonists, both to the 
PLC/Ca2+ signalling pathway via activation of Gq/11, and the PLA2 signalling 
pathway which generates arachidonic acid (AA) from membrane lipids. Ligands 
acting at both the 5-HT2A and 5-HT2C receptors are able to differentially activate 
these two signalling pathways (Berg et al., 1998).   
 
Ligand-directed functional selectivity is not limited to receptor-coupled signal 
transduction pathways, but may include other consequences of receptor/ligand 
interactions including desensitisation and internalisation. For example, a number 
of 5-HT2C receptor ligands exhibit ligand-selective desensitisation of the PLC/Ca2+ 
and PLA2-AA signalling pathways (Stout et al., 2002) while ligands for µ-  į-
RSLRLG DQG ȕ2-adrenergic receptor show different patterns of relative efficacies 
between receptor internalisation and coupling to receptor-mediated effector 
pathways (Urban et al., 2007). 
 
1.5.2. Other Considerations 
Care must be taken to consider the broader effector system when investigating 
ligands with distinct functional profiles, before concluding that true functional 
selectivity is present. Ligands may be acting at more than one pharmacological 
target. This is certainly true of the cannabinoid system, with ligands such as 
anandamide able to activate the vanilloid TRPV1 receptor and certain peroxisome 
proliferator-activated receptor (PPAR) subtypes, and non CB1/CB2 cannabinoid-
like receptors such as GPR55 and GPR119 yet to be fully characterised.  
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Next, partial agonists may be able to maximally activate signalling pathways more 
strongly coupled to the receptor than other pathways. When compared to a full 
agonist, the ligands would appear to have functionally distinct profiles. This 
phenomenon is known as a strength-of-signal effect and differs from true 
functional selectivity, where any receptor-coupled signalling pathway may be 
selectivity activated, not just the most strongly coupled one. 
 
Although functional selectivity is an inherent attribute of the receptor-ligand 
interaction, the receptor is part of a larger signalling complex which includes 
signalling effectors, mediators of desensitisation and internalisation, other 
receptors (both homo- and heteromers) and other proteins. All of these may have a 
direct and/or indirect effect on receptor function and pharmacology, including the 
functional selectivity of agonists (Kenakin, 2010). The presence of such 
modulators is highly tissue/cell type-dependent which means that ligand-selective 
differential signalling observed in one tissue type may be different or absent in 
another tissue type. 
 
The extracellular environment, particularly the concentration of Na+ and Mg2+ 
ions can alter the receptor conformational state which may directly affect the 
binding and functional profile of certain ligands. 
 
1.5.3. Functional Selectivity at Cannabinoid Receptors 
Cannabinoid receptors provide a particularly appealing model to investigate 
functional selectivity for a number of reasons: Firstly, members of the receptor 
family, particularly CB1, are endogenously expressed in a wide array of 
49 
 
mammalian cell and tissue types, including being ubiquitously expressed in 
neuronal tissue.  
 
Next, cannabinoid receptors couple to multiple intracellular signalling pathways, 
which increase their potential ligand-selective specific activation. The various 
structural groups of cannabinoid ligands discussed previously in this chapter may 
each bind to and activate different active receptor conformations. With at least five 
putative endogenous endocannabinoid ligands each with the potential to produce 
differential signalling via cannabinoid receptors, this system could provide a 
model for the role of functional selectivity in an endogenous system. 
 
Finally, the cannabinoid signalling system has huge potential as a target for 
therapeutic treatment of a number of disorders including pain, inflammation and a 
variety of psychiatric disorders. It may be possible, in the future, to develop 
functionally selective compounds which maximise positive effects, while 
minimising activation of pathways associated with negative side-effects. This is 
particularly true of compounds targeting CB1 receptors which often produce 
unwanted psychotropic side effects. 
 
A growing body of research exists which is helping to elucidate the mechanisms 
of cannabinoid functional selectivity. This involves several aspects including 
characterising the distinct profile of signalling pathway activation, desensitisation 
and downregulation of cannabinoid signalling and the molecular mechanisms 
which may facilitate functional selectivity. 
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As previously described, cannabinoid receptors predominantly couple to Gi/o 
proteins. However, there are several subtypes of Gi/o protein, with certain 
cannabinoid ligands having distinct selectivity. Stimulation of CB1 receptors 
exogenously expressed in Sf9 (Spodoptera frugiperda) cells with different 
cannabinoid ligands, led to different levels of Gi/o protein activation (Glass & 
Northup, 1999). The classical cannabinoid HU-210 produced maximal activation 
of both Gi and Go proteins. The endocannabinoid anandamide and 
aminoalkylindole WIN 55,212 both produced maximal activation of Gi proteins, 
but sub-maximal activation of Go7KHSK\WRFDQQDELQRLGǻ9-THC produced a sub-
maximal activation of both G protein subtypes. The rank order of ligand potency 
was consistent for both G protein subtypes. Further study of ligand specificity for 
GĮi subtypes *Įi1, *Įi2 DQG *Įi3 using a co-immunoprecipitation technique in 
N18TG2 neuroblastoma cells showed differential effects of chemically distinct 
ligands (Mukhopadhyay & Howlett, 2005). WIN 55,212-2 exhibited potency for 
all three subtypes investigated, while the tricyclic cannabinoid 
dHVDFHW\OOHYRQDQWUDGRO KDG SRWHQF\ IRU *Įi1 DQG *Įi2 EXW QRW *Įi3, and the 
synthetic eicosanoid methanandamide only had an effect RQ *Įi3. This ligand 
specificity appears to extend to G proteins of other families. In CHO cells 
exogenously expressing human CB1 receptors, WIN 55,212-2 was a full agonist 
for Gi and Gs signalling pathways, measured by the inhibition and accumulation of 
cAMP respectively in forskolin-stimulated cells (Bonhaus et al., 1998), whereas 
ǻ9-THC was a partial agonist for both signalling pathways. Interestingly, from a 
functional selectivity perspective, both the non-classical cannabinoid CP 55,940 
and anandamide exhibited significantly higher intrinsic activity at the Gi signalling 
pathway, acting as full agonists when measuring inhibition of cAMP formation, 
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but acting as partial agonists when measuring cAMP accumulation. CB1 receptor-
mediated activation of Gq/11 protein also appears to be ligand-selective. WIN 
55,212-2 was able to stimulate Gq-dependent intracellular Ca2+ release in HEK 
cells via transfected CB1 receptor activation (Lauckner et al., 2005). A series of 
RWKHUFDQQDELQRLGUHFHSWRUOLJDQGVLQFOXGLQJǻ9-THC, HU-210, CP 55,940 and 2-
AG, were unable to produce any response in the same assay. 
 
A number of structural studies point to the potential mechanisms by which 
cannabinoid functional selectivity might be mediated. CP 55,940 and WIN 
55,212-2 have been shown to induce distinct conformational changes in CB1 
receptors upon binding (Georgieva et al., 2008). Use of the highly sensitive 
plasmon-wavelength resonance (PWR) spectroscopic technique showed that the 
two ligands produced changes in the PWR spectra of myc-His6-tagged receptors 
which were of similar magnitude, but in opposite directions. This study also 
showed that the ability of these distinct receptor conformations to activate the Gi1 
protein subtype was significantly different, with the WIN 55,212-2-induced 
receptor conformation being much more potent. Mutant CB1 receptors with single 
residue substitutions at position L7.60 in the intracellular C-terminal helix 8 
produced ligand-selective receptor activation profiles (Anavi-Goffer et al., 2007). 
Wild type receptors containing a leucine residue at position L7.60 gave a maximal 
response upon stimulation with HU-210, CP 55,940 and WIN 55,212-2. L7.60I 
mutations caused a significant decrease in the maximal response produced by all 
three ligands, while a L7.60F mutation only caused a significant decrease in the 
maximal response produced by CP 55,940 and WIN 55,212-2. Further 
investigation showed that the H8 domain of the receptor is important in CB1-*Įi3 
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DQG*Įo FRXSOLQJEXWQRW*Įi1 DQG*Įi2 (Anavi-Goffer et al., 2007). This research 
suggests that different ligands may preferentially activate signalling pathways 
through distinct receptor domains. 
 
The novel cannabinoid peptide ligands RVD-Hp and VD-Hp appear to exhibit 
functional selectivity at the CB1 receptor. The peptides produced quantitatively 
similar responses compared with HU-210 in a series of assays measuring 
functional consequences of receptor activation including neuronal outgrowth in 
neuro 2A cells and internalisation of myc-tagged receptor expressed in CHO cells 
(Gomes et al., 2009). The profile of ERK phosphorylation differed between HU-
210 and RVD-Hp, with the level and rate of increase in pERK being lower for 
RVD-Hp. The study also showed CB1 receptor-mediated ligand-selective release 
of Ca2+ from intracellular stores in neuro-2A cells. Treatment with RVD-Hp, HU-
210 and the endocannabinoid 2-AG leads to a sustained release in Ca2+ levels; 
however, the RVD-Hp mediated release is much quicker and significantly larger. 
Interestingly, the effects of RVD-Hp on both pERK levels and intracellular Ca2+ 
release are only partially blocked by PTX, whereas the response due to HU-210 is 
almost completely abolished. Further study showed that both RVD-Hp and VD- 
Hp are unable to promote G protein activation as measured by accumulation of 
[35S@*73Ȗ6 in mice striatal and cerebellar membranes (Gomes et al., 2010). These 
results suggest that the peptide ligands activate a Gi-independent signalling 
pathway distinct from HU-210. 
 
While the majority of the reports on CB1 receptor functional selectivity are from in 
vitro studies, there are some reports of ligand-specific responses in vivo (Bosier et 
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al., 2010). A SAR study of aminoalkylindole derivatives using the tetrad test 
demonstrated that while WIN 55,212-2 is more potent in inducing 
hypolocomotion that hypothermia and catalepsy, several WIN 55,212-2 
derivatives were more potent in inducing catalepsy and hypothermia (Wiley et al., 
1998). However, differences in the metabolism of ligands in vivo, the presence of 
multiple pharmacological targets and the complex patterns of receptor distribution 
in various tissue all act to complicate the mechanisms by which ligand-specific 
responses occur in vivo. A more recent study has provided a clearer example of a 
true functionally selective response in vivo (Bosier et al., 2012). Both HU-210 and 
CP 55,940 induced hypolocomotion and catalepsy in male Wistar rats. However, 
only HU-210 was able to upregulate tyrosine hydroylase expression in the 
striatum, in a rimonabant-sensitive manner, despite both agonists exhibiting 
equivalent levels of brain penetration and receptor occupancy, as determined by ex 
vivo binding assays. 
 
1.6. Project Aim 
The aim of the project described in this thesis was to clearly demonstrate ligand-
selective functional selectivity at the cannabinoid receptor both endogenously and 
exogenously expressed in a variety of cell lines and tissues. Receptor stimulation 
by members of all the main groups of cannabinoid ligands was fully characterised 
using a number of functional assays, including [356@*73Ȗ6ELQGLQJWR measure G-
protein activation, measuring changes in cAMP levels induced by Gi/o and Gs 
proteins, immunocytochemical techniques to characterise the pattern of MAP 
kinase activation and measurement of receptor-mediated ȕ-arrestin recruitment, as 
well as the pharmacological profiling of novel cannabinoid allosteric modulators. 
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Chapter 2 
 
Characterisation of fenofibrate as a novel cannabinoid 
receptor agonist and negative allosteric modulator 
56 
 
2.1. Introduction 
The cannabinoid receptors are ligated by a variety of structurally unrelated 
compounds, with a range of potencies, efficacies and selectivities. Anandamide 
(N-arachidonoylethanolamine or AEA) and 2-arachidonoylglycerol (2-AG) are 
endogenous cannabinoid receptor lipid mediators derived from the fatty acid 
arachidonic acid. Other groups of receptor ligands include phytocannabinoids such 
DV ǻ9-WHWUDK\GURFDQQDELQRO ǻ9-THC), derived from Cannabis sativa, and their 
synthetic analogues both classical, such as HU-210, and non-classical such as CP 
55,940; the aminoalkyindoles such as WIN 55,212-2, which are structurally 
related to non-steroidal anti-inflammatory drugs, and diarylpyrazoles such as the 
CB1-selective antagonist rimonabant, otherwise known as SR 141716A (for 
review see Chapter 1). 
 
As well as these orthosteric ligands, a small number of allosteric modulators for 
the CB1 receptor have been described. These are compounds that are proposed to 
interact with binding sites on the receptor which are topographically distinct from 
the orthosteric binding site, allowing them to alter the binding and functional 
properties of orthosteric agonists (Christopoulos & Kenakin, 2002). A series of 
compounds synthesised by Organon, typified by Org 27569 (Price et al., 2005; 
Baillie et al., 2013), and the compound PSNCBAM-1 (Horswill et al., 2007; 
Wang et al., 2011) have been reported to positively enhance agonist binding, 
while negatively modulating agonist function, leading to the recent 
characterization of the Org 27569 binding site (Shore et al., 2013). Most recently, 
D VHULHV RI SHSWLGH HQGRFDQQDELQRLGV WHUPHG µSHSFDQV¶ KDYH EHHQ LGHQWLILHG
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which exhibit negative allosteric modulation of agonist binding and efficacy 
(Bauer et al., 2012). 
 
In addition to acting at cannabinoid receptors, many of the orthosteric ligands bind 
to and/or activate a number of other pharmacological targets, with examples 
including the orphan receptor GPR55, the transient receptor potential cation 
channel subfamily V member 1 (TRPV1) and the peroxisome proliferator-
activated receptors (PPARs), (Pertwee et al., 2010). PPARs are members of the 
nuclear receptor superfamily and function as ligand-activated transcription factors, 
recognising a range of endogenous fatty acids and their derivatives, and are 
generally involved in metabolism and cellular differentiation (Michalik et al., 
2006) 7R GDWH WKUHH UHFHSWRU LVRIRUPV KDYH EHHQ LGHQWLILHG Į ȕį DQG Ȗ
DOWKRXJK DW SUHVHQW RQO\ 33$5Į DQG33$5ȖDUH WKHUDSHXWLF WDUJHWV33$5Į LV
expressed in the liver and adipose tissue, as well as heart, kidney and skeletal 
muscle, where its main function is as a regulator of lipid metabolism. Activation 
RI33$5ĮOHDGVWRXSUHJXODWLRQRIJHQHVLQYROYHGLQWKHXSWDNHDQGXWLOLVDWLRQRI
free fatty acids making it a target in the treatment of hyperlipidemia 
(Rakhshandehroo et al., 2010). 
 
Anandamide, ǻ9-THC and WIN 55,212-2 are UHSRUWHG WR IXQFWLRQ DV 33$5Į
agonists in vitro (Fu et al., 2003; Sun et al., 2007), albeit at concentrations higher 
than those required to activate cannabinoid receptors. 
 
While there has been some exploration of the pharmacology of cannabinoid 
ligands at PPARs, only very limited investigation into the potential 
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pharmacological effects of PPAR ligands at the cannabinoid receptors has been 
reported. Previously, McGuinness et al. (2009) reported that fenofibrate was a 
near-full agonist compared to CP 55,940 in a HEK293-CB2 cell line using the 
3DWK+XQWHU ȕ-arrestin recruitment assay, with an EC50 value of 55nM. In 
addition, Pérez-Fernández et al. (2011) described a series of compounds 
combining pharmacophores of fenofibrate and SR 141716A with nanomolar 
affinity for both CB1 DQG 33$5Į DOWKRXJK DV WKHVH FRPSRXQGV ZHUH VHOHFWLYH
antagonists at the CB1 receptor in the mouse vas deferens bioassay, it is likely that 
their CB1 effects were mediated via the SR 141716A pharmacophore. 
 
 
Figure 2.1 Chemical structure of fenofibrate. 
 
2.2. Aims and objectives 
One of the tools necessary to identify patterns of functional selectivity is having as 
wide a variety of structurally distinct receptor ligands as possible. This increases 
the probability of ligands promoting distinct active receptor conformations and 
thereby activating distinct patterns of signalling cascades. To this end then, the 
aims of this chapter were to identify and characterise any new cannabinoid 
receptor ligands. This was achieved by testing a series of PPAR agonists for 
cannabinoid receptor affinity. These compounds were then subsequently used to 
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investigate functional selectivity at the cannabinoid CB1 receptor in a number of 
different expression systems. 
 
2.3. Methods 
2.3.1. Cell culture 
Chinese Hamster Ovary cells stably transfected with the human CB receptor were 
kindly provided by Dr Sarah Nickolls from Pfizer-Neusentis. All cell culture was 
performed under sterile conditions in a class II laminar flow cabinet. All culture 
reagents were warmed to 37°C before use. Chinese Hamster Ovary (CHO) cells 
stably transfected with human cannabinoid type 1 (CB1) or human cannabinoid 
type 2 (CB2) receptor were cultured in 175 cm2 culture flasks containing 
'XOEHFFR¶V 0RGLILHG (DJOH 0HGLXP 1XWULHQW 0Lxture F12 (DMEM/F12) 
supplemented with 10% foetal bovine serum, 2 mM L-glutamine and 400 µg/ml G 
418, in a humidified incubator at 37°C and 5 % CO2. Cells were cultured for 2 ± 3 
days until ~90% confluent, and then passaged. Cells were washed once with 
phosphate buffered saline (PBS), and then incubated with trypsin/EDTA solution 
for ~3 min until the majority of cells were detached from the culture flask. The 
cell suspension was diluted in culture medium to prevent further action of the 
trypsin, and then cells were collected by centrifugation at 200 x g for 3 min. The 
cell pellet was resuspended in fresh culture medium; the cell number determined 
using the Bio-5DG7&$XWRPDWHG&HOO&RXQWHUDQGFHOOVUHVHHGHGLQWRQHZ
culture flasks containing fresh culture medium (3 million cells per flask).  
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2.3.2. Membrane preparation 
Cells were cultured as described previously (see 2.3.1). At confluence, cells were 
trypsinised for no more than 1 min, allowing for cell detachment from the culture 
flask but minimising proteolytic degradation of the surface proteins. Cells were 
collected by centrifugation at 200 x g for 3 min. All subsequent steps were 
performed at 0 - 4°C. Cell pellets were resuspended in ice-cold homogenisation 
buffer and pooled together (50 mM Tris base, pH 7.4), homogenised using a 
Polytron homogeniser for 30 sec and then washed 3 times by centrifugation 
(30,000 x g for 10 min at 4°C). The membrane pellet was resuspended in 
homogenisation buffer and the protein concentration was determined by Lowry 
protein assay (Lowry et al., 1951). Serial dilution of a BSA standard (1 mg/ml) 
was prepared along with dilutions of membrane (1:10, 1:20 and 1:40). Lowry 
reagent (100 nM NaOH, 7 mM SDS, 200 mM Na2CO3, 0.005 % w/v CuSO4 and 
NaK tartrate) was added to each sample/standard dilution and incubated at room 
temperature for 10 min, followed by addition of Folin phenol reagent and 
incubation at room temperature for 45 min. The samples were then loaded onto a 
clear 96-well assay plate and the absorbance was measured using a 
spectrophotometric plate reader (Molecular Devices, CA). The membrane sample 
protein concentrations were interpolated from the BSA standard curve. The 
membrane concentration was adjusted to 2.5 mg/ml protein and was stored in 
aliquots at -80°C. 
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2.3.3. Radioligand binding assays 
2.3.3.1. Equilibrium binding assays 
Competition binding assays were performed in the presence of either [3H]-CP 
55,940 (1 nM) or [3H]-SR141716A (5 nM). CHO-hCB membrane (50 µg protein) 
was incubated in plastic vials at 30°C for 90 min in 1 ml (final volume) of assay 
buffer (50 mM Tris, 2 mM EDTA, 5 mM MgCl2, 0.2 mg/ml BSA, pH 7.0), with 
radioligand and various serially diluted concentrations of unlabelled ligand or 
buffer. Non-specific binding was determined in the presence of unlabelled CP 
55,940 (1 µM). The assay was terminated by rapid filtration through Whatman 
GF/B filters soaked in cold assay buffer containing 5 mg/ml BSA, using a 24-well 
Brandell harvester and washed three times with ice-cold assay buffer containing 
0.1 mg/ml BSA. Radioactivity on dissected filters was measured by liquid 
scintillation spectrometry. 
 
2.3.3.2. Dissociation Kinetics 
Competition binding assays were performed in the presence of [3H]-CP 55,940 (1 
nM). Rat whole brain membranes (male Wistar rats; 50 µg protein) were 
incubated with radioligand for 90 min at 21°C in 1 ml (final volume) of assay 
buffer (50 mM Tris, 2 mM EDTA, 5 mM MgCl2, 0.2 mg/ml BSA, pH 7.0). 
Dissociation was initiated by the addition of excess unlabelled CP 55,940 (1 µM) 
in the presence or absence of fenofibrate (30 µM), with a subsequent incubation 
time course ranging from 1 ± 120 min at 21°C. Non-specific binding was 
determined by performing the experiment in the presence of unlabelled CP 55,940 
(1 µM). The assay was terminated by rapid filtration through Whatman GF/B 
filters soaked in cold assay buffer containing 5 mg/ml BSA, using a 24-well 
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Brandell harvester and washed three times with ice-cold assay buffer containing 
0.1 mg/ml BSA. Radioactivity on dissected filters was measured by liquid 
scintillation spectrometry. 
 
2.3.4. [35S]-*73Ȗ6ELQGLQJDVVD\V 
CHO membranes were pre-incubated at 30°C for 20 min with GDP (final assay 
concentration 50 µM) in assay buffer (50 mM Tris, 10 mM MgCl2, 100 mM NaCl 
and 0.2 mg/ml BSA, pH 7.4). Membrane (25 µg) was then incubated in plastic 
vials at 30°C for 90 min in 1 ml (final volume) of assay buffer with 0.02 nM [35S]-
*73Ȗ6 DQG YDULRXV FRQFHQWUDWLRQV RI XQODEHOOHG OLJDQG RU EXIIHU 1RQ-specific 
ELQGLQJZDVGHWHUPLQHG LQ WKHSUHVHQFHRI0XQODEHOOHG*73Ȗ67KHDVVD\
was terminated by rapid filtration through Whatman GF/C filters using a 24-well 
Brandell harvester and washed three times with ice-cold distilled water. 
Radioactivity on dissected filters was measured by liquid scintillation 
spectrometry. 
 
2.3.5. Guinea-pig ileum contraction experiments 
Briefly, sections of ileum were removed from Dunkin-Hartley guinea-pigs and 
immersed in Krebs-Henseleit solution [composition (in mM): NaCl - 118, KCl - 
4.8, MgSO4.7H20 - 1.1, NaHCO3 - 25, KH2PO4 - 1.2, D-glucose - 12 and CaCl2 ± 
2.5, gassed with 95% O2 and 5% CO2 at room temperature]. For experimentation, 
the contents of the gut sections were flushed with buffer, and 3 cm segments of 
tissue were removed from the caecal end of the ileum. The tissue segments were 
mounted with cotton sutures onto platinum electrodes positioned transmurally and 
suspended in a 50 ml organ bath containing Krebs-Henseleit solution gassed with 
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95% O2 and 5% CO2 at 37°C at a tension of 0.5g. Tissue contractions were evoked 
by electrical field stimulation, (single pulses of 10 volts, 0.5 ms duration and 0.1 
Hz frequency) from SR1 stimulators. Changes in tension (as g) were recorded via 
force transducers connected to a PowerLab 26T / LabChart data-acquisition 
system (AD Instruments, Charlgrove, Oxford, UK).  
 
No compounds were added until the amplitude of the EFS-evoked responses were 
consistent for at least 30 min. Cumulative concentration-response curves were 
constructed to agonists with a minimum 15 min dosing interval. 
 
2.3.6. Materials 
[3H]-CP 55,940, [3H]-SR141716A, [35S]-Guanosine 5'-O-[gamma-
thio]triphosphate ([35S]-*73Ȗ6 DQG Ultima Gold liquid scintillation counter 
(LSC) cocktail were obtained from PerkinElmer (Boston, MA). Grade GF/B filter 
mats obtained from Brandel Inc. (Gaithersburg, MD). Test compounds, Bovine 
serum albumin*'3*73Ȗ6 and all other cell culture and assay reagents were 
obtained from Sigma-Aldrich (Poole, UK). 
 
2.3.7. Data analysis 
Data analysis was performed using GraphPad Prism v6.0 software (GraphPad 
software, Inc, San Diego, CA, USA). In radioligand binding experiments, the 
mean non-specific binding value was subtracted from all values to give the 
specific binding. The values were then expressed as a percentage of the basal 
binding/response, respectively. The inhibition of EFS-evoked responses by 
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cannabinoid agonists was expressed as a percentage inhibition of the response in 
the absence of compound.  
 
Data for the competition binding assays were analysed using the following 
equation; 
 ܻ ൌ ሺݐ݋݌ െ ܾ݋ݐݐ݋݉ሻሾܮሿሾܮሿ ൅ܫܥହ଴  
 
where Y is the percentage of specific binding, [L] is the concentration of 
unlabelled ligand and IC50 is the concentration of L required to inhibit 50 % of 
radioligand specific binding. 
 
The ligand affinities, as denoted by the equilibrium dissociation constants (Ki), 
were then determined using the Cheng-Prusoff equation; 
 ܭ௜ ൌ ܫܥହ଴ ? ൅ሾܴܮሿȀܭ஽ 
 
where [RL] is the radioligand concentration and Kd is the radioligand equilibrium 
dissociation constant. 
 
7KH FRRSHUDWLYLW\ IDFWRU Į DQG HTXLOLEULXP GLVVRFLDWLRQ FRQVWDQW .B) for 
fenofibrate acting as an allosteric modulator at the CB1 receptor were determined 
by non-linear regression using the allosteric ternary complex model (TCM) 
equation; 
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 ܻ ൌ  ሾܣሿሾܣሿ ൅ܭ஺ ൅ ሺ ? ൅ ሾܤሿȀܭ஻ሻ ? ൅ ߙሾܤሿȀܭ஻  
 
where [A] and [B] represent concentration of orthosteric and allosteric ligands 
respectively, and KA is the equilibrium dissociation constant for the orthosteric 
ligand. 
 
The data for the dissociation kinetic experiments were analysis using the following 
two-phase exponential decay model; 
 ܻ ൌ ݏ݌ܽ݊ ?Ǥ ݁ି ௞భǤ௫ ൅ ݏ݌ܽ݊ ?Ǥ ݁ି ௞మǤ௫ ൅ ݌݈ܽݐ݁ܽݑ 
 
where span 1 and span 2 are the percentage of each phase, the plateau is the 
minimum asymptotic value and k1 and k2 are the respective dissociation rate 
constants. An extra-sum-of-squares (F test) was used to determine whether the 
data were significantly better fitted to this model rather than a simpler one-phase 
exponential decay model. 
 
Concentration-response data were fitted to curves using the following four-
parameter logistical equation; ܻ ൌ ܾ݋ݐݐ݋݉ െ ሺݐ݋݌ െ ܾ݋ݐݐ݋݉ሻ ? ൅ ? ?ሺ௟௢௚ா஼ఱబି௫ሻ௡ಹ 
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where Y is the magnitude of the response, pEC50 is the negative logarithm of the 
curve midpoint, x is the log molar concentration of agonist and nH is the curve 
slope. 
 
2.3.8. Statistics 
All data represents mean ± SEM of at least three independent experiments. 
NormaliW\ RI GDWD VHWV ZDV GHWHUPLQHG XVLQJ WKH '¶$JRVWLQR-Pearson omnibus 
normality test. Statistical differences between mean values were determined using 
6WXGHQW¶VSDLUHG and unpaired, two-tailed t tests or one-way ANOVA followed by 
'XQQHWW¶V PXOWLSOH FRPSDULVRQV post hoc tests, where appropriate. A p value of 
<0.05 was considered significant. 
 
2.4. Results 
2.4.1. Competitive binding characterisation of fenofibrate 
Initially, a range of PPAR ligands (all at 10 µM) were assessed for CB2 receptor 
affinity using CHO membranes expressing hCB2 receptors by Dave Kendall et al. 
at the University of Nottingham. The compounds tested include the fibrates 
fenofibrate, and its active metabolite fenofibric acid, bezafibrate, ciprofibrate, 
clofibrate, gemfibro]LODQGPHWK\OFORIHQDSDWHDV33$5ĮOLJDQGVWKHVWUXFWXUDOO\
XQUHODWHGVHOHFWLYH33$5ĮDJRQLVWWY-14643 (also known as pirinixic acid) and 
WKH KLJKO\ VHOHFWLYH 33$5Ȗ DQWDJRQLVW 7 GDWD QRW VKRZQ 2QO\
fenofibrate exhibited affinity for the CB2 receptor, fully displacing receptor-bound 
[3H]-CP 55,940 - all other compounds tested failed to show any significant 
competition for radioligand binding.  
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Further radioligand binding experiments were performed to characterise the 
binding of fenofibrate to cannabinoid receptors. In CHO cell membranes 
expressing hCB1 receptors, unlabelled CP 55,940 displaced [3H]-CP 55,940 in a 
concentration-dependent manner, with a pIC50 value of 8.8 ± 0.1 (Figure 2.2A and 
Table 2.1). Fenofibrate also displaced [3H]-CP 55,940 binding in an apparently 
incomplete manner (% specific binding- CP 55,940 = 104 ± 3 %, fenofibrate = 80 
± 9 %). The pIC50 value for fenofibrate was 6.1 ± 0.1. In CHO cell membranes 
expressing hCB2 receptors, unlabelled CP 55,940 and fenofibrate both fully 
displaced [3H]-CP 55,940 binding, with pIC50 values of 9.3 ± 0.1 and 7.2 ± 0.1, 
respectively (Figure 2.2B and Table 2.1). These values were then used to 
calculate Ki values for CP 55,940 and fenofibrate at the two receptor subtypes 
(Table 2.1). 
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Figure 2.2 Characterisation of fenofibrate binding at (A) CB1 and (B) CB2 
cannabinoid receptors. Membranes derived from CHO cells stably transfected 
with cannabinoid receptors were incubated with increasing concentrations of CP 
ȡ0± 10 µM) or fenofibraWHȡ0± 100 µM) in the presence of [3H]-
CP 55,940 (1 nM) at 30°C for 90 min followed by filtration. Results were 
expressed as a % of the specific binding of radioligand in the absence of ligand. 
Data shown are the mean ± SEM from three independent experiments performed 
in triplicate. Curves were fitted by non-linear regression to a four parameter 
logistical equation using GraphPad Prism. 
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Table 2.1 
Determination of the affinity (pKi values) of CP 55,940 and fenofibrate at human 
CB1 and CB2 cannabinoid receptors expressed in CHO cells using [3H]-CP 
55,940.  
Ligand CHO-hCB1 CHO-hCB2 
CP 55,940 9.0 ± 0.2 10.0 ± 0.4 
fenofibrate 6.3 ± 0.9 7.7 ± 0.1 
Data shown are mean ± SEM from three independent experiments performed in 
duplicate.  
 
2.4.2. Functional characterisation of fenofibrate at human cannabinoid 
receptors 
The functional pharmacological properties of fenofibrate were investigated using 
WKH *73Ȗ6 ELQGLQJ DVVD\ ZKLFK PHDVXUHV UHFHSWRU-mediated enhancement of 
binding of  radiolabelled [35S]-*73Ȗ6WR*SURWHLQVSUHVHQWLQWKHFHOOPHPEUDQHV
In CHO-hCB1 membranes, CP 55,940 produced a concentration-dependent 
LQFUHDVH LQ *73Ȗ6 ELQGLQJ ZLWK D S(&50 value of 9.0 ± 0.2 (Figure 2.3A and 
Table 2.2). Fenofibrate produced a smaller increase in GT3Ȗ6ELQGLQJUHODWLYHWR
CP 55,940, with a maximally effective concentration of 3.1 µM. However at 
higher concentrations, there was a reduction in [35S]-*73Ȗ6ELQGLQJSURGXFLQJDQ
atypical bell-shaped concentration-response curve (Figure 2.3A). In CHO-hCB2 
membranes, CP 55,940 again produced a concentration-dependent increase in 
*73Ȗ6ELQGLQJZLWKDS(&50 value of 9.7 ± 0.1 (Figure 2.3B and Table 2.2). In 
contrast to the CB1 response, fenofibrate produced a typical concentration-
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dependent response in CHO-hCB2 membranes, with a pEC50 value of 7.7 ± 0.1. 
The fenofibrate Rmax value was only slightly lower than that for CP 55,940, 
suggesting it may be a higher efficacy agonist at the hCB2 receptor (% CP 
response = 90 ± 2%; paired, two-tailed t-test, p<0.05). 
 
Table 2.2 
Determination of potency (pEC50 values) and intrinsic activity (Rmax) for CP 
55,940- and fenofibrate-enhanced binding of [35S]-*73Ȗ6XVLQJKXPDQ&%1 and 
CB2 cannabinoid receptors expressed in CHO cells. 
Ligand CHO-hCB1 CHO-hCB2 
pEC50 Rmax 
(%) 
Rmax 
(% CP 
response) 
pEC50 Rmax 
(%) 
Rmax 
(% CP 
response) 
CP 55,940 9.0 ± 0.2 289 ± 20 100 ± 1 9.7 ± 0.1 400 ± 6 100 ± 1 
fenofibrate N.D. N.D. N.D. 7.7 ± 0.1 359 ± 14 90 ± 2*a 
Data shown are mean ± SEM from three independent experiments performed in 
duplicate. N.D.: not determined due to lack of fit to non-linear regression curve.  
* p<0.05, paired two-tailed t-test.  
a
 compared to the corresponding CP 55,940 response. 
 
2.4.3. Further characterisation of fenofibrate activity at the CB1 receptor 
In order to investigate the biphasic [35S]-*73Ȗ6UHVSRQVHWRIHQRILEUDWHLQ&+2-
hCB1 membranes, the sensitivity of the response to the CB1 selective antagonist 
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AM 251 was investigated (Figure 2.3C). Increasing concentrations of AM 251 
SURGXFHG ULJKWZDUG VKLIWV LQ WKH SRVLWLYH KLJK SRWHQF\ *73Ȗ6 UHVSRQVH
demonstrated by the increase in the fenofibrate concentration required to produce 
an equiefficacious response. Increasing concentrations of AM 251 also caused a 
reduction in the fenofibrate maximum response with 0.1, 1 and 10 nM AM 251 
producing an absolute reduction of 5, 59 and 167 % basal response respectively. A 
concentration of 10 µM AM 251 completely abolished the biphasic fenofibrate 
response (Figure 2.3C). 
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Figure 2.3 Characterisation of fenofibrate functional properties at (A) CB1 and 
(B) CB2 cannabinoid receptors. Membranes, derived from CHO cells stably 
transfected with cannabinoid receptors, and pre-incubated with GDP (50 µM) 
ZHUHLQFXEDWHGZLWKLQFUHDVLQJFRQFHQWUDWLRQVRI&3ȡ0± 10 µM) or 
fenofibrate (1 nM ± 100 µM) in the presence of [35S]-*73Ȗ6Q0DW°C 
for 90 min followed by filtration. Antagonist studies at the CB1 receptor (C) were 
performed in the presence of increasing concentrations of AM 251. Results were 
expressed as a % of the specific binding of [35S]-*73Ȗ6in the absence of ligand. 
Data shown are the mean ± SEM from three independent experiments performed 
in duplicate. Full line curves were fitted by non-linear regression to a four 
parameter logistical equation and dashed lines using straight lines connecting 
neighbouring data points to illustrate overall response trend. 
73 
 
2.4.4. Fenofibrate as a negative allosteric modulator 
One interpretation of these data is that, at higher concentrations, fenofibrate 
functions as a negative allosteric modulator. To test this hypothesis, the ability of 
fenofibrate to modulate CP 55,940-evoked responses was investigated. The 
competition radioligand binding data for fenofibrate (Figure 2.2A) were fitted to 
the allosteric TCM equation (see 2.3.7), yielding estimated pKB DQGĮYDOXHVRI 
6.2 ± 0.1 and 0.12 ± 0.1 respectively, indicating a strongly negative mode of 
modulation. The effect of fenofibrate on the dissociation of [3H]-CP 55,940 
binding to CB1 receptor was determined. High variance in the specific radioligand 
binding in the CHO-hCB1 membranes in provisional experiments meant that 
curves could not be fitted with any confidence; therefore, experiments were 
performed in rat whole brain homogenates, which have a greater level of CB1 
specific binding. Addition of unlabelled CP 55,940 (1 µM) promoted a 
significantly biphasic dissociation of the radioligand (Figure 2.4A and Table 2.3; 
p<0.0001; F test). Inclusion of fenofibrate (30 µM) produced a significant increase 
in both the slow and fast radioligand dissociation rate constants, with no 
significant change of the ratio between the two phases (Table 2.3; *p<0.05, 
**p<0.01; paired two-tailed t-test). 
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Table 2.3 
Determination of the dissociation rate constants for [3H]-CP 55,940 at cannabinoid 
receptor expressed in rat whole brain in the absence and presence of fenofibrate. 
Ligand k1 (slow) Half-life slow k2 (fast) Half-life fast 
x 10-2 min-1 min min-1 min 
CP 55,940  
(1 µM) 
1.19 ± 0.20 61.3 ± 10.4 0.79 ± 0.14 0.93 ± 0.15 
CP 55,940 & 
fenofibrate  
(30 µM) 
3.84 ± 0.08**a 18.1 ± 0.40 1.50 ± 0.16*a 0.47 ± 0.06 
Data shown are mean ± SEM from three independent experiments performed in 
duplicate. * p<0.05, ** p<0.01; paired, two tailed t-test. 
a
 Relative to the corresponding k value in the absence of fenofibrate. 
 
Next, the modulatory effect of fenofibrate on an orthosteric functional response 
was investigated by examining the effect of fenofibrate on the CP 55,940-
HQKDQFHG*73Ȗ6UHVSRQVHFigure 2.4B). Two equiefficacious concentrations of 
fenofibrate were chosen, one representative of the rising half and the other of the 
falling half of the bell-shaped curve. Both concentrations of fenofibrate produced 
DQ LQFUHDVH LQ WKHDSSDUHQWEDVDO OHYHORI*73Ȗ6ELQGLQJ&R-stimulation with a 
low concentration of fenofibrate (0.3 µM) did not significantly alter the maximal 
response to CP 55,940, as described by the upper asymptote of the concentration-
response curve. However, a high concentration (30 µM) produced a significant 
reduction in both the maximal CP 55,940 response (86 ± 2 % control response; 
p<0.01; one-way ANOVA), as well as a significant rightward shift of the 
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concentration- response curve (pEC50 value, without fenofibrate = 8.9 ± 0.1, 
fenofibrate = 6.9 ± 0.1; p<0.0001; one-way ANOVA). 
 
Finally, the effect of fenofibrate on binding to CHO-hCB1 membranes of the 
antagonist radioligand [3H]-SR 141716A was investigated. The CB1±selective 
antagonist AM 251 produced a concentration-dependent displacement of [3H]-SR 
141716A binding, with a pIC50 value of 9.4 ± 0.1. In marked contrast, fenofibrate 
failed to compete for [3H]-SR 141716A binding, but rather significantly enhanced 
binding at higher concentrations, although the magnitude of the enhancement was 
somewhat variable between individual experiments (Figure 2.4C). 
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Figure 2.4 Characterisation of fenofibrate as a negative allosteric modulator.  
A ± Rat whole brain membranes pre-incubated with [3H]-CP 55,940 (1 nM) were 
incubated with CP 55,940 (1 µM) in the absence or presence of fenofibrate (30 
µM) at 21°C over a 120 min time course, followed by filtration. Results were 
expressed as a % of the specific binding of the radioligand in the absence of 
unlabelled ligand. 
B - Membranes derived from CHO cells stably transfected with CB1 receptors 
were incubated with increasing concentrations of AM   ȡ0 ± 100 nM) or 
IHQRILEUDWH  ȡ0 ± 100 µM) in the presence of [3H]-SR 141716A (5 nM) at 
30°C for 90 min followed by filtration. Results were expressed as a % of the 
specific binding of radioligand in the absence of ligand. 
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C - Membranes derived from CHO cells stably transfected with CB1 receptors and 
pre-incubated with GDP (50 µM) were incubated with increasing concentrations 
RI&3ȡ0± 10 µM) in the presence of [35S]-*73Ȗ6Q0DQGLQ
the absence and presence of fenofibrate (0.3 and 30 µM) at 30°C for 90 min 
followed by filtration. Results were expressed as a % of the specific CP 55,940 
response. Data shown are the mean ± SEM from 3 to 5 independent experiments 
performed in duplicate. Full line curves were fitted by non-linear regression to a 
four parameter logistical equation and dashed lines using straight lines connecting 
neighbouring data points to illustrate overall response trend. Statistical 
significance was determined by one-way ANOVA ZLWK 'XQQHWW¶V PXOWLSOH
comparisons tests; * p<0.05, **p<0.01. 
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2.4.5. The effects of fenofibrate in an in vitro isolated tissue preparation 
To determine whether fenofibrate activity at the cannabinoid receptors is likely to 
EHRI UHOHYDQFH LQ µUHDO¶ WLVVXHV WKHHIIHFWVRI IHQRILEUDWHRQ electrically-evoked 
contractions in guinea-pig ileum were investigated (Figure 2.5). CP 55,940 and 
fenofibrate both produced concentration-dependant inhibitions of electrically-
evoked contractions with pEC50 values of 7.4 ± 0.7 and 6.0 ± 0.4, respectively. 
The inhibition evoked by fenofibrate was incomplete relative to the response to 
CP55940, with an Rmax value of 78 ± 10 %, compared to 103 ± 10 % for CP55940. 
AM 251 (30 nM) produced a significant rightward shift in the fenofibrate 
concentration-response curve (pEC50 value = 4.9 ± 0.1; p<0.05; unpaired, two-
tailed t-test), indicating that the effect was mediated via CB1 receptors present in 
WKH WLVVXH 7KH PDMRU 33$5Į-active metabolite fenofibric acid was unable to 
inhibit electrically-evoked tissue contractions in this tissue at concentrations up to 
10 µM. 
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Figure 2.5 Cannabinoid effects on electrically-evoked contraction in guinea-pig 
ileum. Sections of ileum (~ 3 cm) were mounted transmurally onto electrodes and 
suspended in 50 ml organ baths in oxygenated Krebs Buffer. Tissue contractions 
were evoked by electrical field stimulation (single pulses of 10 volts, 0.5 ms 
duration and 0.1 Hz frequency). Tissue was incubated with increasing 
concentrations of compound in a cumulative fashion with a minimum 15 min 
dosing interval. Results were expressed as % inhibition of the electrically-evoked 
tissue contraction immediately prior to the first compound addition. Data shown 
are the mean ± SEM from at least three independent experiments, each using 
tissue from different animals. Curves were fitted by non-linear regression to a four 
parameter logistical equation using GraphPad Prism. 
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2.5. Discussion 
7KHUHVXOWVSUHVHQWHGLQ WKLVFKDSWHU LGHQWLI\ WKH33$5ĮDJRQLVWIHQRILEUDWHDVD
novel agonist at cannabinoid receptors, defining a chemically distinct structural 
group of cannabinoid ligands. In addition, fenofibrate at higher concentrations 
appears to act as a negative allosteric modulator at the CB1 cannabinoid receptor. 
 
Steady state binding experiments using a radiolabelled agonist revealed 
fenofibrate to be a ligand at both receptor subtypes, exhibiting ~25 fold selectivity 
for the CB2 receptor versus CB1 receptors. In addition, fenofibrate also exhibited 
efficacy at both receptor subtypes, as shown in the [35S]-*73Ȗ6 binding assay, 
acting as a near full agonist at the CB2 receptor and a partial agonist at the CB1 
receptor at lower concentrations. Fenofibrate, therefore, is ~60 and 1400 times 
more potent at the CB1 and CB2 UHFHSWRUVUHVSHFWLYHO\WKDQDW33$5Į(EC50 ± 30 
µM; Willson et al., 2000). This is a significant finding given that fenofibrate is a 
common therapy for hypercholesterolemia and hypertriglyceridemia both alone 
and as a combined treatment with statins (Michalik et al., 2006). 
 
Once absorbed, fenofibrate is rapidly metabolised to the active compound 
fenofibric acid by tissue and plasma esterases (Caldwell, 1989), making it 
unfeasible to measure cannabinoid receptor-mediated effects of fenofibrate in 
vivo. Instead, we investigated its effect on isolated guinea-pig ileum tissue, with 
which we showed that fenofibrate, but not fenofibric acid, inhibited electrically-
evoked contractions in guinea pig ileum in an AM 251-sensitive manner, 
confirming  fenofibrate as a cannabinoid CB1 receptor agonist and identifying a 
clinically relevant cannabinoid target for orally administered fenofibrate. 
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A link has been established between the endocannabinoid system and 
hyperlipidemia in vivo, in which low dose cannabinoid therapy (Steffens et al., 
2005), and systemic CB2 gene deletion (Netherland et al., 2010) have been shown 
to reduce the progression of atherosclerosis in  apolipoprotein E and low-density 
lipoprotein receptor-deficient murine models of hyperlipidemia, respectively. 
Therefore, the possibility exists that fenofibrate may be mediating some of its 
hypolipidaemic effects and/or side effects via cannabinoid receptor targets. As 
VWDWHG DERYH IHQRILEUDWH LV UDSLGO\ PHWDEROLVHG WR WKH 33$5Į-active metabolite 
fenofibric acid by tissue and plasma esterases (Caldwell, 1989). As we have 
shown that fenofibric acid exhibits minimal activity at cannabinoid receptors, any 
effects of fenofibrate on cannabinoid receptors post-absorption appear unlikely. 
However, Murakami et al. (2010) reported that fenofibrate, but not fenofibric acid, 
increased AMP kinase phosphorylation in hepatoma cells, and oral administration 
of fenofibrate to C3H mice also increased the phosphorylation of AMP kinase in 
the liver, but not in skeletal muscle, indicating that unmetabolised fenofibrate 
accumulates in the liver. These results suggest that it is unlikely that the AMP 
NLQDVHSKRVSKRU\ODWLRQHIIHFWRIIHQRILEUDWHZDV33$5Į-mediated and it would be 
interesting to determine whether it might be due to CB receptor activation. CB2 
receptor modulation of AMP kinase has previously been reported to be involved in 
neuroprotection against ischaemic damage (Choi et al., 2013) and hepatic 
encephalopathy (Dagon et al., 2007). 
 
Higher concentrations of fenofibrate (10 ± 0SURGXFHGDUHYHUVDOLQ*73Ȗ6
binding mediated via the CB1 receptor, producing a bell-shaped concentration-
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response curve. This response appears to be limited to the CB1 receptor as it was 
not seen with CB2 receptors expressed in the same cell line, also indicating it was 
not a non-specific effect. These results raised the question of whether fenofibrate 
was acting as an allosteric modulator of CB1 receptors at higher concentrations. 
$OWHUDWLRQRIDQRUWKRVWHULFOLJDQG¶VGLVVRFLDWLRQNLQHWLFVE\DVHFRQGFRPSRXQGLV
a clear demonstration of allosteric interaction, as dissociation is independent of 
orthosteric modulation (Christopoulos & Kenakin, 2002; May et al., 2007). Both 
Org 27569 and the pepcan endogenous peptide ligands have been described as 
CB1 allosteric modulators on the basis of this criterion (Price et al., 2005; Bauer et 
al., 2012). Dissociation kinetic experiments showed that fenofibrate significantly 
increased the dissociation rate constants of [3H]-CP 55,940 from the CB1 receptor, 
clearly indicating it to be a negative allosteric modulator of agonist binding at 
higher concentrations. It is noteworthy that radiolabelled agonist dissociation was 
significantly biphasic, which is in keeping with previous reports for this receptor 
(Price et al., 2005). Fenofibrate caused an enhancement of antagonist radioligand 
binding at higher concentrations, though it is important to note there was variation 
between experiments in the magnitude of this response. This may be explained as 
DQ H[DPSOH RI µSUREH GHSHQGHQF\¶ (May et al., 2007), in which the modulator 
effects are dependent on the ligand bound to the receptor. This phenomenon has 
been previously observed for the CB1 receptor with the compounds Org 27569 and 
PSNCBAM-1 which both exhibit opposing effects on [3H]-CP 55,940 and [3H]-
SR 141716A binding. Functionally, fenofibrate appears to act as both an agonist, 
and a negative allosteric modulator, of CB1 receptors. Co-incubation with a high, 
but not a low concentration of fenofibrate promoted a significant reduction in the 
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maximum CP 55,940 response, which is indicative of a negative allosteric 
interaction. 
 
Our data suggest that fenofibrate acts at both orthosteric and allosteric binding 
sites; albeit with different potencies. There are several reports of compounds 
which appear to exhibit both orthosteric and allosteric effect on GPCRs, termed 
µELWRSLF OLJDQGV¶ (Valant et al., 2012). A clear example is the muscarinic M2 
partial agonist McN-A-343, which was initially characterised as both an allosteric 
modulator (Waelbroeck, 1994) and orthosteric agonist (Christopoulos & 
Mitchelson, 1997) in different assay systems. Recently, the compound has been 
identified as containing two distinct pharmacophores, one acting as an orthosteric 
agonist and the other as an allosteric modulator at the receptor (Valant et al., 
2008).  
 
2.6. Conclusions 
In conclusion, we have shown that fenofibrate is a potent agonist at the seven 
transmembrane cannabinoid receptors (CB2 and CB1), which are important 
regulators of neuronal and immune cell activity, in in vitro cell-based and isolated 
tissue systems. Subsequent chapters will aim to more fully characterise the 
signalling pattern of fenofibrate at the CB1 cannabinoid receptor in a number of 
different expression systems, and to compare it to that of other cannabinoid 
ligands. Additionally, fenofibrate also exhibits complex pharmacology at the CB1 
receptor, with the results indicating it acts as a negative allosteric modulator at 
higher concentrations.  
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Overall, these results raise the possibility that some of the clinical effects of 
fenofibrate may involve cannabinoid receptor interactions and also provide the 
basis for the future development of novel compounds acting as cannabinoid 
receptor agonists and allosteric modulators. 
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Chapter 3 
 
Investigation of Functional Selectivity at the Cannabinoid 
Receptor in Human CB1 Receptor-Transfected Chinese 
Hamster Ovary Cells 
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3.1. Introduction 
Chinese hamster ovary or CHO cells are an immortalised cell line developed by 
Theodore T. Puck in the early 1960s. They are the most commonly used cell line 
for expression of recombinant protein owing to their relatively low chromosomal 
number (n =22), ability to express high amounts of protein and their relative 
paucity of endogenously expressed protein. Typically, the cells are cultured as an 
adherent monolayer in media containing the amino acid proline. A large amount of 
the research on cannabinoid receptors has been conducted using CHO cells 
expressing recombinant CB1 receptor; indeed the initial description of the CB1 
receptor by Matsuda et al. (1990) involved transfection into CHO-K1 cells. Other 
important examples of cannabinoid receptor research carried out with transfected 
CHO cells include the initial identification of CB1 coupling to Gs proteins (Glass 
& Felder, 1997), and as well as papers demonstrating functionally selective 
cannabinoid signalling (Bonhaus et al., 1998). 
 
3.2. Aims and objectives 
The aim of this chapter was to investigate functionally selective responses at the 
CB1 receptor expressed in transfected CHO cells. This was achieved by 
stimulating cells with a range of cannabinoid agonists and measuring the 
modulation of a number of signal transduction mediators including the MAP 
kinases ERK, JNK and p38, the enzyme adenylyl cyclase via changes in cAMP 
OHYHOV DQG ȕ-arrestin recruitment to the receptor. This cell line provides an 
attractive model for investigating agonist bias as it has been thoroughly validated 
by previous studies, and the relatively high receptor population should provide 
clear responses, bringing confidence to the data generated. 
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3.3. Methods 
3.3.1. Cell Culture and membrane preparation 
The culture of CHO-hCB1 cells and production of membranes were performed as 
described in Chapter 2 ± Methods (see 2.3.1 and 2.3.2) 
 
3.3.2. Radioligand Binding 
Equilibrium competition radioligand binding assays using [3H]-CP 55,940 were 
performed as described in Chapter 2 ± Methods (see 2.3.3.1). 
 
3.3.3. cAMP accumulation assay 
Levels of cAMP accumulation were determined using the DiscoveRx HitHunter® 
cAMP XS+ assay kit. Cells were seeded into white 96-well assay plates at 20,000 
cells/well (unless otherwise stated) in culture medium, in either the absence of 
presence of pertussis toxin (100 ng/ml), incubated for 1 hour at room temperature 
and then incubated overnight at 37°C. On the day of the assay, the culture medium 
was aspirated and replaced with assay medium, comprising serum-free culture 
medium containing rolipram (10 µM), forskolin (10 µM) and 1 mg/ml BSA. 
Addition of the CB1-selective antagonist AM 251 (final concentration 10 nM) or 
buffer was made and the cells pre-incubated for 30 min at 37°C. Each subsequent 
step was followed by an incubation period of 1 hour at room temperature in a final 
assay volume of 30 µl. Cells were treated with serial dilutions of cannabinoid 
ligands, performed in assay medium. Once ligand treatment was complete, the 
assay was terminated by cell lysis via the addition of ED/Lysis CL working 
solution (40 µl/well) followed by the addition of EA reagent. The 
chemiluminescent signal, corresponding to the cAMP concentration, was detected 
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using a PerkinElmer ToS&RXQW1;77KHGDWDZHUHH[SUHVVHGDVDSHUFHQWDJH
of the forskolin response (10 µM). 
 
3.3.4. Beta-arrestin recruitment assay 
/HYHOV RI ȕ-arrestin recruitment were determined using the DiscoveRx 
PathHunter® assay. This assay utilises a second CHO cell line, different from that 
used in the other assays, stably transfected with a recombinant version of the 
human CB1 receptor. Cells seeded into white 96-well assay plates at 20,000 
cells/well (unless otherwise stated) in culture medium, incubated for 1 hour at 
room temperature and then incubated overnight at 37°C. On the day of the assay, 
cells were pre-treated with buffer or AM 251 (final concentration 10 nM) for 30 
min, followed by treatment with serial dilutions of cannabinoid ligands, performed 
in medium, and incubated at 37°C for 90 min in a final assay volume of 100 µl. 
After incubation, Detection Reagent Solution was added (50 µl/well) and the 
plates incubated for 60 min at room temperature. Chemiluminescent signal was 
GHWHFWHG XVLQJ D 3HUNLQ(OPHU 7RS&RXQW 1;7. The data were expressed as a 
percentage of the span of the HU-210 response curve. 
 
3.3.5. Determination of MAP kinase phosphorylation 
3.3.5.1. Protocol 
Levels of MAP kinase phosphorylation were determined using the In-Cell 
:HVWHUQDVVD\ZKLFKLVDTXDQWLWDWLYHIOXRUHVcent immunoassay where proteins 
are immunocytochemically labelled in situ in fixed cultured cells. Cells were 
seeded into 96-well clear bottom plates, at 40,000 cells/well (unless otherwise 
stated) in culture medium at room temperature for 1 hour and then incubated 
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overnight at 37°C, in the presence of pertussis toxin (100 ng/ml), where 
appropriate. 30 min prior to experimentation, the culture medium was removed 
from the assay plates by aspiration, the cells were washed once with PBS, and the 
medium replaced with serum-free medium containing 1 mg/ml BSA and 2 
units/ml apyrase, unless otherwise stated. Cells were pre-treated with buffer or 
AM 251 for 30 min. Serial dilution of test ligands was performed in serum-free 
medium and added to test wells to a final volume of 200 µl per well. Assay plates 
were incubated for the stated period at 37°C during experimentation. After 
incubation, the assay medium was rapidly aspirated and the cells were fixed with 
4% paraformaldehyde in PBS for 20 min at room temperature (150 µl/well). Each 
reagent was aspirated before the addition of the next reagent. Cells were then 
SHUPHDELOLVHG ZLWK  YY 7ULWRQ ;-100 in PBS for 20 min at room 
temperature (150 µl/well). Non-specific antibody binding sites were blocked with 
5% (w/v) milk powder in PBS for 20 min at room temperature with gentle 
rocking. 
 
Primary antibodies for anti-total and anti-phosphorylated MAP kinases (ERK1/2, 
p38 or JNK1/2/3; see 3.3.6.3) were diluted together in blocking agent to form 
primary antibody solution. The assay of each MAP kinase was performed 
separately. Cells were incubated with primary antibody solution (50 µl/well) 
overnight at 4°C with gentle rocking. The next day, the primary antibody solution 
was aspirated and the cells were washed three times with PBS containing 1 mg/ml 
BSA (150 µl/well) for 5 min at room temperature with gentle rocking. The 
appropriate LI-COR IRDye® secondary antibodies were diluted 3:11000 in 
blocking agent, added to the cells (100 µl/well), and incubated in darkness for 60 
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min at 37°C with gentle shaking. The secondary antibody solution was aspirated 
and the cells washed three times with wash buffer as before. 
 
3.3.5.2. Imaging 
Plates were imaged by scanning simultaneously at 700 and 800 nm with the LI-
COR Odyssey® NIR Imaging System at 82 µm resolution, medium quality and 
focus offset of 4.0123 mm. Quantification was performed using LI-COR 
Odyssey® Software v3.0. The secondary antibody non-specific response was 
subtracted from the data. The phospho- response was then normalised against the 
total protein response for each individual well and then the data was expressed as 
a percentage of the basal response. 
 
3.3.5.3. Antibodies used 
All primary antibodies used were obtained from Cell Signaling Technology 
(Boston, USA). All antibodies were used at the concentrations described below 
unless otherwise stated in Results (see 3.4). Anti-ERK 1/2 rabbit, (1:400) # 9102; 
anti-phospho-ERK1/2 (Thr202/Tyr204) monoclonal mouse, (1:200) # 9106; anti-
p38 rabbit, (1:200) # 9212; anti-phospho-p38 (Thr180/Tyr182) monoclonal 
mouse, (1:200) #9216; anti-JNK rabbit, (1:200) # 9252; anti-phospho-JNK 
(Thr183/Tyr185) monoclonal mouse, (1:200) # 9255. 
 
3.3.6. Data analysis 
All data were analysed using the GraphPad Prism software (v6). The data for the 
equilibrium competition binding assays, and the ligand affinities, as denoted by 
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the equilibrium dissociation constants (Ki), where determined using the equations 
previously described in Chapter 2 ± Methods (see 2.3.7). 
 
Concentration-response data were fitted to curves using the four-parameter logistic 
equation, previously described in Chapter 2 ± Methods (see 2.3.7). 
 
Estimates for the antagonist AM 251 equilibrium dissociation constant (pKB) were 
calculated using the logarithmic form of the Schild equation; 
 ݌ܭ୆ ൌ ሺܥܴ െ  ?ሻ െ ሾܤሿ 
 
where CR is the concentration ratio of agonist EC50 value in the presence of 
antagonist divide by the agonist EC50 value in the absence of antagonist and [B] is 
the antagonist concentration. 
 
Ehlert (2005) GHVFULEHG D SDUDPHWHU WHUPHG µLQWULQVLF UHODWLYH DFWLYLW\¶ 5$i), 
which has subsequently been used to quantify agonist bias and ligand selectivity at 
GPCRs (Griffin et al., 2007; Ehlert, 2008; Figueroa et al., 2009). A value is 
calculated for each agonist A, relative to a constant standard agonist B, for each 
signalling pathway the agonist couples to, using the following equation; 
 
ܴܣ௜ ൌ ܴ௠௔௫஺ܧܥହ଴஻ܴ௠௔௫஻ ܧܥହ଴஺ 
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where the Rmax is the maximum response of the agonist, defined by the span of the 
concentration-UHVSRQVHFXUYH7KHELDVRIDQDJRQLVWRUǻ5$i, is then defined as 
the fold difference between two RAi values. 
 
3.3.7. Statistics 
The quantitative data are expressed as mean ± SEM, obtained from at least three 
independent experiments performed in triplicate, unless otherwise stated. 
1RUPDOLW\ RI GDWD VHWV ZDV GHWHUPLQHG XVLQJ WKH '¶$JRVWLQR-Pearson omnibus 
normality test. 6WDWLVWLFDOVLJQLILFDQFHRIGLIIHUHQFHVZDVGHWHUPLQHGE\6WXGHQW¶V
paired or unpaired, two-tailed t-tests or one-way ANOVA followed by 'XQQHWW¶V
multiple comparison post-hoc tests, where appropriate. Statistical comparison of 
pKB values was using two-way ANOVA. A p value of <0.05 was considered 
significant. 
 
3.4. Results 
3.4.1. Determination of the affinity on cannabinoid CB1 receptors 
The occupancy of a number of cannabinoid ligands from several distinct chemical 
groups at human cannabinoid CB1 receptors expressed in transfected CHO cells 
was investigated to characterise the receptor population present in the cell line, 
and to provide comparison data for subsequent functional experiments. This was 
done by measuring the displacement of [3H]-CP 55,940 specific binding at 
equilibrium in CHO-hCB1 receptor membranes (Figure 3.1). The data were used 
to determine the affinity (expressed as pKi), and the co-operativity (curve slope, or 
nH) as summarised in Table 3.1. The rank order of affinity for the ligands was; 
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HU-!&3!$0!ǻ9-THC > WIN 55,212-PHWKDQDQGDPLGH!
fenofibrate > anandamide.  
 
 
Figure 3.1 Effects of cannabinoid ligands on [3H]-CP 55,940 binding on human 
CB1 receptors expressed in CHO cells. Experiment was performed as stated in the 
methods (see 3.3.2). The data shown represent mean ± SEM values from 3 
independent experiments performed in triplicate. The curves were fitted using 
GraphPad Prism. 
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Table 3.1. Determination of the affinity (pKi) and the co-operativity (nH) of 
cannabinoid ligands on human cannabinoid CB1 receptors expressed in 
transfected CHO cell membranes. 
 Ligand pKi nH 
 HU-210 9.4 ± 0.1 2.2 ± 0.4 
 CP 55,940 9.0 ± 0.1 1.1 ± 0.1 
 WIN 55,212-2 7.8 ± 0.1 1.1 ± 0.2 
 ǻ9-THC 8.2 ± 0.1 2.7 ± 0.7 
 Anandamide 5.9 ± 0.1 0.9 ± 0.3 
 Methanandamide 7.3 ± 0.5 0.9 ± 0.2 
 AM 251 8.3 ± 0.2 1.0 ± 0.2 
 Fenofibrate 6.3 ± 0.1 1.8 ± 0.7 
 Data shown are mean values ± SEM from three separate experiments. 
 3.4.2. Determination of ERK phosphorylation 
3.4.2.1. Assay Optimisation 
No prior comprehensive protocol had been established in-house for the use of the 
In-Cell Western assay, a fluorescence immunocytochemical-based technique, to 
quantify receptor-mediated changes in MAP kinase phosphorylation; therefore it 
was necessary to optimise the assay for use in this, and subsequent chapters. 
 
Reduction of edge effect 
Preliminary experiments revealed a clearly visible edge effect present on the assay 
plates when scanned (Figure 3.2A). Cells in the outer wells of the plate appeared 
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to be localised towards the outer peripheral well edge. Pre-incubation at room 
temperature for 1 hour immediately after seeding and prior to moving to the 
incubator markedly decreased the visible edge effect (Figure 3.2B). 
 
The mean total-ERK signal intensity values for each column of plate A had a 
range of 39.1 to 48.4, with the lowest values at the outer rows A and H (41.9 and 
39.1 respectively) and increasing towards the centre row (Figure 3.2C Ɣ
corresponding to the pattern of the visible edge effect. The mean total-ERK values 
for plate B had a markedly smaller range of 49.0 to 50.2 with little difference 
between each row (Figure 3.2C Ƒ &RPSDULVRQ RI WKH FRHIILFLHQW RI YDULDQFH
(%CV) for each column and row on both plates show the mean %CV was 
significantly lower after pre-incubation at room temperature for 1 hour (Table 3.2; 
paired, two-tailed t-test, column ± p<0.0001; row ± p<0.002,). 
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Figure 3.2 Pre-incubation at room temperature for 1hr decreases edge-effect. 
Composite (700 and 800nm) image of 96-well plate seeded with 40,000 cells/well 
were placed either (A) immediately into 37°C incubator, or (B) pre-incubated for 
60 min at room temperature (21±1°C), prior to incubation at 37°C. Images show 
cells cultured for 48 hours, fixed and labelled with ERK polyclonal antibodies. C - 
Row mean signal intensity values for total-ERK signal (700nm) for plates either 
SODFHGGLUHFWHGLQWRLQFXEDWRUƔRUSUH-incubated at room temperature for 1 hour 
Ƒ 'DWD VKRZQ DUH PHDQ UHSOLFDWH Q  YDOXHV  6(0 IURP D VLQJOH
experiment. 
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Table 3.2 
Coefficient of variance (% CV) values for plate columns and mean %CV values for 
plate rows and columns 
 coefficient of variance (%CV) 
 A B C D E F G H Column 
mean 
Row 
mean 
No pre-
incubation 
(Fig. 3.2A)  
3.0
6 
11.
52 
5.7
9 
10.
01 
4.6
7 
3.0
3 
4.1
4 
5.3
0 
5.94 8.70 
1 hr pre-
incubation 
(Fig. 3.2B) 
4.2
6 
2.7
8 
3.7
7 
6.3
6 
4.8
0 
5.1
7 
4.6
9 
3.4
0 
4.40 
**** 
2.87 
** 
Data shown are values from a single experiment 
****p<0.0001; **p<0.002, paired, two-tailed t-test 
 
Cell Seeding Density 
The cannabinoid agonist HU-210 produced a phospho-ERK response at all cell 
seeding densities tested (Figure 3.3A) with no significant differences. However, 
the basal level of ERK phosphorylation for 40,000 cells/well was markedly lower 
than for the other seeding densities (Figure 3.3A). This cell number corresponded 
closest to 100% confluency. When the HU-210 response was expressed as % basal 
ERK phosphorylation 40,000 cell/well gave the largest response, which was 
significantly greater than the response at 60,000 cells/well (Figure 3.3B; one-way 
ANOVA, p<0.05). 
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Figure 3.3 Effect of cell seeding density expressed as normalised data (A) 
showing values for basal (white) and HU-210-stimulated (grey) ERK 
phosphorylation, and as % basal phosphorylation (B). Data shown are mean 
triplicate values ± SEM. Statistical significance was determined using one-way 
ANOVA, *p<0.05. 
 
Optimisation of primary antibody dilutions 
All dilutions of total-ERK and phospho-ERK antibody tested produced a signal 
greater than that observed in the absence of the appropriate primary antibody i.e. 
non-specific binding (NSB) of the secondary antibody. For the total-ERK 
antibody, there was a significant increase in signal intensity at 1:200, 1:100 and 
1:50 (Figure 3.4A; one-way ANOVA, *p<0.5, ***p<0.0001,). The signal 
intensity at all four antibody dilutions were significantly different from each other 
except for 1:100 and 1:50 where there was no significant difference (Figure 3.4A; 
one-way ANOVA, p>0.05).  
 
For the phospho-ERK antibody, the signal intensity for both the basal phospho-
ERK levels and the elevated HU-210 stimulated levels were measured, to allow 
the calculation of the % basal response. For the HU-210 response, there was a 
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significant increase in the signal intensity compared to the NSB value for all four 
antibody dilutions (and the signal intensity at 1:50 antibody dilution was 
significantly different from that for 1:400 and 1:200 (Figure 3.4B; one-way 
ANOVA, p<0.0001). 
 
 
Figure 3.4 Optimisation of primary antibody concentration. Cells were 
incubated with various dilutions of (A) total ERK- and (B) phospho-ERK primary 
antibody. Blocking solution without primary antibody was included for both 
antibodies as a measure of the non-specific binding (NSB) of the secondary 
antibody. Data shown are mean values ± SEM. Statistical significance was 
determined using one-way ANOVA, *p<0.05. Values are significant relative to 
the corresponding NSB value. 
 
To determine the potential effect of altering antibody dilution on the magnitude of 
the response when expressed as % basal phospho-ERK level, the mean signal 
intensity values for each phospho-ERK antibody dilution were normalised against 
the mean values for each total-ERK antibody dilution (Table 3.3). As the 
phospho-ERK antibody concentration decreased, the magnitude of the response 
increased, indicating increased assay sensitivity. In contrast, the dilution of the 
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total-ERK antibody had no impact on the magnitude of the response. However, as 
the antibody concentration decreased, the %CV of the signal intensities increased, 
for all three conditions (Table 3.3), indicating that the variation within the assay 
increased as the antibody dilution increased. 
 
Table 3.3 
Representative normalised data (phospho-/ total-ERK), expressed as % of the 
basal response, and associated coefficient of variance (% CV: italics) values, for 
various dilutions of the phospho- and total ERK primary antibodies  
 Phospho-ERK (1:x) 
400 200 100 50 
 % CV 18.3 11.4 11.0 5.2 
Total-
ERK 
(1:x) 
400  15.6 196 184 162 140 
200 16.7 196 184 162 140 
100 4.8 196 184 162 140 
50 2.1 196 184 162 140 
 
Effects of apyrase 
Preliminary experiments showed that the addition of vehicle (assay buffer 
containing 1 mg/ml BSA) without any agonist present was able to elicit a 
phospho-ERK response. It was suggested that this effect might be due to 
endogenous ATP release; therefore, the inclusion of apyrase, an ATPase, was 
investigated to test this hypothesis. Incubation with 2 units/ml apyrase for 30 min 
was able to significantly decrease the basal level of ERK phosphorylation (Figure 
3.5A; paired, two-tailed t-test, **p<0.05).  
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Cells were then stimulated over a 20 min time course with the addition of HU-210 
(1 µM), vehicle (assay buffer) and exogenous ATP (10 µM), in the presence and 
absence of apyrase, and the area under the response curve plotted (Figure 3.5B). 
Apyrase significantly decreased the response to vehicle and ATP addition, while 
the response for HU-210 was not significantly affected (Figure 3.5B; paired, two-
tailed t-test, *p<0.05, **p<0.01). 
 
Finally the effect of apyrase on a HU-210 concentration-response curve, at 5 min 
agonist incubation, was investigated. Apyrase did not have any significant effect 
on the HU-210 concentration-response curve; however it did cause a reduction in 
basal and vehicle addition response and a related increase in the slope of the 
concentration response curve (Figure 3.5C; nH without apyrase± 1.48, 2 units/ml - 
2.09). 
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Figure 3.5 Effect of apyrase on phospho-ERK response. A ± Basal ERK phosphorylation in the absence (white bar), or presence (grey bar) of 2 
units/ml apyrase incubation for 30 min.  B ± Phospho-ERK response upon stimulation by HU-210 (1 µM), vehicle and exogenous ATP (1 µM) 
over a 20 min time course, expressed as the area under the curve (AUC). C ± HU-210 concentration response curve at 5 min in the absence and 
presence of 2 units/ml apyrase. Individual ERK phosphorylation values were normalised to the corresponding total-ERK values.  Data shown are 
mean ± SEM values from three independent experiments performed in duplicate. *p<0.05, **p<0.01, paired, two-tailed t-test. 
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3.4.2.2. Effect of cannabinoid agonists on ERK phosphorylation ± time 
course 
CHO-hCB1 cells were treated with high concentrations (10 µM) concentrations of 
the cannabinoid agonists HU-210, CP 55,940, WIN 55,212- ǻ9-THC, 
anandamide, methanandamide, arachidonyl-2'-chloroethylamide (ACEA) and 
fenofibrate at various time points (2 ± 60 min), and the phospho-ERK responses 
measured. This temporal characterisation allowed for determination of the 
optimum agonist stimulation period for subsequent concentration-response 
experiments as well as providing the means to identify any multiphasic responses. 
All agonists produced a rapid increase in phospho-ERK levels, with a maximum 
response achieve between 4 ± 6 min (Figure 3.6). After this time period, the 
phospho-ERK levels steadily decreased to reach near-basal levels by 20 min. 
From 20 min onwards, the HU-210 and CP 55,940 responses showed a gradual 
increase up to 60 min, while the response for the other agonists remained constant. 
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Figure 3.6 Effect of cannabinoid agonists on ERK phosphorylation in CHO-hCB1 
cells against time. Cells (40,000 cells/well) were cultured in medium for 24 hr, 
followed by serum starvation for 24 hr. Cells were stimulated with cannabinoid 
agonists (10 µM) at various time points (2 ± 60 min), followed by rapid fixation 
with PFA solution. Detection of total and phospho-ERK levels was as stated in 
methods (see 3.3.5). Individual ERK phosphorylation values were normalised to 
the corresponding total-ERK values. The data shown are mean ± SEM values from 
3 independent experiments performed in duplicate. 
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Next, the experiments were repeated in cells pre-treated with pertussis toxin (100 
ng/ml), to determine the role of Gi/o protein in the cannabinoid-mediated phospho-
ERK response, and whether any alternative Gi/o protein-independent signalling 
could be identified. PTX was able to completely abolish all cannabinoid-mediated 
responses across the 60 min time course (Figure 3.7). 
 
 
Figure 3.7 Effects of cannabinoid agonists on ERK phosphorylation in pertussis 
toxin-treated CHO-hCB1 cells over time. Cells (40,000 cells/well) were cultured in 
medium for 24 hr, followed by serum starvation for 24 hr in medium containing 
100 ng/ml PTX. Cells were stimulated with cannabinoid agonists (10 µM) at 
various time points (2 ± 60 min), followed by rapid fixation with PFA solution. 
Detection of total and phospho-ERK levels was as stated in methods (see 3.3.5). 
Individual ERK phosphorylation values were normalised to the corresponding 
total-ERK values. The data shown are mean ± SEM values from 3 independent 
experiments performed in duplicate. 
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A series of extended (5 ± 360 min) time-course experiments were performed to 
further investigate the gradual second phase increases in phospho-ERK levels seen 
with CP 55,940. All four agonists tested (HU-210, CP 55,940, WIN 55,212-2 and 
methanandamide) produced a significant increase in phospho-ERK levels at 5 min, 
corresponding to the peak of the response seen previously (Figure 3.8). Both CP 
55,940 and HU-210 produced a second, late phase with a peak at 90 min (CP - 184 
±1). The methanandamide-induced response returned to a near basal level 60 min 
after stimulation, while WIN 55,212-2 produced a sustained decrease in phospho-
ERK levels with a profile distinct from those of CP 55,940 and HU-210 responses 
(~35 % basal response). At 180 min onwards, HU-210 caused cells to exhibit an 
atypical morphology, as well as causing a reduction in total-ERK levels, indicative 
of a cytotoxic effect (data not shown); therefore the data was not considered 
further. This effect was not observed with the other agonists tested. Overnight 
treatment of cells with PTX (100 ng/ml) was again used to determine the role of 
Gi/o protein in the late-phase signal for CP 55,940. PTX was able to completely 
abolish both the initial and late phase phospho-ERK responses for CP 55,940 
(Figure 3.8¸V\PERO). 
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Figure 3.8 Effect of cannabinoid agonists on ERK phosphorylation in CHO-hCB1 
cells over time. Cells (40,000 cells/well) were cultured in medium for 24 hr, 
followed by serum starvation for 24 hr, with PTX where appropriate (100 ng/ml). 
Cells were stimulated with cannabinoid agonists (10 µM) at various time points (5 
± 360 min), followed by rapid fixation with PFA solution. Detection of total and 
phospho-ERK levels was as stated in methods (see 3.3.5). Individual ERK 
phosphorylation values were normalised to the corresponding total-ERK values. 
The data shown are mean ± SEM values from 3 independent experiments 
performed in duplicate. 
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3.4.2.3. Effects of cannabinoid agonists on ERK phosphorylation ± 
concentration-response. 
Initially, a stimulation period of 5 min was chosen for cannabinoid concentration-
response experiments, representing the peak of the first phase response. All 
agonists produced a concentration-dependent increase in phospho-ERK levels 
(Figure 3.9). Higher concentrations of fenofibrate produced a clear decrease in the 
phospho-ERK response, generating an atypical bell-shaped concentration-response 
curve. It was, therefore, excluded from curve fitting. The rank order of potency 
(pEC50 values) of the agonists acting on CHO-hCB1 cells from highest to lowest 
was HU-  &3  ! ǻ9-7+& ! $&($  :,1 -2 > 
methanandamide  anandamide (Table 3.4). There were some significant 
differences in the agonist Rmax values. The Rmax YDOXH IRU ǻ9-THC was 
significantly lower than that for HU-210 and ACEA, while the Rmax value for 
methanandamide was significantly lower than that for HU-210 (Table 3.4; one-
way ANOVA; p<0.05). To confirm the role of the CB1 receptor in the cannabinoid 
agonist responses, the concentration-response experiments were repeated in the 
presence of the CB1-selective competitive antagonist AM 251 (10 nM). AM 251 
produced a significant rightwards shift of all the agonist concentration-response 
curves, resulting in significant decreases in all the pEC50 values (two-way 
ANOVA; p<0.05). These data were used to estimate the equilibrium dissociation 
constant for AM 251 (pKB) in the presence of each individual agonist (Table 3.4).  
There was no significant difference between the pKB values, except for the value 
GHWHUPLQHG XVLQJ ǻ9-THC, which was significantly greater than that determined 
using anandamide (Table 3.4; one-way ANOVA; p<0.01). 
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Figure 3.9 Effect of cannabinoid agonists on ERK phosphorylation in CHO-hCB1 
cells. Cells (40,000 cells/well) were cultured in medium for 24 hr, followed by 
serum starvation for 24 hr. Cells were stimulated with various concentrations of 
cannabinoid agonists for 5 min, followed by rapid fixation with cold PFA solution 
(4 % w/v). Detection of total and phospho-ERK levels was as stated in methods 
(see see 3.3.5). Individual ERK phosphorylation values were normalised to the 
corresponding total-ERK values. The data shown represent mean ± SEM values 
from 3-4 independent experiments performed in duplicate. The curves were fitted 
using GraphPad Prism. Dashed lines indicate that the data were not curve-fitted. 
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Table 3.4 
Determination of potency (pEC50), percentage of basal maximal response (Rmax), 
curve slope (nH) and estimated AM 251 dissociation constant (pKB) of 
cannabinoid agonists on ERK phosphorylation in CHO-hCB1 cells. 
Agonists pEC50 Rmax nH pKB 
HU-210 9.3 ± 0.3 172 ± 18 1.0 ± 0.1 9.4 ± 0.2 
CP 55,940 9.1 ± 0.3 143 ± 18 0.8 ± 0.1 9.5 ± 0.2 
WIN 55,212-2 7.5 ± 0.4 142 ± 9 1.2 ± 0.1 9.4 ± 0.2 
ǻ9-THC 8.6 ± 0.1 82 ± 7bc 1.3 ± 0.2 9.9 ± 0.1 
Anandamide 6.6 ± 0.2 143 ± 1 0.9 ± 0.2 8.9 ± 0.1 
Methanandamide 6.7 ± 0.8 108 ± 7b 1.0 ± 0.3 9.1 ± 0.2 
ACEA 7.6 ± 0.1 157 ± 3 1.5 ± 0.1a 9.7 ± 0.1 
Data shown are mean ± SEM values from 3-4 independent experiments performed 
in duplicate. 
a
 nH value significantly difference from unity (nH = 1). Unpaired t-test; p<0.05 
b
 value significantly less than that for HU-210. One-way ANOVA; p<0.05 
c
 value significantly less than that for ACEA. One-way ANOVA; p<0.05 
 
Concentration-response experiments using CP 55,940, with a stimulation period of 
60 min were then performed to more fully characterise the nature of the second-
phase response. CP 55,940 produced a concentration-dependent response best 
fitted by a biphasic concentration-response curve as determined by a F sum-of-
squares test, with pEC50 values of 9.0 ± 0.2 and 4.5 ± 0.4 for the high and low 
potency responses respectively (Figure 3.10). Inhibition with a high concentration 
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of AM 251 (1 µM) appeared to abolish the high potency response, but had no 
observable impact on the low potency response (pEC50 ± 5.3 ± 0.1). 
 
 
Figure 3.10 Effect of CP 55,940 on ERK phosphorylation in CHO-hCB1 cells. 
Cells (40,000 cells/well) were cultured in medium for 24 hr, followed by serum 
starvation for 24 hr. Cells were stimulated with various concentrations of CP 
55,940 for 1 hr, followed by rapid fixation with cold PFA solution (4 % w/v). 
Detection of total and phospho-ERK levels was as stated in methods (see see 
3.3.5). Individual ERK phosphorylation values were normalised to the 
corresponding total-ERK values. The data shown represents mean ± SEM values 
from 3 independent experiments performed in duplicate. The most appropriate 
curve was determined by an extra sum-of-squares F test and fitted using GraphPad 
Prism. 
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3.4.3. Determination of JNK1/2/3 phosphorylation 
The cannabinoid agonists were tested for their potential to promote JNK1/2/3 
phosphorylation. The positive control, hydrogen peroxide (H2O2; 5 mM), 
produced a significant increase in phospho-ERK levels between 5 and 25 min 
(Figure 3.11; one-way ANOVA p<0.0001). None of the cannabinoid agonists 
tested significantly increased the phospho-JNK response above the basal level 
(Figure 3.11; one way ANOVA; p>0.05). 
 
3.4.4. Determination of p38 phosphorylation 
The cannabinoid agonists were tested for their potential to promote p38 MAP 
kinase phosphorylation. The positive control hydrogen peroxide (H2O2; 5 mM) 
produced a clear increase in phospho-p38, which was significantly greater than the 
basal from 50 min onwards (Figure 3.12; one-way ANOVA p<0.0001). None of 
the cannabinoid agonists tested were able to significantly increase the phospho-
p38 response above the basal (Figure 3.12; one way ANOVA; p>0.05). 
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Figure 3.11 Effects of cannabinoid agonists on JNK phosphorylation in CHO-
hCB1 cells against time. Cells (40,000 cells/well) were cultured in medium for 24 
hr, followed by serum starvation for 24 hr. Cells were stimulated with cannabinoid 
agonists (10 µM) or hydrogen peroxide (5 mM) at various time points (2.5 ± 60 
min), followed by rapid fixation with PFA solution. Detection of total and 
phospho-JNK1/2/3 levels was as stated in methods (see 3.3.5). Individual JNK 
phosphorylation values were normalised to the corresponding total-JNK values. 
The data shown are mean ± SEM values from 3 independent experiments 
performed in duplicate. 
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Figure 3.12 Effects of cannabinoid agonists on p38 MAP kinase phosphorylation 
in CHO-hCB1 cells against time. Cells (40,000 cells/well) were cultured in 
medium for 24 hr, followed by serum starvation for 24 hr. Cells were stimulated 
with cannabinoid agonists (10 µM) or hydrogen peroxide (5 mM) at various time 
points (2.5 ± 60 min), followed by rapid fixation with PFA solution. Detection of 
total and phospho-p38 levels was as stated in methods (see 3.3.5). Individual p38 
phosphorylation values were normalised to the corresponding total-p38 values. 
The data shown are mean ± SEM values from 3 independent experiments 
performed in duplicate. 
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3.4.5. cAMP accumulation 
Assay Optimisation 
A preliminary experiment was performed to determine the optimal cell seeding 
density and concentration of forskolin for use in subsequent cAMP assays (Figure 
3.13). Forskolin produced a concentration-dependent increase in intracellular 
cAMP levels at all cell seeding densities tested. There was no apparent effect of 
the cell number on the span of the forskolin concentration-response. However, 
there was an apparent modest leftward shift in the concentration-response curve 
with increasing cell number, as well as a modest increase in the basal cAMP 
levels. 
 
On the basis of these results, a cell seeding density of 20,000 cells/well and a 
forskolin concentration of 10 µM, as corresponding to the pEC80, were chosen as 
optimised conditions for all subsequent experiments.  
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Figure 3.13 Optimisation of cAMP assay in CHO-hCB1 cells. Cells (20, 40 and 
80,000 cells/wells) in suspension in serum-free medium were pre-treated with 
rolipram for 10 min before incubation with increasing concentrations of forskolin 
(1 nM ± 100 µM) for 30 min at room temperature. At the end of the incubation, 
the assay was terminated by the addition of lysis buffer, and the relative levels of 
cAMP determined using the HitHunter assay kit. The data shown represent a 
single experiment performed in duplicate and is given as the mean ± SEM value. 
The curves were fitted using GraphPad Prism. 
 
Inhibition of forskolin-stimulated cAMP accumulation 
CHO-hCB1 cells treated with forskolin and the phosphodiesterase PDE4 inhibitor 
rolipram (both 10 µM), were stimulated with increasing concentrations of the 
cannabinoid agonists to determine the ability of these compounds to inhibit 
forskolin-stimulated cAMP accumulation (Figure 3.14). All agonists produced a 
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concentration-dependent inhibition of forskolin-stimulated cAMP accumulation. 
The rank order potency (pEC50 values) of the agonists acting on CHO-hCB1 cells 
from highest to lowest was HU-  &3  ! ǻ9-THC > ACEA  :,1
55,212-  PHWKDQDQGDPLGH ! DQDQGDPLGH  IHQRILEUDWH 7KH 5max RI ǻ9-THC 
was significantly less than for HU-210 and CP 55,940 (one-way ANOVA; 
p 7UHDWPHQW ZLWK  0 ǻ9-THC, produced an atypical enhancement of 
cAMP accumulation in all experiments (124 ± 15 %), which was not significantly 
affected by AM 251 (10 nM; 130 ± 19 %). As this was indicative of a distinct 
(non-CB1) signalling mechanism, the data points derived from the highest 
concentrations were excluded from the concentration-response curve fitting. 
 
To confirm the role of the CB1 receptor in the cannabinoid agonist responses, the 
concentration-response experiments were repeated in the presence of the CB1-
selective competitive antagonist AM 251 (10 nM). AM 251 produced a rightward 
shift of all the agonist concentration-response curves, resulting in significant 
decreases in all the pEC50 values (two-way ANOVA; p<0.05). These data were 
used to estimate the equilibrium dissociation constant for AM 251 (pKB) in the 
presence of each individual agonist (Table 3.5).  There was no significant 
difference between the pKB values, except for the value determined using ACEA, 
which was significantly less than that determined using HU-210 and CP 55,940 
(one-way ANOVA; p<0.01). 
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Figure 3.14 Effect of cannabinoid agonists on cAMP accumulation in CHO-hCB1 
cells. Cells in suspension in serum-free medium were pre-treated with forskolin 
and rolipram (both 10 µM) for 10 min before incubation with increasing 
concentrations of cannabinoid agonists for 30 min at room temperature. At the end 
of the incubation period, the assay was terminated by the addition of lysis buffer 
and the relative levels of cAMP determined using the HitHunter assay kit. The 
data shown represent mean ± SEM values from 4 individual experiments 
performed in triplicate. The curves were fitted using GraphPad Prism. 
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Table 3.5 
Determination of potency (pEC50), percentage of basal maximal response (Rmax), 
curve slope (nH) and estimated AM 251 dissociation constant (pKB) of 
cannabinoid agonists on inhibition of forskolin-stimulated cAMP accumulation in 
CHO-hCB1 cells. 
Agonists pEC50 Rmax nH pKB 
HU-210 10.3 ± 0.2 47 ± 4 -1.6 ± 0.8 9.5 ± 0.3 
CP 55,940 9.9 ± 0.1 48 ± 9 -1.0 ± 0.3 9.4 ± 0.1 
WIN 55,212-2 7.6 ± 0.1 43 ± 8 -1.6 ± 0.3 9.3 ± 0.1 
ǻ9-THC 8.8 ± 0.2 23 ± 11b -1.4 ± 0.6 9.6 ± 0.3 
Anandamide 6.7 ± 0.3 28 ± 7 -1.8 ± 0.7 8.9 ± 0.3 
Methanandamide 7.4 ± 0.2 37 ± 9 -1.6 ± 1.0 9.2 ± 0.1 
ACEA 8.1 ± 0.3 28 ± 10 -1.1 ± 0.3 8.5 ± 0.2 
fenofibrate 6.4 ± 0.1 33 ± 5 -1.7 ± 0.1a 9.1 ± 0.1 
Data shown are mean ± SEM values from 4 independent experiments performed 
in triplicate. 
a
 nH value significantly difference from unity (nH = -1); unpaired t-test, p<0.05. 
b
 significantly less than that for HU210 and CP 55,940; one-way ANOVA, p<0.05 
 
The experiments were then repeated using cells which had been pre-treated with 
PTX (100ng/ml) and in the absence of forskolin, to determine the role of Gi/o 
protein in the cannabinoid-mediated cAMP response, and whether any alternative 
Gi/o protein-independent signalling could be identified. As before, forskolin 
produced a concentration-dependent increase in intracellular cAMP levels. None 
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of the cannabinoid agonists tested produced any significant effect on the cAMP 
levels (Figure 3.15). 
 
 
Figure 3.15 Effect of cannabinoid agonists on cAMP accumulation in pertussis 
toxin-treated CHO-hCB1 cells. Cells in suspension in serum-free medium were 
pre-treated with PTX (100 ng/ml) overnight and rolipram (10 µM) for 10 min 
before incubation with increasing concentrations of cannabinoid agonists for 30 
min at room temperature. At the end of the incubation period, the assay was 
terminated by the addition of lysis buffer and the relative levels of cAMP 
determined using the HitHunter assay kit. The data shown represents mean ± SEM 
values from 3 individual experiments performed in triplicate. The curves were 
fitted using GraphPad Prism. 
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3.4.6. ȕ-arrestin recruitment 
7KH FDQQDELQRLG DJRQLVWV ZHUH WHVWHG IRU WKHLU DELOLW\ WR SURPRWH ȕ-arrestin 
recruitment to the CB1 receptor using thH 3DWK+XQWHU ȕ-arrestin assay. All 
agonists produced a concentration-GHSHQGHQWLQFUHDVHLQȕ-arrestin recruitment as 
measured by an increase in chemiluminescent signal, which was then expressed as 
a % of the maximum HU-210 response (Figure 3.16). Higher concentrations of 
fenofibrate produced a clear decrease in the phospho-ERK response, producing an 
atypical bell-shaped concentration-response curve. It was, therefore, excluded 
from curve fitting. The rank order of potency (pEC50 values) of the agonists acting 
on CHO-hCB1 cells from highest to lowest was HU-&3!ǻ9-THC > 
WIN 55,212-$&($PHWKDQDQGDPLGHDQDQGDPLGHTable 3.6). There was 
significant difference between the Rmax values for the various agonists, in 
SDUWLFXODU ǻ9-THC, anandamide and methanandamide were significantly less 
efficacious than HU-210, CP 55,940 and WIN 55,212-2, while ACEA was a 
partial agonist, relative to HU-210 only (Table 3.6; one-way ANOVA; p<0.0001). 
 
To confirm the role of the CB1 receptor in the cannabinoid agonist responses, the 
concentration-response experiments were repeated in the presence of the CB1-
selective competitive antagonist AM 251 (10 nM). AM 251 produced a rightward 
shift of all the agonist concentration-response curves, resulting in significant 
decreases in all the pEC50 values, except HU-210 (two-way ANOVA; p<0.01). 
These data were used to estimate the equilibrium dissociation constant for AM 
251 (pKB) in the presence of each individual agonist (Table 3.6).  There was no 
significant difference between the pKB values, except for the value determined 
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using HU-210, which was significantly less than that determined using all other 
agonists, except WIN 55,212-2 (one-way ANOVA; p<0.01). 
 
Figure 3.16 (IIHFWRIFDQQDELQRLGDJRQLVWVRQȕ-arrestin in CHO-hCB1 cells. Cells 
(20,000 cells/well) were cultured in medium for 24 hr, before incubation with 
increasing concentrations of cannabinoid agonists for 90 min at 37°C. At the end 
of the incubation period, the assay was terminated by the addition of 
l\VLVGHWHFWLRQ EXIIHU DQG WKH UHODWLYH OHYHOV RI UHFHSWRU ȕ-arrestin recruitment 
measured using the PathHunter detection kit. The data shown represents mean ± 
SEM values from 3 individual experiments performed in triplicate. The curves 
were fitted using GraphPad Prism. Dashed lines indicate that the data were not 
curve-fitted.  
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Table 3.6 
Determination of potency (pEC50), percentage of basal maximal response (Rmax), 
curve slope (nH) and estimated AM 251 dissociation constant (pKB) of 
cannabinoid agonists on ȕ-arrestin recruitment in CHO-hCB1 cells. 
Agonists pEC50 Rmax nH pKB 
HU-210 8.8 ± 0.1 103 ± 4 1.0 ± 0.1 8.3 ± 0.1 
CP 55,940 8.5 ± 0.1 93 ± 9 0.7 ± 0.1a 9.1 ± 0.2 
WIN 55,212-2 6.6 ± 0.2 94 ± 8 0.7 ± 0.1a 8.8 ± 0.1 
ǻ9-THC 7.6 ± 0.2 49 ± 5b 0.8 ± 0.3 9.2 ± 0.1 
Anandamide 5.5 ± 0.1 62 ± 3b 0.9 ± 0.1 9.1 ± 0.1 
Methanandamide 6.5 ± 0.1 64 ± 7b 1.1 ± 0.1 9.1 ± 0.1 
ACEA 6.5 ± 0.2 72 ± 2c 0.8 ± 0.1 9.4 ± 0.1 
Data shown are mean ± SEM values from 3 independent experiments performed 
in triplicate. 
a
 nH value significantly difference from unity (nH = 1). ); unpaired t-test, p<0.05. 
b
 value significantly less than that for HU-210, CP 55,940 and WIN 55,212-2; 
one-way ANOVA, p<0.0001 
c
 value significantly less than that for HU-210 only; one-way ANOVA, p<0.05. 
 
3.4.7. Analysis of agonist bias 
In an effort to graphically represent the agonist bias present at the CB1 receptor, a 
series of bias plots were produced. The datasets for each pathway were first 
expressed as a % of the HU-210 response, to allow for direct comparison between 
pathways. Then, the response of an agonist in one pathway was expressed as a 
function of the response in another pathway for equimolar concentrations of 
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agonist, producing a correlation plot (Figure 3.17). When the curves deviate from 
unity, this indicates that an agonist produces a relatively higher response in one 
pathway over the other. Differences between the curves for two agonists provide a 
graphical representation of their bias for a particular pathway or pathways relative 
WRHDFKRWKHU'XH WR WKHDW\SLFDOQDWXUHRI WKH(5.DQGȕ-arrestin responses to 
fenofibrate, it was not included in this analysis. Of particular note, anandamide 
and ACEA appear to exhibit a clear bias towards ERK phosphorylation, relative to 
the other agonists. 
 
Next, to quantify the agonist bias present at the CB1 receptor, intrinsic relative 
activity (RAi) values were calculated for all agonists except fenofibrate. The RAi 
values were calculated using HU-210 as the reference agonist, as opposed to the 
endogenous ligand anandamide, as anandamide did not produce a clear response 
from which to derive curve parameters in all experiments (Table 3.7). In 
particular, WIN 55,212-ǻ9-THC, anandamide and ACEA all exhibited at least a 
10-fold bias for ERK phosphorylation versus inhibition of cAMP accumulation, 
compared to HU-210. These parameters were then plotted on a histogram, to allow 
for easier interpretation (Figure 3.18). 
 
As previously highlighted, while all responses appeared to be sensitive to 
antagonism by AM 251, there was significant variation in the calculated pKB 
values, dependent on the agonist and signalling pathway involved. In an effort to 
graphically represent this variation, the individual pKB values from one signalling 
pathway were plotted against the respective values from another signalling 
pathway, akin to the bias plots previously described for the agonist responses 
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(Figure 3.19). The majority of the agonists exhibited no preference for one 
signalling pathway over the other, with the clear exceptions of HU-210 which was 
significantly less susceptible to AM251 antagonism (i.e. lower pKB value) in the 
ȕ-arrestin assay, compared to both ERK and cAMP (two-way ANOVA; 
p<0.0001), and ACEA which was significantly less antagonised in the cAMP 
assay compared to the other two effector systems (two-way ANOVA; p<0.01). 
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Figure 3.17 Bias plots for ERK phosphorylation, inhibition of forskolin-VWLPXODWHGF$03DFFXPXODWLRQ DQGȕ-arrestin recruitment in CHO-
hCB1 cells. Curves represent responses for the two respective pathways at equivalent concentrations of agonist. Divergence from unity 
represents agonist pathway selectivity, while divergence between curves in each plot represents agonist bias. Data is expressed as a % of HU-
210 response, and represents mean values from 3-4 independent experiments. Curves of best fit were fitting using GraphPad Prism.
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Table 3.7 'HWHUPLQDWLRQRILQWULQVLFUHODWLYHDFWLYLWLHV5$LDQGFRPSDULVRQRI5$LYDOXHVǻ5$LIRUFDQQDELQRLGDJRQLVWVDFWLQJDWhuman CB1 receptors 
expressed in CHO cells. 
agonist RAi ǻ5$L 
ERK cAMP ȕ-arrestin ERK v cAMP ȕ-arrestin v cAMP  ERK v ȕ-arrestin 
CP 55,940 7.36 ± 2.61 
(x10-1) 
3.83 ± 1.91 
(x10-1) 
4.69 ± 0.67 
(x10-1) 
1.9 1.2 1.6 
WIN 55,212-02 2.09 ± 0.55 
(x10-2) 
2.01 ± 0.78 
(x10-3) 
6.14 ± 1.19 
(x10-3) 
10.4a 3.1 3.4 
ǻ9-THC 8.04 ± 1.49 
(x10-2) 
8.79 ± 6.42 
(x10-3) 
3.23 ± 1.07 
(x10-2) 
9.1a 3.7 2.5 
Anandamide 1.44 ± 0.16 
(x10-3) 
1.71 ± 0.95 
(x10-4) 
3.29 ± 0.45 
(x10-4) 
8.4a 1.9 4.4 
Methanandamide 4.62 ± 2.30 
(x10-3) 
1.49 ± 1.28 
(x10-3) 
3.24 ± 0.84 
(x10-3) 
3.1 2.2 1.4 
ACEA 3.05 ± 1.57 
(x10-2) 
3.12 ± 1.23 
(x10-3) 
3.79 ± 1.69 
(x10-3) 
9.8a 1.2 8.1a 
RAi values shown are mean ± SEM values from 3-LQGHSHQGHQWH[SHULPHQWVSHUIRUPHGLQWULSOLFDWHǻ5$LYDOXHVDUHFRPSDULVRQRIPHDQ5$L 
a
 GLIIHUHQFHEHWZHHQ WKH WZR5$LYDOXHVVWDWHG LQ WKHFROXPQKHDGHUDVTXDQWLILHGE\ WKHǻ5$LYDOXHDUH VLJQLILFDQWO\GLIIHUHnt, indicating agonist bias 
(unpaired, t-test; p<0.05). 
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Figure 3.18 Comparison of the RAi values of cannabinoid agonists modulating 
ERK, cAMP DQG ȕ-arrestin recruitment responses at human CB1 receptors 
expressed in CHO cells. The data shown represents mean ± SEM values from 3-4 
individual experiments performed in replicate. Statistical significance was 
determined using unpaired, two-tailed t-tests; *p<0.05, **p<0.01. 
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Figure 3.19 Correlation plots for calculated AM 251 (10 nM) pKB values determined via measurement of ERK phosphorylation, inhibition of 
forskolin-stimulated cAMP accuPXODWLRQ DQG ȕ-arrestin recruitment in CHO-hCB1 cells. Divergence from unity (dashed line) represents 
pathway selectivity, while divergence between data points represents difference between agonists. Data points are mean ± SEM values from 3-4 
independent experiments. Statistical significance was determined by two-way ANOVA. *p<0.05; **p<0.01; ****p<0.0001. 
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3.5. Discussion 
The Chinese hamster ovary cell line, stably transfected with human CB1 receptor 
is a well characterised model for investigating CB1-mediated signalling, including 
some reports of agonist bias, and, therefore, was an appropriate model in which to 
study functional selectivity at the CB1 receptor.  
 
To begin with, competition radioligand binding assays were performed with 
membranes derived from CHO-hCB1 cells, using [3H]-CP 55,940. All ligands 
tested were able to inhibit competitively the specific binding of the radioligand in 
a concentration-dependent manner. Both the absolute equilibrium dissociation 
constant values (Ki) and the rank orders of affinity were consistent with previously 
reported values for the CHO-hCB1 receptor (Govaerts et al., 2004).  In particular, 
the Ki value for the CB1-selective antagonist AM 251 was consistent with its 
reported affinity for the CB1 receptor, confirming the presence of CB1 receptors in 
this cell line. These results validate the use of this cell line for functional studies of 
the CB1 receptor, as well as providing reference data with which to compare 
subsequent results. 
 
The first intracellular mediators to be investigated were the extracellular signal-
regulated kinases or ERKs, a family of mitogen-activated protein kinases which 
regulate numerous cellular functions, including gene expression, growth, cellular 
transformation and apoptosis (Pearson et al., 2001). This investigation was 
performed using the In-cell Western assay, a fluorescence immunocytochemical-
based technique in which the target protein is probed with epitope-specific 
antibodies in fixed cultured cells in 96-well plates (Chen et al., 2005; Daigle et al., 
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2008). As this technique had not been used extensively in-house, it was necessary 
to determine its feasibility for measuring signalling in our cell line. Preliminary 
experiments revealed a clearly visible edge effect in the outer wells of the assay 
plate, due to an uneven distribution of cells. Edge effects are a well-recognised 
phenomenon in plate-based assays, and in this instance, they were most likely due 
to thermal gradients across the microplate affecting the cell adherence to the well 
bottom. Lundholt et al. (2003) reported that this effect could be minimised by 
incubating the plates at room temperature. Application of the same methodology 
to the CHO-hCB1 In-Cell Western assay produced a clearly visible reduction in 
the edge effect which resulted in significantly less variation between wells. One 
major caveat of this approach is the potential impact on cell viability. While this 
technique is appropriate for CHO cells, the cell viability at room temperature over 
an hour is likely to vary significantly depending on the cell line used.  
 
Initial testing showed that HU-210 was able to elicit a phospho-ERK response in 
CHO-hCB1 cells after 5 min stimulation. These results are in keeping with 
previous reports of cannabinoid-mediated ERK signalling. Optimisation of the cell 
seeding number showed that 40,000 cells/well gave the lowest basal phospho-
ERK level, and, therefore, the largest response to agonist when expressed as a % 
of the normalised basal response. Interestingly, this cell seeding number produced 
a cell monolayer closest to confluency at the point of experimentation (data not 
shown), while the other cell numbers were either under- or over-confluent. 
 
Optimisation of primary antibody concentration is an important step in assay 
development, which can be seen as a balance between two considerations ± on the 
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one hand determining the lowest effective antibody concentration to minimise the 
costs per assay plate, and on the other, choosing a high enough antibody 
concentration so as to minimise assay variance. Our results show that as the 
phospho-ERK antibody concentration was decreased, the assay sensitivity, i.e. the 
magnitude of the HU-210 response, relative to the basal response, increased. 
However, this was matched by an increase in the variance between assay 
replicates. The total-ERK primary antibody concentration did not have an impact 
on the magnitude of the normalised phospho-ERK response, but as with the 
phospho-ERK antibody, the variance did increase as antibody concentration 
decreased.  
 
All cell lines, including CHOs, endogenously express an array of receptors, many 
of which couple to the ERK signalling pathway, which is why cells must be serum 
starved prior to stimulation with cannabinoid agonists. In addition, many of these 
cell lines produce endogenous ligands for these receptors, resulting in tonic ERK 
activation. In this instance, addition of vehicle to test wells without agonist (as a 
negative control) was able to elicit a phospho-ERK response. Addition of the 
ADP/ATP hydrolase enzyme apyrase was able to inhibit not only this effect, but 
also that due to addition of exogenous ATP, as well as reduce the basal level of 
phospho-ERK in unstimulated cells. These finding strongly indicate the vehicle 
response occurs via an endogenous-nucleotide (presumably ATP/P2Y receptor) 
signalling pathway and inhibition of this pathway is useful for increasing the 
signal to noise ratio of the cannabinoid-mediated response. 
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Time course experiments showed that all the cannabinoid agonists tested were 
able to promote ERK phosphorylation. The temporal profiles for all agonists 
tested were generally similar to each other, as well as being consistent with those 
reported previously in the literature (Daigle et al., 2008; Dalton & Howlett, 2012); 
i.e. phospho-ERK levels increased rapidly upon stimulation with agonist, reaching 
a peak between 4 - 8 min, after which they steadily returned to near basal levels 
after 15 min. The exceptions to this pattern were HU-210 and CP 55,940, which 
both showed a modest second phase increase from 30 min onwards. Extension of 
the time course to 360 min confirmed that these two agonists did indeed promote a 
delayed-phase ERK response, reaching peak magnitude at 60 ± 90 min. The other 
two agonists tested over the extended time course, WIN and mAEA did not 
produce any second-phase response, indeed WIN produced a clear reduction in 
phospho-ERK levels after 60 min, relative to the basal and the other agonists. At 
least one report exists which describes WIN-mediated inhibition of ERK, in rat C6 
glioma cells; however no mechanism of action was suggested (Ellert-
Miklaszewska et al., 2005). Multiphasic ERK signalling via GPCRs is a well-
recognised phenomenon, which can be mediated E\ * SURWHLQV ȕ-arrestins and 
other scaffolding proteins (Lefkowitz & Whalen, 2004; Kolch, 2005), as well as 
via transactivation of receptor tyrosine kinases (Wetzker & Bohmer, 2003). In the 
case of the CB1 receptor, Asimaki et Mangoura (2011) reported biphasic ERK 
activation in cultured primary neurons derived from chick embryo telencephalon, 
involving sequential Gq and Gi/o protein-mediated signalling, at 5 and 15 min 
respectively. In our study, treatment of CHO-hCB1 cells with pertussis toxin 
completely abolished the ERK response of all agonists tested, including the CP 
55,940-mediated late-phase response, clearly indicating the essential role of Gi/o 
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protein in ERK signalling in our cells. From 240 min onwards, cells treated with 
HU-210, but not the other test compounds, began to exhibit increased alterations 
in cell morphology and reduced cell number, indicative of a cytotoxic effect. This 
is in keeping with reports of some cannabinoids having toxic effects on certain cell 
types after prolonged exposure (Tomiyama & Funada, 2014). 
 
All agonist-mediated phospho-ERK responses at 5 min were clearly shown to be 
concentration-dependent, with a rank order of potency consistent with their 
calculated pKi values. Clear patterns of partial agonism were evident, with the 
Rmax YDOXHVIRUǻ9-THC and methanandamide significantly less than that of HU-
210. Fenofibrate, as described in the previous chapter, showed a clear decline in 
the phospho-ERK response at higher concentrations, resulting in an atypical 
concentration-response curve. This is not surprising given that the CB1/ERK 
response is Gi/o dependent, and the same pattern was seen when measuring G 
protein activation (see Figure 2.3). These results also demonstrate that the atypical 
fenofibrate response is not an artefact of using a membrane-based assay, as the 
profile was also evident when using whole cells. To the best of my knowledge, 
this is the first comprehensive characterisation of concentration-dependent CB1-
mediated ERK signalling in CHO-hCB1 cells, using this or any other assay 
technique, though there are reports in the literature of ERK concentration- 
response experiments with individual cannabinoids (Bouaboula et al., 1995; 
McIntosh et al., 2007; Baillie et al., 2013). The CB1-selective antagonist AM 251 
was able to produce a significant rightwards shift of all agonist concentration-
response curves, clearly indicating that the responses were CB1-receptor mediated. 
Interestingly, the calculated equilibrium dissociation constant (pKB) values for 
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AM 251 in the ERK activation assay varied depending upon the agonist 
employed; this is discussed later in this chapter. 
 
CP 55,940 produced a biphasic concentration-response curve at 60 min and the 
high potency component had an equivalent pEC50 to that seen at the 5 min 
stimulation time-point and was sensitive to AM 251, indicating a CB1-mediated 
effect, while the low potency component had a very low pEC50 and was 
insensitive to AM 251. Both responses were Gi/o protein-dependent as 
demonstrated by the abolition of the second phase response in the time course 
experiments. These responses provide a novel example of temporal functionally 
selective signalling in which CP 55,940 and HU-210 are able to promote two 
distinct ERK responses (albeit both apparently mediated by Gi/o), while the 
agonists WIN 55,212-2 and methanandamide are not, with at least part of both 
phases of the CP 55,940 response being CB1-mediated. 
 
The next signalling pathways investigated were the c-Jun N-terminal kinases or 
JNK, and p38 kinase, both of which are MAP kinase families which typically 
respond to stress stimuli including inflammatory cytokines, UV radiation, heat 
shock and reactive oxygen species (ROS) (Pearson et al., 2001). Addition of 
hydrogen peroxide, a noxious stimulant and ROS at high concentrations produced 
clear phospho-JNK and phospho-p38 responses, demonstrating that these 
signalling pathways are functional in the CHO-hCB1 cell line. None of the 
cannabinoid agonists tested elicited a phospho-JNK or p38 response up to 60 min 
stimulation. This is in contrast to a previous report in which CB1 receptors were 
reported, using immunoblotting, to couple to JNK and p38 in transfected CHO 
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cells (Rueda et al., 2000). Potentially, our particular subclone of CHO cells may 
be unsuited to CB1/JNK/p38 coupling or alternatively the technique used is not 
sensitive enough to detect phospho-JNK or p38 levels present. A future step 
would be to repeat these experiments using conventional Western 
immunoblotting, to confirm that the results are independent of the assay technique 
used. 
 
The CB1 receptor is well known to couple to Gi/o proteins in transfected CHO 
cells, which among other functions, inhibit the activity of the enzyme adenylyl 
cyclase (AC), an effect which can be observed by measuring changes in 
intracellular cAMP levels (Felder et al., 1995; Bonhaus et al., 1998). Stimulation 
of cells with forskolin (FSK), a receptor-independent activator of AC, produced a 
concentration-dependent increase in cAMP levels. All agonists tested produced 
clear concentration-dependent inhibitions of FSK-stimulated cAMP accumulation 
which were sensitive to AM 251, with a rank order of potency which was 
consistent with that seen in the radioligand binding and ERK activation assays. 
However, the absolute EC50 value for HU-210, but no other agonist, was 
significantly greater in the cAMP assay, compared to the ERK activation assay by 
approximately 10-fold, indicative of HU-210 positive agonist bias for cAMP vs. 
ERK signalling. Clear patterns of partial agonism could be identified, with the 
Rmax YDOXH IRU ǻ9-THC being significantly less than that for HU and CP. These 
patterns of potency and intrinsic activity closely match literature reports for cAMP 
signalling in CHO-hCB1 cells (Bonhaus et al., 1998). One anomalous result of 
QRWH ZDV WKH FRQVLVWHQW DELOLW\ RI D KLJK FRQFHQWUDWLRQ RI ǻ9-THC (10 µM) to 
enhance cAMP accumulation in these cells. This would be expected to be a 
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receptor-mediated activation of Gs protein, which activates AC; however, in this 
instance, the response was insensitive to AM 251 antagonism, indicating that it is 
not CB1-mediated. While interesting, the response falls beyond the remit of this 
thesis, and was excluded from analysis of the cAMP data. 
 
Next, the effect of pertussis toxin on CB1 receptor modulation of cAMP 
accumulation was investigated. Previous reports have clearly demonstrated that 
inhibition of Gi/o-mediated signalling can facilitate receptor coupling to other 
signalling mediators, such as Gs proteins (Glass & Felder, 1997; Maneuf & 
Brotchie, 1997; Bonhaus et al., 1998). However, none of the cannabinoid agonists 
tested were able to produce a significant change in cAMP levels in PTX-treated 
cells, in stark contrast to the previous reports. As with the lack of JNK and p38 
signalling, a probable explanation is that, in this particular subclone of CHO cells, 
coupling of the transfected CB1 receptors to endogenous Gs proteins is weak 
and/or negligible. 
 
The final signalling system to be investigated was receptor-PHGLDWHG ȕ-arrestin 
recruitment. These are proteins which bind to intracellular portions of GPCRs, and 
mediate receptor internalisation and coupling to signalling pathways. In this 
instance, the DLVFRYH5[ 3DWK+XQWHU V\VWHP ZDV XVHG WR PHDVXUH WKH ȕ-arrestin 
response. In this assay, binding of arrestin protein to the receptor unifies two 
FRPSOLPHQWDU\ FRPSRQHQWV RI D ȕ-galactosidase enzyme, which is then used to 
catalyse the formation of a chemiluminescent detection product. All agonists 
tested produced a concentration-GHSHQGHQW LQFUHDVH LQ ȕ-arrestin recruitment 
which was sensitive to AM 251 antagonism. To the best of my knowledge, this is 
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the first reported concentration-dependent characterisation of cannabinoid agonist 
action at the CB1 receptor using this reporter system. The rank order of potency 
was again consistent with that seen with the previously described signalling 
mediators, cAMP and ERK. Importantly however, the absolute pEC50 values of all 
DJRQLVWVIRUWKHȕ-arrestin assay were significantly lower than those for the cAMP 
assay, while the anandamide and ACEA values were significantly lower than 
those for the ERK assay. These discrepancies are most likely due to the proximity 
RI ȕ-arrestin recruitment to the receptor activation event and the unitary ratio 
QDWXUHRI WKLV LQWHUDFWLRQ LHRQH DFWLYDWHG UHFHSWRUELQGVRQHȕ-arrestin protein 
only), resulting in a lack of signal amplification when compared to cAMP 
inhibition and ERK phosphorylation, which are events much further downstream 
in the signalling cascade with G protein and enzyme involvement. As with the 
(5.DQGF$03DVVD\VFOHDUSDWWHUQVRISDUWLDODJRQLVPZHUHLGHQWLILHGZLWKǻ9-
THC, anandamide and methanandamide partial, relative to HU-7KHȕ-arrestin 
response to fenofibrate, as with the G protein and ERK responses, produced an 
atypical bell-shaped concentration-response curve, demonstrating that this effect is 
mediated via multiple signalling pathways. 
 
While comparison of response curve parameters between various signal mediators 
can give an indication of functional selectivity, this approach does not take into 
account other factors which may impact the results -  differences in the sensitivity 
of an assay used to measure a particular pathway, termed observational bias, and 
the bias a receptor has for one pathway over another, as seen in the present results 
LQGLFDWLQJGLIIHUHQFHVEHWZHHQȕ-arrestin and the other two signalling mediators, 
termed system bias.  
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It is, therefore, necessary to analyse the data in a way that compensates for these 
other factors and focuses only on genuine agonist bias (Kenakin & Christopoulos, 
2013b). Bias plots (also known as equimolar comparison) are a novel means of 
graphically illustrating the potential bias of several agonists with regard to two 
pathways (Gregory et al., 2010; Kenakin & Miller, 2010; Rajagopal et al., 2011), 
in which responses to the two pathways are normalised, in our case to HU-210-
mediated responses, and then plotted against each other. In this instance, bias of 
individual agonists for particular pathways, in relation to other agonists can be 
easily identified; in particular anandamide and ACEA appeared to be clearly 
ELDVHG WRZDUGV (5. DFWLYDWLRQ FRPSDUHG ZLWK ȕ-arrestin recruitment, and to a 
lesser extent cAMP accumulation. A limitation of using bias plots is that they do 
not allow for direct quantification of agonist bias. To overcome this limitation we 
have used a parameter termed intrinsic relative activity (RAi) which is calculated 
using both the potency and intrinsic activity of an agonist, in relation to a 
reference agonist, which in our case, was again HU-210. Our analysis confirmed 
the trends illustrated in the bias plots, as both anandamide and ACEA exhibited 
8.4 and 9.8-fold bias towards ERK activation vs. cAMP signalling and 4.4 and 
8.1-IROGELDVYVȕ-arrestin recruitment. This signalling bias may have an impact 
RQ WKH GRZQVWUHDP IXQFWLRQDO FRQVHTXHQFH RI ȕ-DUUHVWLQ UHFUXLWPHQW :KLOH ȕ-
arrestin can mediate ERK activation, the bias we have demonstrated as well as the 
data showing the Gi/o protein-dependent nature of the ERK responses indicates this 
is not likely in our cell line. Anandamide and ACEA may be less likely to promote 
UHFHSWRU LQWHUQDOLVDWLRQ DQRWKHU IXQFWLRQDO FRQVHTXHQFH RI UHFHSWRUȕ-arrestin 
recruitment, which may have a major impact on agonist-selective responses.  
141 
 
Relative activity values are just one method available for quantifying agonist bias, 
with another being transduction coefficients, which are derived by fitting 
concentration-response data to the Black-Leff operational model. The advantage 
of using relative activities is that they are easy to understand and to calculate - 
however they become less accurate as measures of agonist bias when the 
concentration-response data differs significantly from unity. While this is not the 
case for the majority of the concentration response data in this chapter, the ERK 
UHVSRQVHIRU$&($DQGWKHȕ-arrestin responses for CP 55,940 and WIN 55,212-
2 are significantly different from nH = 1. Future work should aim to quantify the 
agonist bias using the transduction coefficient model, which is independent of the 
curve slope. 
 
The equilibrium dissociation constant (pKB) for AM 251 calculated using the 
Schild equation, was determined using all agonists, at all signalling pathways. 
Typically, it is expected that all calculated pKB values should be equal, regardless 
of the agonist or signalling mediator involved. Assay-dependent differences in 
incubation periods or temperatures may alter the antagonist binding kinetics and 
pKB as measured between different signalling pathways, while differences 
between agonists in non-HTXLOLEULXPDVVD\VPD\EHGXHWRGLIIHUHQFHVLQDJRQLVWV¶
association rate constants. However, the complexity of divergence in our results, 
in which different agonists exhibit significantly different susceptibility to AM251 
antagonism cannot be explained by these considerations and is most likely 
indicative of agonist-dependent bias in the activity of the antagonist. With this in 
mind, we posit that comparison of antagonist equilibrium dissociation constants, 
calculated using the Schild equation is a novel way of indicating agonist bias at a 
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GPCR. Our results show that HU-210 and ACEA are clearly biased against 
DQWDJRQLVPRIWKHȕ-arrestin and cAMP pathways respectively, while WIN 55212-
2 55,212- DQG ǻ9-7+& DUH ELDVHG DJDLQVW WKH ȕ-arrestin pathway to a lesser 
degree.  
 
3.6. Conclusions 
In conclusion, the results in this chapter clearly demonstrate that cannabinoid 
DJRQLVWVDUHDEOHWRPRGXODWH(5.$&DQGȕ-arrestin signalling in CHO cells via 
transfected human CB1 receptors. Furthermore, activation of these signalling 
pathways appears to exhibit clear examples of agonist bias, with ligand-specific 
differences in temporal ERK signalling, as well as differential activation of the 
three signalling pathways investigated. 
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Chapter 4 
 
Investigation of Functional Selectivity at the Cannabinoid 
Receptor in Human CB1 Receptor-Transfected Human 
Embryonic Kidney 293 cells 
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4.1. Introduction 
Expression of receptors in a cell line with a relatively uncomplicated spectrum of 
protein expression is an effective method for the study of signal transduction 
SDWKZD\V&RPPRQDPRQJVWWKHVHµVLPSOH¶KRVWFHOOOLQHVLVWKHKXPDQHPEU\RQLF
kidney 293, HEK 293, or simply HEK cells, an immortalised cell line developed 
at Alex van der Eb's laboratory in Leiden, The Netherlands in the early 1970s 
(Graham et al., 1977). Cultures of normal human embryonic kidney cells were 
transformed with sheared adenovirus 5 DNA which resulted in a ~4.5 kilobase 
insertion of viral genome into human chromosome 19 (Louis et al., 1997). While 
the specific cell type of the HEK progenitor has been debated, the most recent 
consensus is that the cell line is neuronal in origin (Shaw et al., 2002). HEK cells 
are extensively used in the study of transfected proteins, owing to the ease with 
which they can be cultured and transfected. A large amount of research on 
cannabinoid receptor has been conducted using HEK cells expressing transfected 
recombinant receptor, including studies on receptor-mediated modulation of ion 
channels (Vasquez et al., 2003), coupling to Gq proteins (Lauckner et al., 2005), 
formation of heteromeric receptor dimers (Kearn et al., 2005) and characterisation 
of CB1 receptor allosteric modulators (Horswill et al., 2007). 
 
4.2. Aims and objectives 
The aim of this chapter was to investigate functionally selective responses 
mediated by the CB1 receptor expressed in HEK cells. The objectives were to 
stimulate cells with a range of cannabinoid agonists and to measure the 
engagement of a number of signal transduction mediators including the MAP 
kinases ERK, JNK and p38 and the enzyme adenylyl cyclase (AC) via changes in 
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cAMP levels. The HEK cell line provides an attractive model for investigating 
agonist bias as it has been thoroughly validated by previous studies; the relatively 
high receptor population generated by transfection should provide clear responses, 
bringing confidence to the data generated, and it is a human cell line of potentially 
neuronal origin which is more physiologically relevant to  CB1 receptor function 
than some other cell lines of non-human, non-neuronal origin, such as the CHO 
cell line that have also been used for cannabinoid receptor studies. 
 
4.3. Methods 
4.3.1. Cell culture 
HEK 293 cells stably transfected with the human cannabinoid CB1 receptor, with a 
tetracycline inducer, and genes encoding antibiotic resistance, were cultured in 
'XOEHFFR¶V PRGLILHG HDJOH¶V PHGLXP '0(0 FRQWDLQLQJ  WHWUDF\FOLQH-
negative foetal bovine serum, 2 mM L-glutamine and 200 µg/ml hygromycin at 
37°C, 5% CO2 in a humidified incubator. Cells were passaged every 2-3 days 
using TrypLE-E dissociation buffer. HEK-hCB1 cells were treated with 
doxycycline (1 µg/ml) 24 hrs prior to experimentation to promote receptor 
expression. 
 
4.3.2. Determination of MAP kinase phosphorylation 
4.3.2.1. Time Course experiments - In-Cell Western 
4.3.2.1.1. Protocol 
Levels of MAP kinase phosphorylation were determined using the In-Cell 
:HVWHUQ DVVD\ SUHYLRXVO\ GHVFULEHG &HOOV ZHUH VHHGHG LQWR -well clear 
bottom plates, at 5,000 cells/well (unless otherwise stated) in culture medium at 
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room temperature for 1 hour and then incubated overnight at 37°C, in the presence 
of pertussis toxin (500 ng/ml) where appropriate. 30 min prior to experimentation, 
the culture medium was removed from the assay plates by aspiration, the cells 
were washed once with PBS, and the medium replaced with serum-free medium 
containing 1 mg/ml BSA. Dilution of test ligands was performed in serum-free 
medium and added to test wells to a final volume of 25 µl per well. Assay plates 
were incubated for the stated period at 37°C during experimentation. After 
incubation, the assay medium was rapidly aspirated and the cells were fixed with 
4% paraformaldehyde in PBS for 20 min at room temperature (40 µl/well). Each 
reagent was aspirated before the addition of the next reagent. Cells were then 
SHUPHDELOLVHG ZLWK  YY 7ULWRQ ;-100 in PBS for 20 min at room 
temperature (40 µl/well). Non-specific antibody binding sites were blocked with 
5% (w/v) milk powder in PBS for 60 min at room temperature with gentle 
rocking. 
 
Primary antibodies for anti-total and anti-phosphorylated MAP kinases (ERK1/2, 
p38 and JNK1/2/3; see 4.3.2.1.3) were diluted together in blocking agent. Cells 
were incubated with primary antibody solution (25 µl/well) overnight at 4°C with 
gentle rocking. The next day, the primary antibody solution was aspirated and the 
cells were washed three times with PBS containing 1 mg/ml BSA (40 µl/well) for 
5 min at room temperature with gentle rocking. The appropriate LI-COR IRDye® 
secondary antibodies were diluted 1:4000 in blocking agent, added to the cells (25 
µl/well), and incubated in darkness for 60 min at room temperature with gentle 
shaking. The secondary antibody solution was aspirated and the cells washed three 
times with wash buffer as before. 
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4.3.2.1.2. Imaging 
Plates were imaged by scanning simultaneously at 700 and 800 nm with the LI-
COR Odyssey® NIR Imaging System at 82 µm resolution, medium quality and 
focus offset of 4.0123 mm. Quantification was performed using LI-COR 
Odyssey® Software v3.0. The secondary antibody non-specific response was 
subtracted from the data. The phospho- response was then normalised against the 
total protein response for each individual well and then the data was expressed as 
a percentage of the basal response. 
 
4.3.2.1.3. Antibodies used 
All primary antibodies used were obtained from Cell Signaling Technology 
(Boston, USA). Antibodies were used at the concentrations described below 
unless otherwise stated in Results (see 4.4). Anti-ERK 1/2 rabbit, (1:400) # 9102; 
anti-phospho-ERK1/2 (Thr202/Tyr204) monoclonal mouse, (1:200) # 9106; anti-
p38 rabbit, (1:200) # 9212; anti-phospho-p38 (Thr180/Tyr182) monoclonal 
mouse, (1:200) #9216; anti-JNK rabbit, (1:200) # 9252; anti-phospho-JNK 
(Thr183/Tyr185) monoclonal mouse, (1:200) # 9255. 
 
4.3.2.2. ERK phosphorylation concentration-response - AlphaScreen 
SureFire 
4.3.2.2.1. Protocol 
Levels of ERK phosphorylation in concentration-response experiments were 
determined using the AlphaScreen SureFire assay kit. Antibodies targeting the 
phospho-Thr202/Tyr204 epitope and a distal epitope capture AlphaScreen donor 
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and acceptor beads. Excitation of the donor beads promotes energy transfer to the 
acceptor beads resulting in emission of a detectable light signal, which 
corresponds to the relative level of ERK1/2 phosphorylation. Cells were plated 
into a 384-well plate at 5,000 cell/well unless otherwise stated, and incubated at 
37°C for 24 hours, in the presence of pertussis toxin (500 ng/ml) where 
appropriate. 30 min prior to experimentation, the culture medium was removed 
from the assay plates by aspiration, the cells were washed once with PBS, and the 
medium replaced with serum-free medium containing 1 mg/ml BSA. Serial 
dilution of test ligands was performed in serum-free medium and added to test 
wells to a final volume of 25 µl per well, followed by 5 or 20 min incubation at 
37°C. The assay was terminated by the addition of 5x lysis buffer (6.25 µl/well) 
and agitated for 10 min at ~350 rpm on a plate shaker 
 
4 µl of the cell lysate was transferred to a white 384-well PerkinElmer proxiplate 
plus. The SureFire assay kit reaction mix was prepared by combining the 
Activation and Reaction buffers with AlphaScreen protein-conjugated acceptor 
and steptavidin-coated donor beads. 7 µl of reaction mix was added to the 
proxiplate; the plate was sealed with an opaque cover and incubated for 2 hours at 
room temperature. Preparation of the reaction mix and addition to the proxiplate 
was performed in low light conditions to minimise degradation of the reaction 
mix. The phospho-ERK1/2 levels were determined by exciting the proxiplate at 
680 nm and detecting the emission of light at 520 ± 620 nm using a PerkinElmer 
EnVision plate reader. The data were expressed as a percentage of the basal 
response . 
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4.3.3. cAMP accumulation assay 
Intracellular cAMP levels were determined using the Cisbio HTRF femto cAMP 
kit, a TR-FRET-based immunoassay kit. Cells were passaged and pelleted by 
FHQWULIXJDWLRQ DQG UHVXVSHQGHG LQ DVVD\ EXIIHU +DQN¶V EXIIHUHG VDOW VROXWLRQ
containing 20 mM HEPES (pre-prepared, Life Technologies), 0.5 mM MgCl2, pH 
adjusted to 7.4 at room temperature), containing NKH 477 (3 µM) and IBMX (0.5 
mM), unless otherwise stated. Cells (1,000 cells/well, unless otherwise stated) 
were incubated with increasing concentrations of cannabinoid agonist for 20 min 
at 37°C in a black 384-well micro volume plate in a final assay volume of 8 
µl/well. A cAMP standard was included on each plate adding increasing 
concentrations of cAMP to cell-free assay buffer. The assay was terminated by the 
addition of detection mix and plates were then incubated for 24 hours at room 
temperature. Fluorescence emitted at 665 nm following stimulation at 320nm was 
measured using a PerkinElmer EnVision plate reader.  
 
4.3.4. Materials 
WIN 55,212-2, CP 55,940, arachidonoyl-¶-chloroethylamide, anandamide, (R)-+-
methanandamide, AM 251, fenofibrate, bovine serum albumin and 
isobutylmethylxanthine (IBMX) were obtained from Sigma Aldrich (Poole, UK). 
HU- DQG ǻ9-tetrahydrocannabinol were purchased from Tocris Biosciences 
(Bristol, UK). Cell culture reagents DMEM, L-*OXWDPDWH 7U\S/( ([SUHVV
dissociation buffer, hygromycin, phosphate-buffered saline, HEPES buffer and 
+DQN¶V EXIIHUHG VDOW VROXWLRQ +%66 ZHUH SXUFKDVHG IURP /LIH 7HFKQRORJLHV
(Paisley, UK). Tetracycline negative foetal bovine serum was obtained from 
Lonza (Slough, UK). The cAMP femto 2 assay kit was purchased from Cisbio 
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Bioassays (Bedford, MA, USA). The AlphaScreen® SureFire® pERK1/2 
(Thr202/Tyr204) Assay Kit was obtained from PerkinElmer (Bucks, UK). HEK 
293 cells stably transfected with the human cannabinoid CB1 receptor with a 
tetracycline promoter were kindly provided by Neusentis Ltd (Cambridge, UK). 
 
4.3.5. Data Analysis 
All data was analysed using the GraphPad Prism software (v6). Concentration-
response data were fitted to curves using the four-parameter logistic equation, 
previously described in Chapter 2 ± Methods (see 2.3.7). 
 
For the cAMP experiments, the raw counts were interpolated against an internal 
cAMP standard curve on a logarithmic x axis, and then transformed to actual 
cAMP concentration ([cAMP]) in nM. 
 
Estimates for the antagonist AM 251 equilibrium dissociation constant (pKB) and 
calculation of the intrinsic relative activities (RAi) for each individual agonist 
were as previously described in Chapter 3 ± Methods (see 3.3.6). 
 
4.3.6. Statistics 
The quantitative data are expressed as means ± SEM, obtained from at least three 
independent experiments performed in replicate, unless otherwise stated. 
1RUPDOLW\ RI GDWD VHWV ZDV GHWHUPLQHG XVLQJ WKH '¶$JRVWLQR-Pearson omnibus 
normality test. 6WDWLVWLFDOVLJQLILFDQFHRIGLIIHUHQFHVZDVGHWHUPLQHGE\6WXGHQW¶V
paired or unpaired, two-tailed t-tests or ANOVA followed by 'XQQHWW¶VPXOWLSOH
comparisons post-hoc tests where appropriate. Statistical comparison of pKB 
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values, and responses in non-toxin treated cells with the corresponding responses 
in PTX-treated cells was made using two-ZD\ $129$ IROORZHG E\ 6LGDN¶V
multiple comparisons test. A p value of <0.05 was considered significant. 
 
4.4. Results 
4.4.1. Determination of ERK phosphorylation 
Assay Optimisation 
A preliminary experiment was performed to determine the optimal cell seeding 
density and phospho-ERK1/2 antibody concentration for use in subsequent assays 
(Figure 4.1). Cell were stimulated with HU-210 (1 µM) for 7.5 min before 
fixation and immunocytochemical staining. A cell seeding density of 5,000 
cells/well produced the largest magnitude response of all cell densities at all 
antibody dilutions tested, apart from 1:100. Within this, there was an increase in 
response magnitude as antibody dilution increased, with a 1:400 dilution giving 
the largest response. 
 
On the basis of these results, a cell seeding density of 5,000 cells/well and a 
phospho-ERK primary antibody dilution of 1:400 were chosen as optimal 
conditions for all subsequent ERK time course experiments. 
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Figure 4.1 Optimisation of ERK phosphorylation assay in HEK-hCB1 cells. Cells 
(5, 10, 20 and 40 000 cells/well) were cultured in medium for 24 hr, followed by 
serum starvation for 24 hr. Cells were stimulated with HU-210 (1 µM) for 7.5 
min, followed by rapid fixation with cold PFA solution (4 % w/v). Detection of 
total and phospho-ERK levels was as stated in methods (see 4.3.2.1). Individual 
ERK phosphorylation values were normalised to the corresponding total-ERK 
values. The data shown represent a single experiment, performed with six 
replicates and are presented as mean ± SEM. 
 
Effect of cannabinoid agonists of ERK phosphorylation ± time course 
HEK-hCB1 cells were treated with high (presumed to be maximally effective) 
concentrations of the cannabinoid agonists HU-210, CP 55,940 (both 1 µM), WIN 
55,212-2 and methanandamide, (10 µM) at various time points (2 ± 60 min) to 
identify any differences in the agoQLVWV¶ WHPSRUDO UHVSRQVH SURILOH DQG WR
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determine which time point would provide the maximum phospho-ERK response 
for use in concentration-response experiments.  
 
All agonists produced a rapid, significant increase in phospho-ERK levels with the 
maximum response occurring at 4 min (Figure 4.2, black symbols; one way 
ANOVA; p<0.001). After this time the phospho-ERK levels for all agonists 
steadily decreased, reaching a constant, but still elevated level from 10 min 
onwards. There were clear patterns of partial agonism present, with 
methanandamide producing a significantly smaller maximum response than those 
of the representative full agonists HU-210 and WIN 55-212-2 (one-way ANOVA; 
p<0.05). While the maximum WIN response appeared larger than that for HU and 
CP, there were no significant differences between the three. Some cells were pre-
treated with pertussis toxin (PTX; 500 ng/ml) overnight to test for the involvement 
of Gi/o proteins in the responses. PTX produced a significant decrease in the 
phospho-ERK responses to all agonists (Figure 4.2, white symbols; two-way 
ANOVA; p<0.01). In addition, the temporal profile of the response was slightly 
shifted, with the maximum response now typically achieved after 6 min of 
stimulation. As with the untreated cells, there were patterns of partial agonism 
observable in the presence of PTX, with the methanandamide maximum response 
being significantly lower than that for HU-210 (one-way ANOVA; p<0.01). PTX 
did not appear to have any effect on the post-10 min stimulation phospho-ERK 
response, as seen in the untreated cells. 
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Figure 4.2 Time courses of the effects of 
cannabinoid agonists in the presence and absence of 
pertussis toxin on ERK phosphorylation in HEK-
hCB1 cells. Cells (5,000 cells/well) were cultured in 
medium for 24 hr, followed by serum starvation for 
24 hr. Cells were stimulated with cannabinoid 
agonists at various time points (2 - 60 min), 
followed by rapid fixation with cold PFA solution (4 
% w/v). Detection of total and phospho-ERK levels 
was as stated in methods (see 4.3.2.1). The data 
shown represents mean ± SEM values from four 
independent experiments performed in triplicate. 
155 
 
Effect of cannabinoid agonists on ERK phosphorylation ± concentration-response 
The concentration-dependent effects of the cannabinoid agonists on ERK 
phosphorylation were assayed using the AlphaScreen SureFire kit; the cell seeding 
density was kept the same as that used in the time-course experiments to allow for 
more relevant comparison. The cannabinoid agonists HU-210, CP 55,940, WIN 
55,212- ǻ9-THC, anandamide, methanandamide, arachidonyl-2'-
chloroethylamide (ACEA) and fenofibrate all produced a concentration-dependent 
increase in phospho-ERK levels after 5 min stimulation (Figure 4.3). The rank 
order of potency (pEC50) values of the agonists acting on HEK-hCB1 cells from 
highest to lowest was CP 55,940 > HU-  ǻ9-THC > WIN 55,212-2 > 
IHQRILEUDWH  P$($  $&($  $($ Table 4.1). The Rmax YDOXH IRU ǻ9-THC 
was significantly less than that for HU-210, CP 55,940 and WIN 55,212-2 (one-
way ANOVA; p<0.05). To confirm the role of the CB1 receptor in the cannabinoid 
agonist responses, the concentration-response experiments were repeated in the 
presence of the CB1-selective competitive antagonist AM 251 (10 nM). AM 251 
produced a significant rightwards shift of all the agonist concentration-response 
FXUYHV H[FHSW IRU ǻ9-THC and fenofibrate whose responses were completely 
abolished, resulting in significant decreases in all the pEC50 values. These data 
were used to estimate the equilibrium dissociation constant (pKB) for AM 251 in 
the presence of each individual agonist (Table 4.1).  There were no significant 
differences between the pKB values (one-way ANOVA; p>0.05). 
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Figure 4.3 Effect of cannabinoid agonists on ERK phosphorylation in HEK-hCB1 
cells. Cells (5,000 cells/well) were cultured in medium for 24 hr, followed by 
serum starvation for 24 hr. Cells were stimulated with various concentrations of 
cannabinoid agonists for 5 min, followed by rapid addition of  lysis buffer. 
Determination of the phospho-ERK response was as stated in methods (see 
4.3.2.2). The data shown represents mean ± SEM values from 3-6 independent 
experiments performed in duplicate. The curves were fitted using GraphPad 
Prism. 
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The concentration-response experiments were repeated with cells which had been 
pre-treated with PTX overnight (Figure 4.4). All agonists produced a 
concentration-dependent increase in phospho-(5.OHYHOVH[FHSWǻ9-THC, which 
produced no response up to 10 µM. While fenofibrate was able to produce a clear 
concentration-dependent increase in phospho-ERK levels, it was impossible to fit 
a response curve to the data using GraphPad Prism.  The rank order of pEC50 
values of the agonists acting on HEK-hCB1 cells, from highest to lowest 
potencies, was CP 55,940 > HU-210 > WIN 55,212-2 > anandamide 
methanandamide  $&($ Table 4.1). The Rmax value for WIN 55,212-2 was 
significantly greater than that for HU-210, anandamide, methanandamide and 
ACEA, while the value for CP 55,940 was significantly greater than that for 
methanandamide (one-way ANOVA; p<0.05).  Comparing the responses in the 
PTX-treated cells to those observed in untreated cells, the Rmax for all agonists, 
and the pEC50 values for HU-210, CP 55,940 and WIN 55,212-2 were 
significantly smaller than the corresponding responses seen in untreated cells 
(two-way ANOVA; p<0.05). 
 
To confirm the role of the CB1 receptor in the cannabinoid agonist responses, the 
concentration-response experiments were repeated in the presence of the CB1-
selective competitive antagonist AM 251 (10 nM). AM 251 produced a significant 
rightward shift in the HU-210, CP 55,940 and WIN 55,212-2 concentration-
response curves, resulting in significant decreases in all the pEC50 values. These 
data were used to estimate the equilibrium dissociation constant (pKB) for AM 251 
in the presence of each individual agonist (Table 4.1). There was no significant 
difference between the three pKB values (one-way ANOVA; p>0.05). The 
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responses to the other agonists were either completely abolished, or could not be 
fitted to response curves by GraphPad Prism, in the presence of AM 251, therefore 
no pKB values were estimated.  
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Figure 4.4 Effects of cannabinoid agonists on ERK phosphorylation in HEK-
hCB1 cells, pre-treated with pertussis toxin. Cells (5,000 cells/well) were cultured 
in medium for 24 hr, followed by serum starvation and treatment with PTX (500 
ng/ml) for 24 hr. Cells were stimulated with various concentrations of cannabinoid 
agonists for 5 min, followed by rapid addition of lysis buffer. Determination of the 
phospho-ERK responses was as stated in methods (see 4.3.2.2). The data shown 
represent mean ± SEM values from 3-6 independent experiments performed in 
duplicate. The curves were fitted using GraphPad Prism. 
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Table 4.1 
Determination of potency (pEC50), maximal response, expressed as % of the basal (Rmax), and estimated AM 251 dissociation constant (pKB) of 
cannabinoid agonists on ERK phosphorylation in HEK-hCB1 cells at 5 min stimulation, in cells either untreated or pre-treated with PTX (500 
ng/ml) overnight. 
Agonist Non-treated cells PTX-treated cells (500 ng/ml) 
pEC50 Rmax nH pKB pEC50 Rmax nH pKB 
HU-210 8.3 ± 0.1 372 ± 49 1.3 ± 0.2 9.2 ± 0.3 7.5 ± 0.2 168 ± 28e 0.9 ± 0.1 9.1 ±0.1 
CP 55,940 8.7 ± 0.1 412 ± 33 1.1 ± 0.1 9.0 ± 0.4 7.9 ± 0.2 185 ± 15 1.4 ± 0.3 9.6 ± 0.1 
WIN 55,212-2 7.6 ± 0.1 432 ± 36 1.1 ± 0.1 9.4 ± 0.2 7.1 ± 0.1 262 ± 16 1.9 ± 0.1c 9.6 ± 0.1 
ǻ9-THC 8.2 ± 0.5 145 ± 28d 1.1 ± 0.1 b a a a b 
anandamide 6.3 ± 0.1 306 ± 41 1.4 ± 0.1 8.9 ± 0.4 6.1 ± 0.1 146 ± 4e 1.9 ± 0.1 b 
methanandamide 6.4 ± 0.3 295 ± 34 1.0 ± 0.1 9.4 ± 0.5 5.9 ± 0.4 66 ± 7ef 1.7 ± 0.4 b 
ACEA 6.3 ± 0.1 299 ± 40 1.3 ± 0.1c 9.2 ± 0.1 5.7 ± 0.2 107 ± 11e 1.4 ± 0.5 b 
fenofibrate 6.7 ± 0.1 337 ± 33 1.4 ± 0.4 b a a a b 
The data shown represents mean ± SEM values from 4-5 independent experiments performed in triplicate. 
a It was impossible to fit a response curve using GraphPad Prism. b It was not possible to calculate values for pKB. 
c
 nH value significantly difference from unity (nH = 1). d value significantly less than that for HU-210, CP 55,940 and WIN 55,212-2. 
e
 value significantly less than that for WIN 55,212-2. f value significantly less than that for CP 55,940. 
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In an effort to determine the mechanistic differences between the PTX-sensitive 
and PTX-insensitive responses, the WIN 55,212-2 concentration-response 
experiments were repeated in the presence of a hypertonic concentration of 
sucrose (0.5 M), a known inhibitor of the formation of clathrin complexes, 
LQYROYHG LQ ȕ-arrestin-mediated endocytosis and signalling (Goggi et al., 2007; 
Ivanov, 2008). WIN 55,212-2 was chosen as a representative agonist in these 
experiments as it produced the largest magnitude response, as typified by the Rmax 
value (Table 4.1). The presence of sucrose caused a significant reduction in WIN 
55,212-2 Rmax, from 403 ± 28 to 191 ± 46 % basal response (Figure 4.5; one-way 
ANOVA; p<0.05). The addition of sucrose to cells pre-treated with PTX resulted 
in an almost complete abolishment of the WIN 55,212-2 response. 
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Figure 4.5 Effect of hypertonic sucrose on WIN 55,212-2-mediated ERK 
phosphorylation in HEK-hCB1 cells. Cells (5,000 cells/well) were cultured in 
medium for 24 hr, followed by serum starvation and treatment with PTX (500 
ng/ml) for 24 hr were appropriate. Cells were stimulated with various 
concentrations of cannabinoid agonists for 5 min, in the presence of sucrose (0.5 
M), followed by rapid addition of assay lysis buffer. Detection of the phospho-
ERK response was as stated in methods (see 4.3.2.2). Individual ERK 
phosphorylation values were normalised to the corresponding total-ERK values. 
The data shown represents mean ± SEM values from 3 independent experiments 
performed in duplicate. The curves were fitted using GraphPad Prism 
 
Next, concentration-response experiments were performed with HU-210, CP 
55,940 and WIN 55,212-2 at 20 min stimulation to characterise the second-phase 
phospho-ERK response. All three agonists had concentration-dependent effects on 
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phospho-ERK levels, which were markedly less that those observed after 5 min 
stimulations (Figure 4.6). Both HU-210 and CP 55,940 produced a concentration-
dependent increase in phospho-ERK levels, best fit with a sigmoidal 
concentration-response curve (Figure 4.6A). There were no significant differences 
in pEC50 and Rmax values for the two agonists (Table 4.2). Both responses were 
antagonised by AM 251 (10 nM), allowing for the calculation of pKB values 
(Table 4.2). In contrast to the results seen at 5 min stimulation, the pKB value 
determined using HU-210 was significantly lower than that determined using CP 
55,940.  
 
WIN 55,212-2 produced an increase in phospho-ERK levels up to 100 nM (Figure 
4.6B). At higher concentrations, the phospho-ERK responses to WIN were 
significantly sub-maximal (one-way ANOVA; p<0.01), resulting in a bell-shaped 
response curve which could not be fitted to a sigmoidal response curve (Figure 
4.6B); however, the maximum response at 100 nM was not significantly different 
from the HU-210 and CP 55,940 Rmax values (one-way ANOVA; p>0.05). 
Addition of a low concentration of AM 251 (10 nM) antagonised both components 
of the WIN 55,212-2 response, as characterised by a rightwards shift in the high 
potency positive response, and a reversal of the downturn in the phospho-ERK 
response at higher agonist concentrations (Figure 4.6B; black triangle). A high 
concentration of AM 251 (1 µM) was able to completely abolish the WIN 55,212-
2 response (Figure 4.6B; white triangle).  
 
As with 5 min stimulation, the experiments were repeated with cells pre-treated 
with PTX (500 ng/ml). All three agonists produced a concentration-dependent 
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increase in phospho-ERK levels. The reversal of elevated phospho-ERK levels by 
WIN 55,212-2 at higher concentrations was abolished by PTX, allowing the data 
for all three agonists to be fitted to sigmoidal response curves. The rank order of 
pEC50 values of the agonists from highest to lowest was HU-&3!
WIN 55,212-2 (Table 4.2). There were no significant differences in the Rmax 
values for the three agonists (one-way ANOVA; p>0.05). When compared to the 
responses seen in untreated cells, the Rmax and pEC50 values for HU and the pEC50 
values for CP were significantly less in PTX-treated cells (two-way ANOVA; 
p<0.05), although the magnitude of the reduction in Rmax with PTX was not as 
large as that seen after a 5 min stimulation. All three responses were antagonised 
by AM 251 allowing for the calculation of pKB values (Table 4.2). As in the 
untreated cells, the pKB value determined using HU-210 was significantly lower 
than that determined using the other agonists (one-way ANOVA; p<0.05). 
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Figure 4.6 Effect of cannabinoid agonists on ERK phosphorylation in HEK-hCB1 
cells at 20 min stimulation. Cells (5,000 cells/well) were cultured in medium for 
24 hr, followed by serum starvation and treatment with PTX (500 ng/ml) where 
appropriate, for 24 hr. Cells were stimulated with various concentrations of 
cannabinoid agonists for 20 min, followed by rapid addition of lysis buffer. 
Detection of the phospho-ERK response was as described in methods (see 
4.3.2.2). Individual ERK phosphorylation values were normalised to the 
corresponding total-ERK values. The data shown represent mean ± SEM values 
from 4-5 independent experiments performed in duplicate. Curves represented by 
unbroken lines were fitted by non-linear regression to a four parameter logistical 
equation and dashed lines simply join neighbouring data points to illustrate overall 
response trend. Statistical significance was determined by one-way ANOVA; ** 
p<0.01, ****p<0.0001. 
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Table 4.2 
Determination of potency (pEC50), maximal response, expressed as % of the basal (Rmax), and estimated AM 251 dissociation constant (pKB) of 
cannabinoid agonists with regard to ERK phosphorylation in HEK-hCB1 cells after 20 min stimulations, either untreated or pre-treated with PTX 
(500 ng/ml) overnight. 
Agonist Non-treated cells PTX-treated cells (500 ng/ml) 
pEC50 Rmax nH pKB pEC50 Rmax nH pKB 
HU-210 8.9 ± 0.1 204 ± 188 1.4 ± 0.2 8.6 ± 0.1 8.5 ± 0.1 156 ± 16 1.3 ± 0.3 8.4 ± 0.2 
CP 55,940 9.0 ± 0.1 177 ± 6 1.4 ± 0.1c 9.2 ± 0.1 8.3 ± 0.1 181 ± 19 0.9 ± 0.2 9.0 ± 0.1 
WIN 55,212-2 a a a b 7.3 ± 0.1 170 ± 17 1.4 ± 0.1c 9.2 ± 0.1 
The data shown represents mean ± SEM values from 4-5 independent experiments performed in triplicate. 
a It was impossible to fit a response curve using GraphPad Prism. 
b It was not possible to calculate values for pKB. 
c
 nH value significantly difference from unity (nH = 1). 
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4.4.2. Determination of JNK1/2/3 phosphorylation 
The cannabinoid agonists were tested for their ability to promote JNK1/2/3 
phosphorylation. The antibiotic anisomycin (1 µM), a known activator of stress-
activated protein kinases, produced a significant increase in phospho-JNK levels 
from 6 min onwards (Figure 4.7; one-way ANOVA p<0.0001). None of the 
cannabinoid agonists tested were able to significantly increase phospho-JNK 
levels above basal (Figure 4.7; one way ANOVA; p>0.05). 
 
4.4.3. Determination of p38 MAP kinase phosphorylation 
The cannabinoid agonists were tested for their ability to promote p38 MAP kinase 
phosphorylation. Anisomycin (1 µM) produced a clear increase in phospho-p38 
levels, which was significantly greater than the basal from 6 min onwards (Figure 
4.8; one-way ANOVA p<0.0001). None of the cannabinoid agonists tested were 
able to significantly increase the level of phospho-p38 above basal (Figure 4.8; 
one way ANOVA; p>0.05). 
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Figure 4.7 Lack of effect of cannabinoid agonists on JNK phosphorylation in 
HEK-hCB1 cells over time. Cells (5,000 cells/well) were cultured in medium for 
24 hr, followed by serum starvation for 24 hr. Cells were stimulated with 
cannabinoid agonists (1 or 10 µM) or anisomycin (1 µM) at various time points (2 
± 60 min), followed by rapid fixation with PFA solution. Detection of total and 
phospho-JNK levels were as stated in methods (see 4.3.2.1). Individual JNK 
phosphorylation values were normalised to the corresponding total-JNK values. 
The data shown are means ± SEM values from 3 independent experiments 
performed in duplicate. 
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Figure 4.8 Lack of effect of cannabinoid agonists on p38 kinase phosphorylation 
in HEK-hCB1 cells over time. Cells (5,000 cells/well) were cultured in medium 
for 24 hr, followed by serum starvation for 24 hr. Cells were stimulated with 
cannabinoid agonists (1 or 10 µM) or anisomycin (1 µM) at various time points (2 
± 60 min), followed by rapid fixation with PFA solution. Detection of total and 
phospho-p38 levels were as stated in methods (see 4.3.2.1). Individual p38 
phosphorylation values were normalised to the corresponding total-p38 values. 
The data shown are mean ± SEM values from 3 independent experiments 
performed in duplicate. 
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4.4.4. cAMP accumulation 
Assay Optimisation 
A preliminary experiment was performed to determine the optimal conditions for 
cAMP assays using the transfected HEK cells. The raw signal was converted to 
[cAMP] (nM), by interpolating the data with the linear range of a cAMP standard 
curve (0.3 to 30 nM; Figure 4.9, black circle). Anything outside this range cannot 
be accurately expressed as [cAMP]. Cells were pre-treated with the non-selective 
phosphodiesterase inhibitor IBMX to prevent conversion of cAMP. Increasing 
concentrations of NKH 477, a water-soluble derivative of forskolin and direct 
activator of AC, produced a concentration-dependent decrease in fluorescent 
signal, corresponding to an increase in cAMP levels. A cell density of 1000 
cells/well, and a NKH 477 concentration of 3 µM were chosen as optimised 
conditions as they provided the NKH 477 EC80 value most closely corresponding 
to the top of the linear range of the cAMP standard curve, which allows for the 
largest window for agonist-mediated inhibition of cAMP accumulation. 
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Figure 4.9 Optimisation of the cAMP assay in HEK-hCB1 cells. Cells (0.5, 1, 2 
and 4000 cells/well) in suspension in assay buffer were pre-treated with the 
phosphodiesterase inhibitor IBMX (0.5 mM) for 10 min before incubation with 
increasing concentrations of NKH 477 (0.3 ± 30 µM) for 20 min at 37°C. A cAMP 
standard (1 nM ± 1 µM) in cell-free media was included. At the end of the 
incubation period, the assay was terminated by the addition of detection mix and 
the actual levels of cAMP determined using the Cisbio femto cAMP assay kit (see 
4.3.3). The data shown represent a single experiment performed in triplicate, and 
are shown as means ± SEM. The curves were fitted using GraphPad Prism. 
 
Inhibition of NKH 477-stimulated cAMP accumulation 
HEK-hCB1 cells pre-treated with NKH 477 (3 µM) and IBMX (0.5 mM), were 
stimulated with increasing concentrations of the cannabinoid agonists to determine 
the ability of these compounds to inhibit NKH 477-stimulated cAMP 
accumulation (Figure 4.10). All agonists produced a concentration-dependent 
inhibition of NKH 477-stimulated cAMP accumulation. The rank order of potency 
172 
 
of agonists acting on HEK-hCB1 cells from highest to lowest was HU-&3
 ! ǻ9-7+&  :,1 -  DQDQGDPLGH ! PHWKDQDQGDPLGH 
IHQRILEUDWH$&($Table 4.3$OODJRQLVWVH[FHSWǻ9-THC, appeared to act as 
full agonists, with no significant differences between Rmax values (Table 4.3; one-
way ANOVA; p>0.05). Treatment with 100 µM anandamide, failed to inhibit 
NKH 477-stimulated cAMP accumulation. As this is indicative of a distinct 
signalling mechanism, the data point was excluded when fitting the concentration-
response curves. 
 
Next, the experiments were repeated in cells pre-treated with PTX (500 ng/ml) and 
in the absence of NKH 477, to determine the role of Gi/o protein in the 
cannabinoid-mediated cAMP response, and whether any alternate Gi/o protein-
independent signalling could be identified. The agonists HU-210, C 55,940 and 
WIN 55,212-2 all produced clear, reproducible concentration-dependent increases 
in cAMP levels (Figure 4.11). Anandamide produced a clear increase in cAMP 
levels at 30 and 100 µM, but this response could not be fitted with a 
concentration-response curve. The other agonists tested, including the novel 
peptide cannabinoid agonist/allosteric modulator RVD-hemopressin, failed to 
produce a significant increase in cAMP levels. The rank order of potency from 
highest to lowest was HU-  &3  ! :,1 -2 (Table 4.3). The 
Rmax value for WIN 55,212-2 was significantly greater than that for HU-210 and 
CP 55,940 (Table 4.3; one-way ANOVA; p<0.05). Comparing the responses in 
the PTX-treated cells to those observed in untreated cells, the pEC50 values for the 
three agonists were all significantly smaller than the corresponding responses seen 
in untreated cells (two-way ANOVA; p<0.0001). 
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Figure 4.10 Effect of cannabinoid agonists on cAMP accumulation in HEK-hCB1 
cells. Cells in suspension in assay medium were pre-treated with NKH 477 (3 µM) 
and IBMX (0.5 mM) for 10 min before incubation with increasing concentrations 
of cannabinoid agonists for 20 min at 37°C. At the end of the incubation period, 
the assay was terminated by the addition of detection mix and the levels of cAMP 
(nM) determined using the Cisbio femto cAMP assay kit. The data shown 
represent mean ± SEM values from 6-7 individual experiments performed in 
triplicate. The curves were fitted using GraphPad Prism 
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Figure 4.11 Effect of cannabinoid agonists on cAMP accumulation in HEK-hCB1 
cells, pre-treated with pertussis toxin. Cells, previously treated with PTX (500 
ng/ml) for 24 hr, in suspension in assay medium were pre-treated with NKH 477 
(3 µM) and IBMX (0.5 mM) for 10 min before incubation with increasing 
concentrations of cannabinoid agonists for 20 min at 37°C. At the end of the 
incubation period, the assay was terminated by the addition of detection mix and 
the actual levels of cAMP (nM) determined using the Cisbio femto cAMP assay 
kit. The data shown represent mean ± SEM values from 4 individual experiments 
performed in triplicate. The curves were fitted using GraphPad Prism.  
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Table 4.3 Determination of potency (pEC50), concentration-response curve span (Rmax), and curve slope (nH) of cannabinoid agonists on cAMP 
accumulation in HEK-hCB1 cells at 20 min stimulation, either untreated or pre-treated with PTX (500 ng/ml) overnight. 
Agonist Inhibition of cAMP accumulation (untreated cells) Stimulation of cAMP accumulation (PTX-treated cells) 
pEC50 Rmax nH pEC50 Rmax nH 
HU-210 9.7 ± 0.1 10.4 ± 1.9 -1.3 ± 0.1b 8.3 ± 0.2 0.4 ± 0.1c 1.3 ± 0.4 
CP 55,940 9.6 ± 0.1 10.7 ± 2.3 -1.1 ± 0.1 8.0 ± 0.1 0.4 ± 0.1c 1.2 ± 0.1 
WIN 55,212-2 8.0 ± 0.2 12.0 ± 2.7 -1.0 ± 0.1 6.1 ± 0.2 0.7 ± 0.1 0.8 ± 0.1 
ǻ9-THC 8.2 ± 0.7 8.6 ± 2.0 -1.1 ± 0.3 a a a 
anandamide 7.6 ± 0.4 8.8 ± 3.8 -0.9 ± 0.1 a a a 
methanandamide 6.7 ± 0.1 11.6 ± 0.9 -1.4 ± 0.1b a a a 
ACEA 6.3 ± 0.1 13.2 ± 1.6 -1.6 ± 0.1b a a a 
fenofibrate 6.3 ± 0.3 14.9 ± 2.9 -2.2 ± 0.6b a a a 
The data shown represents mean ± SEM values from 4-7 independent experiments performed in triplicate. 
a It was impossible to determine values for these parameters using GraphPad Prism. 
b
 nH value significantly difference from unity (nH = +/-1). 
c
 value significantly less than that for WIN 55-212-2. 
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4.4.5. Analysis of bias 
In an effort to quantify bias at the CB1 receptor between the different agonist 
responses, intrinsic relative activity (RAi) values were calculated for all agonists 
(see 4.3.5), using HU-210 as the reference agonist (Table 4.4). WIN 55,212-ǻ9-
THC, ACEA and fenofibrate were all shown to be significantly positively biased 
towards ERK signalling versus inhibition of NKH 477-mediated cAMP 
accumulation (Table 4.4; unpaired, two-tailed t-test; p<0.05). In addition, WIN 
was also biased towards PTX-insensitive ERK activation versus PTX-sensitive 
ERK activation, after 5 min of agonist stimulation (Table 4.4; unpaired, two-tailed 
t-test; p<0.05). Some of these parameters were then plotted on a histogram, for 
easier interpretation, with comparison made between the ERK and cAMP 
responses in non-toxin treated cells (Figure 4.12A), and PTX treated cells (Figure 
4.12B).
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Table 4.4 'HWHUPLQDWLRQRILQWULQVLFUHODWLYHDFWLYLWLHVDQGFRPSDULVRQRI5$LYDOXHVǻ5$LIRUFDQQDELQRLGDJRQLVWVDFWLQJDWhuman CB1 receptors expressed in HEK cells 
Agonist RAi - Non-treated cells RAi - PTX-treated cells (500 ng/ml) ǻ5$L-fold difference) 
ERK 
(5 min) 
ERK 
(20 min) 
cAMP ERK 
(5 min) 
ERK 
(20 min) 
cAMP ERK (5 min) 
vs. cAMP 
ERK (5 min) 
PTX vs. NT 
ERK 
(20 min) NT 
vs. PTX 
cAMP NT vs. 
PTX 
CP 55,940 2.44 ± 0.38 
(x100) 
1.14 ± 0.19 
(x100) 
1.43 ± 0.62 
(x100) 
3.41 ± 0.94 
(x100) 
8.34 ± 1.80 
(x10-1) 
5.65 ± 2.15 
(x10-1) 
1.7 1.4 1.4 2.5 
WIN 55,212-2 2.48 ± 0.33 
(x10-1) 
N.D. 4.68 ± 2.82 
(x10-2) 
6.53 ± 1.73 
(x10-1) 
8.59 ± 2.41 
(x10-2) 
1.61 ± 0.85 
(x10-2) 
5.3a 
 
2.6a N.D. 2.9 
ǻ9-THC 1.12 ± 1.06 
(x100) 
N.D. 3.68 ± 2.81 
(x10-2) 
N.D. N.D. N.D. 30.3a N.D. N.D. N.D. 
anandamide 8.06 ± 1.12 
(x10-3) 
N.D. 2.35 ± 1.50 
(x10-2) 
2.28 ± 1.21 
(x10-2) 
N.D. N.D. 0.3 2.8 N.D. N.D. 
methanandamide 1.17 ± 0.30 
(x10-2) 
N.D. 1.63 ± 0.63 
(x10-3) 
1.49 ± 0.12 
(x10-2) 
N.D. N.D. 7.2a 
 
1.3 N.D. N.D. 
ACEA 8.90 ± 2.10 
(x10-3) 
N.D. 6.64 ± 1.96 
(x10-4) 
1.60 ± 0.50 
(x10-2) 
N.D. N.D. 13.4a 
 
1.8 N.D. N.D. 
fenofibrate 1.47 ± 0.33 
(x10-2) 
N.D. 1.12 ± 0.55 
(x10-3) 
N.D. N.D. N.D. 13.2a 
 
N.D. N.D. N.D. 
RAi values are mean ± SEM values from 3-LQGHSHQGHQWH[SHULPHQWVSHUIRUPHGLQUHSOLFDWHǻ5$LYDOXHVDUHWKHIROGGLIIHUHQFHEHWZHHQWKHVWDWHG5$LYDOXHV 
N.D. ± not determined due to lack of curve parameters. 
a
 ± difference between the two RAi values sWDWHGLQWKHFROXPQKHDGHUDVTXDQWLILHGE\WKHǻ5$LYDOXHDUHVLJQLILFDQWO\GLIIHUHQWLQGLFDWLQJDJRQLVWELDVunpaired, t-test; p<0.05). 
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Figure 4.12 Comparison of the RAi values of cannabinoid agonists modulating 
ERK and cAMP responses at CB1 receptors expressed in HEK cells either 
untreated (A), or pre-treated with pertussis toxin (B). The data shown represents 
mean ± SEM values from 3-7 individual experiments performed in replicate. 
Statistical significance was determined using unpaired, two-tailed t-test; *p<0.05, 
**p<0.01, ***p<0.001.  
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4.5. Discussion 
The human embryonic kidney 293 (HEK) cell line, stably transfected with the 
human CB1 receptor is a well characterised model for investigating CB1-mediated 
signalling, including some reports of agonist bias (Lauckner et al., 2005), and, 
therefore, is an attractive model for studying signalling at the CB1 receptor.  
 
Time-course experiments revealed a unique temporal profile for cannabinoid-
mediated ERK activation in HEK-hCB1 cells ± while the initial phase was 
consistent with that observed previously with CHO-hCB1 cells, as well as previous 
reports in the literature (Daigle et al., 2008; Dalton & Howlett, 2012), the 
phospho-ERK response remained elevated from 10 min onwards, rather than 
returning to near basal levels. Furthermore, the initial phase response was only 
partially sensitive to inhibition with pertussis toxin, while the second phase 
appeared to be unaffected. Taken together, these results strongly indicate there are 
two distinct pathways for cannabinoid-mediated ERK signalling in HEK-hCB1 
cells ± a large Gi/o protein-dependent response with a rapid on-set and off-set, and 
a smaller Gi/o protein-independent, PTX-insensitive, response, with a slightly 
delayed onset, which remains activated up to 60 min after agonist stimulation. It 
has been shown that, in addition to Gi/o proteins, CB1 receptor-dependent ERK 
activation can be mediated by activation of Gq proteins (Asimaki et al., 2011), 
ZKLFKLVW\SLFDOO\YHU\UDSLGDQGWUDQVLHQWDQGDOVRYLDȕ-arrestin recruitment (Ahn 
et al., 2013), which is typified by a delayed response of longer duration, making it 
the more likely mediator of the second phase responses. To test this, the effect of a 
hypertonic concentration of sucrose on both the Gi/o protein-dependent and 
independent responses to WIN 55,212-2 was investigated. Sucrose is one of a 
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number of experimental tools used to inhibit the formation of clathrin lattices, 
ZKLFK DUH LPSRUWDQW WR ȕ-arrestin function both in internalisation, and as a 
signalling mediator, with inhibition of this process having previously been shown 
WR GLVUXSW ȕ-arrestin-mediated ERK activation (Luttrell et al., 1997; Lin et al., 
1998). In the present study, the addition of sucrose completely inhibited the Gi/o 
protein-independent response, and while it is not conclusive evidence, it is 
FRQVLVWHQWZLWKPHGLDWLRQRIWKHUHVSRQVHE\ȕ-arrestin. 
 
Characterisation of the initial-phase ERK response using concentration-response 
experiments revealed a familiar pattern of agonist potency and intrinsic activity to 
that reported in the literature (Howlett et al., 2002), as well as that observed in the 
previous chapters, with the notable exceptions of ACEA being less potent than 
expected, relative to the other agonists, while competitive inhibition of all agonist 
responses with AM 251 confirmed that ERK activation was mediated via CB1 
receptors. ACEA had a similar potency in the cAMP assays; these results 
contrasting sharply with those for CHO-hCB1 cells, and with the description in the 
literature of ACEA as a high affinity agonist (Ki ± 1.4 nM; Hillard et al., 1999). It 
is uncertain whether this discrepancy is due to functionally selective signalling or 
whether the agonist undergoes enzymatic degradation in HEK cells.  
 
The agonist-mediated Gi/o protein-independent response at 5 min, in addition to 
being smaller than the Gi/o protein-dependent responses, were also less potent for 
HU-210, CP 55,940 and WIN 55,212-2, further indicating the involvement of a 
distinct signalling pathway. 
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The Gi/o protein-dependent WIN 55,212-2 response at 20 min, produced a bell-
shaped concentration-response curve, characterised by a high potency increase in 
phospho-ERK levels, followed by a sub-maximal ERK activation at 
concentrations above 100 nM - in stark contrast to the responses seen with HU-
210 and CP 55,940. Both the pattern of the response and the fact that both 
components were sensitive to antagonism by AM 251 strongly suggests that WIN 
55,212-2 is functionally selective in regards to ERK signalling at the CB1 receptor. 
Despite the WIN response being qualitatively different from responses to the other 
two agonists, all three responses appeared to be Gi/o protein-dependent. One 
potential explanation for this is that the WIN-mediated inhibition of ERK 
activation may be dependent on a subtype of Gi/o protein distinct from that which 
mediates ERK phosphorylation. The Gi/o protein family includes three subtypes of 
*Įi SURWHLQ DV ZHOO DV WKH *Įo protein. WIN was previously been shown to 
DFWLYDWH D GLVWLQFW SDWWHUQ RI *Įi/o protein subtypes from that of tricyclic 
cannabinoid agonists, such as HU-210 and synthetic endocannabinoid analogues 
(Glass & Northup, 1999; Mukhopadhyay & Howlett, 2005). The WIN response 
was also functionally selective when compared to Gi/o protein-independent ERK 
responses at 20 min, which were sigmoidal for all three agonists. As stated in the 
previous chapter, there is a report of WIN-mediated inhibition of ERK activation 
in rat C6 glioma cells, which activates the Bcl-2-associated death promoter or 
BAD and leads to activation of pro-apoptotic changes in cell physiology (Ellert-
Miklaszewska et al., 2005). The possibility exists, therefore, that WIN may 
selectively activate pro-apoptotic responses in cells via a functionally selective 
CB1 receptor mechanism. Future research should investigate the long term effect 
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of WIN exposure on HEK cell viability and whether WIN selectively activates 
BAD or associated signalling mediators compared to other agonists. 
 
The antibiotic anisomycin, a known activator of stress-activated protein kinases 
produced a significant increase in phospho-JNK and phospho-p38 kinase levels, 
clearly demonstrating that these signalling pathways were active in the HEK cells. 
However, none of the cannabinoid agonists tested was able to activate JNK or p38 
kinase signalling, despite CB1±mediated signalling being previously reported in a 
number of other cell types (Rueda et al., 2000; Bosier et al., 2008; Rajesh et al., 
2010). This lack of JNK and p38 kinase signalling is in agreement with our 
previous observations in CHO-hCB1 cells (see 3.4.4 and 3.4.5), and is potentially 
due to an inability of the receptor to couple to the SAP kinase pathways in these 
cells. 
 
In addition to ERK activation, the cannabinoid agonists were able to inhibit the 
function of AC, as demonstrated by the inhibition of NKH 477-mediated cAMP 
accumulation, which is consistent with the results for CHO-hCB1 cells. However, 
in PTX-treated HEK cells HU-210, CP 55,940 and WIN 55,212-2 produced a 
clear concentration-dependent increase in cAMP levels, most likely due to a shift 
in receptor coupling from Gi/o to Gs proteins, which activate AC. The receptor 
coupling to Gs proteins appeared to be much weaker that the coupling to Gi/o 
proteins as illustrated by the significant decrease in the magnitude of the Gs 
protein responses relative to the Gi/o protein-dependent responses. This is 
potentially due to difference in the expression levels of the various G protein 
subtypes, and the coupling efficiency of the G proteins to AC. While this 
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phenomenon was not observed in our study with CHO-hCB1 cells, CB1 receptor 
coupling to Gs protein in the presence of PTX in other transfected CHO cells and 
primary cultured rat neurons has been reported in the literature (Glass & Felder, 
1997; Maneuf & Brotchie, 1997; Bonhaus et al., 1998). As far as is known, this 
thesis provides the first characterisation of CB1 receptor/Gs protein coupling in 
HEK cells. Furthermore, the responses exhibit a complex pattern of agonist bias ± 
HU-210, CP 55,940, WIN 55,212-2 and anandamide activated both pathways, but 
the other agonists were only effective in the Gi/o protein-dependent pathway. Also, 
while HU-210, CP 55,940, WIN 55,212-2 were equally efficacious in the 
reduction of cAMP levels, WIN 55,212-2 was more efficacious than the other two 
agonists in the Gi/o protein-independent increase in cAMP levels, a pattern which 
is identical to that reported by Bonhaus et al. (1998) in CB1-transfected CHO 
cells. 
 
While separate investigation of the signalling pathways has revealed some clear 
examples of functionally selective signalling, comparison of the agonist responses 
across the signalling pathways by use of intrinsic relative activity (RAi) values is 
QHFHVVDU\ WR TXDQWLI\ OHVV REYLRXV DJRQLVW ELDV ,Q SDUWLFXODU ǻ9-THC was 
markedly positively biased towards ERK activation versus inhibition of cAMP 
accumulation, shown by the relatively greater intrinsic activity in ERK activation, 
compared to modulation of cAMP. In addition WIN 55,212-2 appeared uniquely 
biased towards Gi/o protein-independent versus Gi/o protein-dependent ERK 
signalling at the 5 min stimulation time-point, again demonstrated by the relatively 
greater intrinsic activity at the Gi/o protein-independent signalling pathway. These 
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results illustrate the sometimes subtle pattern of agonist bias, as well as validating 
the use of RAi to quantify functional selectivity at the CB1 receptor. 
 
4.6. Conclusions 
In conclusion, the results shown in this chapter clearly demonstrate that 
cannabinoid agonists are able to modulate ERK and AC signalling in HEK cells 
via transfected human CB1 receptors coupled to Gi/o protein-dependent and 
independent signalling pathways. Furthermore, activation of these signalling 
pathways exhibits clear examples of agonist bias, with ligand-selective differences 
in temporal ERK signalling, coupling to AC and differential activation between 
these two main signalling pathways. 
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Chapter 5 
 
Investigation of Functional Selectivity at the Cannabinoid 
Receptor in an Endogenously Expressing Cell Line, Neuro 
2a  
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5.1. Introduction 
The Neuro-2a cell line is a neuroblastoma cell line derived from a spontaneous 
tumour from a strain A albino mouse (Klebe & Ruddle, 1969). Under normal 
culture conditions, the cells are spherical and undergo mitotic division. Removal 
of serum from the culture medium, or treatment with retinoic acid promotes cell 
differentiation, halting mitosis and causing cells to produce neurite outgrowths, 
needle-like projections several times the length of the cell body. 
 
PCR analysis has detected CB1 receptor mRNA in both native (Graham et al., 
2006; Jung et al., 2011) and differentiated Neuro 2a cells, with treatment with 
retinoic acid resulting in a 3-fold increase in the observed mRNA levels (Jung et 
al., 2011). Immunocytochemical studies have confirmed the presence of receptor 
protein, the majority of which appears to be within the cytoplasm with the 
remainder present in the cell membrane (Graham et al., 2006; Rozenfeld et al., 
2012). Indeed, a recent study calculated the proportion of intracellular receptor 
expression to be 68% of the total receptor population (Grimsey et al., 2010). No 
report has been made on the presence of CB2 receptor in Neuro 2a cells, however 
due to their neuronal phenotype, they are unlikely to be present. 
 
Treatment of undifferentiated Neuro 2a cells with cannabinoid agonists induces 
neurite outgrowth, akin to that seen in cell differentiation. Indeed, there is some 
evidence to suggest that Neuro 2a differentiation involves the cannabinoid system. 
Treatment of Neuro 2a cells with retinoic acid, causes an elevation of 2-AG levels, 
DVZHOODVXSUHJXODWLRQRIWKH'$*OLSDVHĮDQGȕDQGWKH&%1 receptor (Jung et 
al., 2011), which is coupled to increased levels of neurite outgrowth. Addition of 
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the CB1-selective antagonist rimonabant blocks retinoic acid-mediated neurite 
outgrowth. 
 
Jordan et al. (2005) were the first to characterise CB1 receptor-linked signalling in 
Neuro 2a cells, by demonstrating receptor-mediated regulation of Rap1, a member 
of the Ras superfamily of small GTPases, important to signal transduction. 
Treatment with the cannabinoid agonist HU-210 promoted the proteasomal 
degradation of the precursor Rap1GAPII, leading to Rap1 activation, in a 
rimonabant- and pertussis toxin-sensitive manner. In addition, treatment with 
rimonabant, PTX and expression of dominant negative Rap1 all blocked 
cannabinoid-induced neurite outgrowth. Further research more fully characterised 
this signalling pathway as illustrated in Figure 5.1, revealing sequential signal 
transduction, leading to STAT3 activation (He et al., 2005). STAT3 is a 
transcription factor known to regulate numerous cell processes in response to cell 
stimuli, including growth and apoptosis (Qi & Yang, 2014). Treatment with HU-
210 led to phosphorylation of Src and STAT3 in a rimonabant and PTX-sensitive 
manner, resulting in neurite outgrowth. A series of experiments determining the 
effects of dominant negative variant of the proteins Rap1, Ral, Src, STAT3 and 
Rac on protein activation and neurite outgrowth enabled the sequential profile of 
the transduction pathway to be elucidated (Figure 5.1). Src appeared to activate 
STAT3 both directly and indirectly via the phosphorylation of JNK. More 
recently, other studies have used STAT3 phosphorylation as a measure of CB1 
receptor activation in Neuro 2a cells, further validating this pathway (Rios et al., 
2006; Zorina et al., 2010). 
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Figure 5.1 Schematic of CB1 receptor Rap1/STAT3 signal transduction 
pathway in Neuro 2a cells. Activation of the cannabinoid CB1 receptor results in 
the sequential activation of proteins leading to the phosphorylation of STAT3 and 
induction of neurite outgrowth. Adapted from He et al., 2005. 
 
Separately, Graham et al. (2006), identified a second CB1 receptor signalling 
cascade in Neuro 2a cells involving the ERK-dependent activation of early growth 
response protein 1 or EGR1 (previously referred to as Krox-24), illustrated in 
Figure 5.2. Like STAT3, EGR1 is a transcription factor which upregulates target 
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genes involved in differentiation and mitogenesis. It appears to have a particular 
role in neuronal tissue, where EGR1 activation is associated with increased 
neuronal activity and neuronal plasticity (Knapska & Kaczmarek, 2004). 
Stimulation of Neuro 2a cells with HU-210 led to increased levels of ERK1/2 
phosphorylation and induction of EGR1 mRNA and protein. Both responses were 
blocked by the addition of rimonabant and U0126, a MEK inhibitor. Interestingly, 
it was observed that blockade of the PI3K/Akt pathway or short term removal of 
serum (which contains factors which activate the PI3K/Akt pathway), resulted in a 
large increase in the proportion of cells exhibiting CB1-dependent EGR1 
induction, as well as an increase in the magnitude of both the pERK and EGR1 
responses. Serum starvation or treatment with retinoic acid over 3 days (i.e. 
differentiating cells) all but abolished CB1-mediated EGR1 responses, suggesting 
that this pathway is present only in mitotic cells. 
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Figure 5.2 Schematic of CB1 receptor ERK/CREB/EGR1 (Krox-24) signal 
transduction pathway in Neuro 2a cells. Activation of CB1 receptor leads to 
activation of the ERK signalling pathway resulting in induction of EGR1 (Krox-
24). Adapted from Graham et al., 2006. 
 
It is interesting to note that Graham et al. (2006) clearly state they were unable to 
detect any change in the level of phospho-JNK, as well as phospho-p38, upon 
stimulation with HU-210. These results are in contrast to the pattern of JNK 
activation observed by He et al. (2005). These conflicting results may potentially 
be explained by differences in the cell culture regimens used - He et al., cultured 
cells in DMEM/F12 mixture with cells being serum starved for 24 hours prior to 
HU-210 treatment while Graham et al., cultured cells in DMEM alone, and treated 
cells in medium containing 10% FBS. Additionally, it is possible that the two 
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studies used two different sub clones of the Neuro 2a cell line, leading to putative 
differences in protein expression and phosphorylation. 
 
5.2. Aims and objectives 
As far as can be ascertained, only HU-210 and rimonabant have been used to 
investigate CB1-mediated functional responses in Neuro 2a cells. The aim of this 
chapter was to investigate functionally selective responses at the CB1 receptor in 
Neuro 2a cells by stimulating cells with a range of cannabinoid agonists. This will 
be achieved by measuring the modulation of a number of signal transduction 
mediators including the MAP kinases ERK, JNK, the transcription factor STAT3 
and the enzyme adenylyl cyclase (AC) via changes in cAMP levels. This cell line 
provides an attractive model to investigate CB1 receptor functional selectivity as it 
endogenously expresses the receptor, and has been shown to couple to at least two 
distinct signalling pathways. 
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5.3. Methods 
5.3.1. Cell culture 
Neuro 2a cells were kindly provided by Annabelle Chambers, (University of 
Nottingham). All cell culture was performed under sterile conditions in a class II 
laminar flow cabinet. All culture reagents were heated to 37°C before use. Cells 
were cultured in 175 cm2 FXOWXUH IODVNV FRQWDLQLQJ 'XOEHFFR¶V 0RGLILHG (DJOH
Medium supplemented with 10% foetal bovine serum, 2 mM L-glutamine and 1% 
penicillin-streptomycin, in a humidified incubator at 37°C and 5 % CO2. Cells 
were cultured for 3 days until ~90% confluent, and then passaged. Cells were 
washed once with phosphate-buffered saline (PBS), and then incubated with 
trypsin/EDTA solution for at least 5 min until the majority of cells were detached 
from the culture flask. The cell suspension was diluted in culture medium to 
prevent further action of the trypsin, and then cells were collected by 
centrifugation at 200 x g for 5 min. The cell pellet was resuspended in fresh 
culture medium and the cell number determined using the Bio-5DG 7&
Automated Cell Counter; cells were then reseeded into new culture flasks 
containing fresh culture medium (4 million cells/flask). 
 
5.3.2. cAMP accumulation assay 
Levels of cAMP accumulation were determined using the DiscoveRx HitHunter® 
cAMP XS+ assay kit. Cells were seeded into white 96-well assay plates at 10,000 
cells/well (unless otherwise stated) in assay medium, comprising serum-free 
culture medium containing rolipram (10 µM), forskolin (10 µM) and 1 mg/ml 
BSA. Each subsequent step was followed by an incubation period of 30 min at 
room temperature in a final assay volume of 30 µl. Cells were treated with serial 
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dilutions of cannabinoid ligands, performed in assay medium. Once ligand 
treatment was complete, the assay was terminated by cell lysis via the addition of 
ED/Lysis CL working solution (40 µl/well) followed by the addition of EA 
reagent (40 µl/well). The relative chemiluminescent signal, corresponding to the 
cAMP concentration, was detected using a PerkinEOPHU 7RS&RXQW 1;7 7KH
data were expressed as a % of the cAMP accumulation in the presence of forskolin 
(10 µM). 
 
5.3.3. Determination of protein phosphorylation 
5.3.3.1. Protocol 
Levels of protein phosphorylation were determined using the In-&HOO :HVWHUQ
assay. Cells were seeded into 96-well clear bottom plates, at 20,000 cells/well 
(unless otherwise stated) in culture medium overnight at 37°C. All subsequent 
additions to assay plates, including compound addition were made against the well 
wall, to minimise perturbation of the cell monolayer. 24 hrs prior to 
experimentation, the culture medium was removed from the assay plates by gentle 
aspiration, and the medium replaced with serum-free medium. Cells were not 
washed with PBS, to minimise perturbation of the cell monolayer. Serial dilution 
of test ligands was performed in serum-free medium and added to test wells to a 
final volume of 200 µl per well. Assay plates were incubated for the stated period 
at 37°C during experimentation. After incubation, the assay medium was rapidly 
aspirated and the cells were fixed with 4% paraformaldehyde in PBS for 20 min at 
room temperature (150 µl/well). Each reagent was aspirated before the addition of 
WKHQH[WUHDJHQW&HOOVZHUHWKHQSHUPHDELOLVHGZLWKYY7ULWRQ;-100 in 
PBS for 20 min at room temperature (150 µl/well). Non-specific antibody binding 
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sites were blocked with 5% (w/v) milk powder in PBS for 20 min at room 
temperature with gentle rocking. 
 
Primary antibodies for anti-total and anti-phosphorylated proteins (ERK1/2, 
JNK1/2/3 and STAT3; see 5.3.3.3) were diluted together in blocking agent. Cells 
were incubated with primary antibody solution (50 µl/well) overnight at 4°C with 
gentle rocking. Control wells without primary antibody, to give a measure of the 
non-specific binding of the secondary antibody, were incubated with blocking 
solution only. The next day, the primary antibody solution was aspirated and the 
cells were washed three times with PBS containing 1 mg/ml BSA (150 µl/well) 
for 5 min at room temperature with gentle rocking. The appropriate LI-COR 
IRDye® secondary antibodies were diluted 1:4000 in blocking agent, added to the 
cells (50 µl/well), and incubated in darkness for 60 min at 37°C with gentle 
shaking. The secondary antibody solution was aspirated and the cells washed three 
times with wash buffer as before. 
 
5.3.3.2. Imaging 
Plates were imaged by scanning simultaneously at 700 and 800 nm with the LI-
COR Odyssey® NIR Imaging System at 82 µm resolution, medium quality and 
focus offset of 4.0123 mm. Quantification was performed using LI-COR 
Odyssey® Software v3.0. Unless otherwise stated, the secondary antibody non-
specific response was subtracted from the data. The phospho- response was then 
normalised against the total protein response for each individual well and then the 
data was expressed as a percentage of the basal response. 
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5.3.3.3. Antibodies used 
All primary antibodies used were obtained from Cell Signaling Technology 
(Boston, USA). All antibodies were used at the concentrations described below 
unless otherwise stated in Results (see 5.4). Anti-ERK1/2 rabbit, (1:400) # 9102; 
anti-phospho-ERK1/2 (Thr202/Tyr204) monoclonal mouse, (1:800) # 9106; anti-
JNK rabbit, (1:400) # 9252; anti-phospho-JNK (Thr183/Tyr185) monoclonal 
mouse, (1:400) # 9255.; anti-STAT3 monoclonal mouse (1:800) #9139; anti-
phospho-STAT3 (Tyr705) XP monoclonal rabbit #9145. Secondary antibodies 
were obtained from LICOR, IRDye® labelled goat anti mouse (IRDye® 800CW 
conjugate) and goat anti-rabbit (IRDye® 680CW conjugate) secondary antibodies. 
 
5.3.4. Data and statistical analysis 
All data were analysed using the GraphPad Prism software (v6). Concentration-
response data were fitted to curves using the four-parameter logistic equation, 
previously described in Chapter 2 ± Methods (see 2.3.7). 
 
Estimates for the antagonist AM 251 equilibrium dissociation constant (pKB) and 
calculation of the intrinsic relative activities (RAi) for each individual agonist 
were as previously described in Chapter 3 ± Methods (see 3.3.6). 
 
5.3.5. Statistics 
The quantitative data are expressed as means ± SEM, obtained from at least three 
independent experiments performed in replicate, unless otherwise stated. 
1RUPDOLW\ RI GDWD VHWV ZDV GHWHUPLQHG XVLQJ WKH '¶$JRVWLQR-Pearson omnibus 
normality test. 6WDWLVWLFDOVLJQLILFDQFHRIGLIIHUHQFHVZDVGHWHUPLQHGE\6WXGHQW¶V
196 
 
paired, two-tailed t-test or ANOVA followed by 'XQQHWW¶VPXOWLSOHFRPSDULVRQV
post-hoc multiple comparison tests where appropriate. A p value of <0.05 was 
considered significant. 
 
5.4. Results 
5.4.1. Determination of ERK phosphorylation 
Assay Optimisation 
Initial testing of undifferentiated Neuro 2a cells revealed them to be only semi-
adherent when cultured, with excessive perturbation of the cell monolayer causing 
significant cell detachment. An optimised protocol for the experiment was 
developed in which changing of culture medium and washing was minimised, 
additions to test wells, including addition of compound were made slowly and 
against the side of the well and the volume of the addition was minimised. This 
experimental technique resulted in suitable numbers of adherent Neuro 2a cells for 
use in immunocytochemical-based In-Cell Western assays, and was employed in 
all subsequent phosphorylation assays. Once fixed with paraformaldehyde, the cell 
monolayers were found to be highly adherent, with no additional measures 
necessary.  
 
A preliminary experiment was performed to determine the optimal cell seeding 
number and phospho-ERK antibody concentration for all subsequent assays 
(Figure 5.3). Cells were stimulated with HU-210 (1 µM) for 5 min, before 
fixation and immunocytochemical staining. A cell seeding density of 20,000 
cells/well produced the largest magnitude response of all cell densities at all three 
antibody dilutions tested. Within this there was an increase in response magnitude 
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as antibody concentration decreased with a 1:800 dilution giving the largest 
response. 
 
On the basis of these results, a cell seeding density of 20,000 cells/well and a 
phospho-ERK primary antibody dilution of 1:800 were chosen as optimal 
conditions for all subsequent experiments. 
 
 
 
Figure 5.3 Optimisation of ERK phosphorylation assay in Neuro 2a cells. Cells 
(20, 40, 60 and 80 000 cells/well) were cultured in medium for 24 hr, followed by 
serum starvation for 24 hr. Cells were stimulated with HU-210 (1 µM) for 5 min, 
followed by rapid fixation with cold PFA solution (4 % w/v). Detection of total 
and phospho-ERK levels was as stated in methods (see 5.3.3). Individual ERK 
phosphorylation values were normalised to the corresponding total-ERK values. 
The data shown represent a single experiment performed in quadruplicate and are 
given as mean ± SEM. 
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Effect of cannabinoid agonists on ERK phosphorylation ± time course 
Neuro 2a cells were treated with high concentrations of the cannabinoid agonists 
HU-210, CP 55,940 (both 1 µM), WIN 55,212- ǻ9-THC, anandamide, 
methanandamide, arachidonyl-2'-chloroethylamide (ACEA) and fenofibrate (all 
10 µM) at various time point (2.5 ± 90 min) to identify any differences in the 
DJRQLVWV¶ WHPSRUDO SURILOH DQG WRGHWHUPLQHZKLFK WLPHSRLQWZRXOGSURYLGH WKH
maximum phospho-ERK response for use in concentration-response experiments. 
Addition of vehicle (assay buffer) was included as a negative control. 
 
All agonists produced a rapid increase in phospho-ERK levels with the maximum 
response occurring between 5 and 10 min (Figure 5.4). After this time period the 
phospho-ERK levels for all agonists steadily decreased, reaching a constant, near-
EDVDOOHYHODWPLQ7KHUHZHUHFOHDUSDWWHUQVRISDUWLDODJRQLVPSUHVHQWZLWKǻ9-
THC, anandamide and ACEA all producing smaller maximum responses than 
those of the representative full agonist HU-210. None of the agonists tested 
produced a noticeable second-phase response, up to 90 min. 
 
On the basis of these results, an agonist stimulation period of 7.5 min was chosen 
for the subsequent concentration-response experiments. 
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Figure 5.4 Effect of cannabinoid 
agonists on ERK phosphorylation 
in Neuro 2a cells over time. Cells 
(20,000 cells/well) were cultured 
in medium for 24 hr, followed by 
serum starvation for 24 hr. Cells 
were stimulated with cannabinoid 
agonists at various time points 
(2.5 - 90 min), followed by rapid 
fixation with cold PFA solution (4 
% w/v). Detection of total and 
phospho-ERK levels was as stated 
in methods (see 5.3.3). The data 
shown represents mean ± SEM 
values from five independent 
experiments performed in 
triplicate. 
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Effect of cannabinoid agonists on ERK phosphorylation ± concentration response 
All agonists produced a concentration-dependent increase in phospho-ERK levels 
(Figure 5.5). The rank order of pEC50 values of the agonists acting on Neuro 2a 
cells from highest to lowest was HU-&3!:,1-ǻ9-THC 
! $&($  P$($ ! $($ ! IHQRILEUDWH Table 5.1). There was no significant 
difference in the agonist Rmax values (Table 5.1; one-way ANOVA; p>0.05). 
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Figure 5.5 Effect of cannabinoid agonists on ERK phosphorylation in Neuro 2a 
cells. Cells (20,000 cells/well) were cultured in medium for 24 hr, followed by 
serum starvation for 24 hr. Cells were stimulated with various concentrations of 
cannabinoid agonists for 7.5 min, followed by rapid fixation with cold PFA 
solution (4 % w/v). Detection of total and phospho-ERK levels was as stated in 
methods (see 5.3.3). Individual ERK phosphorylation values were normalised to 
the corresponding total-ERK values. The data shown represents mean ± SEM 
values from 4-5 independent experiments performed in triplicate. The curves were 
fitted using GraphPad Prism. 
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To confirm the role of the CB1 receptor in the cannabinoid agonist responses, the 
concentration-response experiments were repeated in the presence of the CB1-
selective competitive antagonist AM 251 (10 nM). AM 251 produced a significant 
rightward shift of all the agonist concentration-response curves, resulting in 
significant decreases in all the pEC50 values (Figure 5.6). These data were used to 
estimate the equilibrium dissociation constant (pKB) for AM 251 in the presence 
of each individual agonist (Table 5.1).  There was no significant difference 
between the pKB YDOXHV H[FHSW IRU WKH YDOXH GHWHUPLQHG XVLQJ ǻ9-THC, which 
was significantly greater than that determined using anandamide (one-way 
ANOVA; p<0.01). 
 
Table 5.1 
Determination of potency (pEC50), maximal response, expressed as a % of the 
basal response (Rmax), and estimated AM 251 dissociation constant (pKB) of 
cannabinoid agonists on ERK phosphorylation in Neuro-2a cells. 
Agonists pEC50 Rmax (%  basal) pKB 
HU-210 10.3 ± 0.1 113 ± 17 9.4 ± 0.1 
CP 55,940 10.0 ± 0.1 112 ± 23 9.6 ± 0.2 
WIN 55,212-2 9.0 ± 0.1 86 ± 15 9.5 ± 0.4 
ǻ9-THC 8.7 ± 0.2 96 ± 14 10.3 ± 0.1a 
Anandamide 7.3 ± 0.4 107 ± 28 8.9 ± 0.2 
Methanandamide 8.0 ± 0.2 85 ± 10 9.6 ± 0.1 
arachidonyl-2'-chloroethylamide 8.2 ± 0.2 96 ± 8 9.5 ± 0.2 
Fenofibrate 7.2 ± 0.1 98 ± 14 9.6 ± 0.1 
Data shown are mean ± SEM values from 5 independent experiments performed 
in triplicate. 
a
 Value significantly greater than that calculated using anandamide; one-way 
$129$ZLWK'XQQHWW¶VPXOWLSOHFRPSDULVRQVWHVW, p<0.01. 
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Figure 5.6 Effect of CB1-selective antagonist AM 251 on cannabinoid agonists 
ERK phosphorylation concentration-response curves in Neuro 2a cells. Cells 
(20,000 cells/well) were cultured in medium for 24 hr, followed by serum 
starvation for 24 hr. Cells were pre-treated with AM 25żRUOHIWXQWUHDWHGƔ
for 10 min, followed by stimulation with various concentrations of cannabinoid 
agonists for 7.5 min, followed by rapid fixation with cold PFA solution (4 % w/v). 
Detection of total and phospho-ERK levels was as stated in methods (see 5.3.3). 
Individual ERK phosphorylation values were normalised to the corresponding 
total-ERK values. The data shown represents mean ± SEM values from 4-5 
independent experiments performed in triplicate. The curves were fitted using 
GraphPad Prism.  
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5.4.2. Determination of JNK1/2/3 phosphorylation 
Assay Optimisation 
A preliminary experiment was performed to determine the optimal phospho-
JNK1/2/3 antibody concentration for all subsequent assays (Figure 5.7). Cells 
were stimulated with hydrogen peroxide (5 mM) at various time points (5 ± 60 
min), before fixation and immunocytochemical staining. Hydrogen peroxide 
produced an apparent continual increase in phospho-JNK levels. The magnitude of 
this response was greatest for 1:400 dilution of the primary phospho-JNK 
antibody, followed by 1:800 and then 1:200. On the basis of these results, a 
primary antibody dilution of 1:400 was chosen as optimal for all subsequent 
experiments. 
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Figure 5.7 Optimisation of JNK1/2/3 phosphorylation assay in Neuro 2a cells. 
Cells (20,000 cells/well) were cultured in medium for 24 hr, followed by serum 
starvation for 24 hr. Cells were stimulated with hydrogen peroxide (5 mM) for 
various time points (5 - 60 min), followed by rapid fixation with cold PFA 
solution (4 % w/v). Detection of total and phospho-JNK levels was as stated in 
methods (see 5.3.3 ZLWK  Ÿ  Ƒ DQG  Ɣ GLOXWLRQ RI WKH
primary phospho-JNK antibody tested. Individual JNK phosphorylation values 
were normalised to the corresponding total-JNK values. The data shown represent 
a single experiment performed in quadruplicate and are given as mean ± SEM. 
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Effect of cannabinoid agonists on JNK phosphorylation ± time course 
As in the optimisation experiment, the positive control hydrogen peroxide was 
able to significantly increase phospho-JNK levels in Neuro 2a cells from 5 min 
onwards (Figure 5.8; one way ANOVA; p<0.05). None of the cannabinoids tested 
was able to elicit a phospho-JNK response which was either significantly different 
from the basal phospho-JNK levels, or significantly different from the vehicle 
control (Figure 5.8; one-way ANOVA; p>0.05). 
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Figure 5.8 Effect of cannabinoid agonists on JNK 
phosphorylation in Neuro 2a cells against time. 
Cells (20,000 cells/well) were cultured in medium 
for 24 hr, followed by serum starvation for 24 hr. 
Cells were stimulated with cannabinoid agonists 
at various time points (5 - 60 min), followed by 
rapid fixation with cold PFA solution (4 % w/v). 
Detection of total and phospho-JNK levels was as 
stated in methods (see 5.3.3). The data shown 
represents mean ± SEM values from four 
independent experiments performed in triplicate. 
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5.4.3. Determination of STAT3 phosphorylation 
Assay Optimisation 
A preliminary experiment was performed to optimise the phospho-STAT3 
antibody concentration for all subsequent assays. Cells were stimulated with foetal 
bovine serum (FBS; 10 % v/v) for 5 min before fixation and immunocytochemical 
staining. FBS produced an apparent increase in phospho-STAT3 levels, relative to 
the basal. The magnitude of this response was greatest with the 1:50 dilution of the 
phospho-STAT3 antibody, and decreased as the antibody concentration decreased. 
On the basis of these results, a primary phospho-STAT3 antibody dilution of 1:50 
was chosen as optimal for all subsequent experiments. 
 
One technical issue with the assay was the lack of discernible difference between 
the basal phospho-STAT3 levels and the non-specific binding (NSB) of the 
secondary antibody (i.e. binding of secondary antibody in the absence of the 
phospho-STAT3 primary antibody), at even the highest primary antibody 
concentration, as shown in Figure 5.9. This indicates that the basal phospho-
STAT3 levels are below the sensitivity range of the assay. In some instances, 
subtraction of the mean NSB values from the datasets, as stated in Methods (see 
5.3.3.), resulted in non-representative negative values. For this reason, the NSB for 
the phospho-STAT3 results was not subtracted from the other data as part of the 
data analysis.  
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Figure 5.9 Effects of FBS on STAT3 phosphorylation in Neuro 2a. Cells (20,000 
cells/well) were cultured in medium for 24 hr, followed by serum starvation for 24 
hr. Cells were stimulated with foetal bovine serum (10 % v/v)  for 5 min, followed 
by rapid fixation with cold PFA solution (4 % w/v). Detection of total and 
phospho-STAT3 levels was as stated in methods with various primary phospho-
STAT3 antibody dilutions tested (see 5.3.3). The data shown represent a single 
experiment, performed in quadruplicate and are given as mean ± SEM. 
 
Effect of cannabinoid agonist HU-210 on STAT3 phosphorylation ± time course 
The positive control FBS produced a rapid increase in the phospho-STAT3 levels, 
reaching a maximum response at 5 min, and steadily decreasing to return to a 
basal plateau from 60 min onwards (Figure 5.10). HU-210 was unable to produce 
a marked change in phospho-STAT3 levels over the same time course. Due to the 
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prohibitively high primary antibody concentration needed for a functional assay, 
and given that HU-210 appeared to have no effect on phospho-STAT3 levels, no 
additional cannabinoid agonist was tested for STAT3 activation. 
 
 
Figure 5.10 Effect of HU-210 on STAT3 phosphorylation in Neuro 2a cells 
against time. Neuro 2a cells (20,000 cells/well) were cultured in medium for 24 hr, 
followed by serum starvation for 24 hr. Cells were stimulated with foetal bovine 
serum (10 % v/v) or HU-210 (1 µM)  at various time points (5 ± 180 min), 
followed by rapid fixation with cold PFA solution (4 % w/v). Detection of total 
and phospho-STAT3 levels was as stated in methods (see 5.3.3). The data shown 
are given as mean ± SEM. 
 
5.4.4. Determination of agonist effects on intracellular cAMP levels 
Assay Optimisation 
A preliminary experiment was performed to determine the optimal cell seeding 
density and concentration of forskolin for use in subsequent assays (Figure 5.11). 
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Forskolin produced a concentration-dependent increase in intracellular cAMP 
levels at all cell seeding densities tested. The span of the forskolin concentration-
response markedly increased as the cell number was increased from 5,000 to 
10,000 cells/well, while there appeared to be no apparent difference in the curve 
spans between 10, 20 and 40,000 cells/well. There was no apparent effect of the 
cell number on the concentration-response curve pEC50 values.  
 
On the basis of these results, a cell seeding density of 10 000 cells/well and a 
forskolin concentration of 10 µM, as corresponding to the pEC80, were chosen as 
optimised conditions for all subsequent experiments. 
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Figure 5.11 Optimisation of the cAMP assay in Neuro-2a cells. Cells (5, 10, 20 
and 40 000 cells/well) in suspension in serum-free medium were pre-treated with 
the phosphodiesterase inhibitor rolipram for 10 min before incubation with 
increasing concentrations of forskolin (0.1 ± 100 µM) for 30 min at room 
temperature. At the end of the incubation period, the assay was terminated by the 
addition of lysis buffer and the relative levels of cAMP determined using the 
HitHunter assay kit. The data shown represents a single experiment performed in 
triplicate, and are shown as mean ± SEM. The curves were fitted using GraphPad 
Prism. 
 
Inhibition of forskolin-stimulated cAMP accumulation 
Neuro 2a cells, treated with forskolin and the phosphodiesterase PDE4 inhibitor 
rolipram (both 10 µM), were stimulated with increasing concentrations of the 
cannabinoid agonists to determine the ability of these compounds to inhibit 
forskolin-stimulated cAMP accumulation (Figure 5.12). HU-210, CP 55,940, 
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WIN 55,212-2, anandamide and ACEA produced concentration-dependent 
GHFUHDVHV LQ F$03 DFFXPXODWLRQ ZKLOH ǻ9-THC, methanandamide and 
fenofibrate had no apparent effect with GraphPad Prism software unable to fit 
concentration-response curves to these data. 
 
 
Figure 5.12 Effect of cannabinoid agonists on cAMP accumulation in Neuro 2a 
cells. Cells in suspension in serum-free medium were pre-treated with forskolin 
and rolipram (both 10 µM) for 10 min before incubation with increasing 
concentrations of cannabinoid agonists (see figure legend for list) for 30 min at 
room temperature. At the end of the incubation period, the assay was terminated 
by the addition of lysis buffer and the relative levels of cAMP determined using 
the HitHunter assay kit. The data shown represent mean ± SEM values from 4-6 
individual experiments performed in triplicate. The curves were fitted using 
GraphPad Prism. 
 
The rank order of potency (pEC50) of the agonists which are able to inhibit cAMP 
DFFXPXODWLRQIURPKLJKHVWWRORZHVWZDV&3+8-210 > WIN 55,212-2 > 
$&($  DQDQGDPLGH Table 5.2). The Rmax of WIN 55,212-2 was significantly 
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greater than all the other agonists except CP 55,940, (Table 5.2; one-way 
ANOVA; p<0.05) while the Rmax values for the other agonists were not 
significantly different from each other. 
 
Table 5.2 
Determination of potency (pEC50) and percentage of basal maximal response 
(Rmax) of cannabinoid agonists on Neuro-2a cells measuring inhibition of 
forskolin-stimulated cAMP accumulation 
Agonists pEC50 Rmax 
HU-210 7.9 ± 0.1 10 ± 1 
CP 55,940 8.1 ± 0.2 15 ± 2 
WIN 55,212-2 7.1 ±0.2 20 ± 4b 
ǻ9-THC a a 
Anandamide 6.3 ± 0.1 13 ± 3 
Methanandamide a a 
arachidonyl-2'-chloroethylamide 6.5 ± 0.2 12 ± 1 
Fenofibrate a a 
Data shown are mean ± SEM values from 5 independent experiments performed 
in triplicate. 
a It was impossible to determine values for these parameters using GraphPad 
Prism. 
b
 Value significantly greater than that for all other agonists, except CP 55,940. 
   
  
Effect on cAMP accumulation in pertussis toxin-treated cells 
Neuro 2a cells, treated overnight (16-18 hr) with pertussis toxin, which inhibits 
Gi/o protein function, were stimulated with increasing concentrations of the 
cannabinoid agonists to determine the potential ability of these compounds to 
increase, rather than inhibit cAMP accumulation (Figure 5.13). Forskolin 
produced a concentration-dependent increase in cAMP levels (Figure 5.13A). 
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Interestingly, the pEC50 for forskolin in the PTX-treated cells was markedly lower 
than compared to in the untreated cells (PTX ± 4.9 ± 0.1; untreated ± 5.6 ± 0.1). 
None of the cannabinoid agonists tested produced any significant effect on the 
cAMP levels (Figure 5.13B). High concentrations of some agonists, particularly 
anandamide and ACEA, were able to produce an increase in cAMP levels of 
around 5 % of the forskolin stimulated response, however as stated, these were not 
significantly greater than the basal. 
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Figure 5.13 Effect of forskolin (A) and cannabinoid agonists (B) on cAMP 
accumulation in Neuro 2a cells cultured with PTX (100 ng/ml). Cells in 
suspension in serum-free medium were pre-treated with rolipram (both 10 µM) for 
10 min before incubation with increasing concentrations of cannabinoid agonists 
for 30 min at room temperature. At the end of the incubation period, the assay was 
terminated by the addition of lysis buffer and the relative levels of cAMP 
determined using the HitHunter assay kit. The data shown represent mean ± SEM 
values from four individual experiments performed in triplicate. The curves were 
fitted using GraphPad Prism. 
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5.4.5. Analysis of agonist bias 
To quantify the agonist bias present at the Neuro 2a CB1 receptor, intrinsic relative 
activity (RAi) values were calculated for the agonists HU-210, CP 55,940, WIN 
55,212-2, AEA and ACEA for both the ERK and cAMP responses (Figure 5.14). 
The RAi values were estimated using WIN 55,212-2 as the reference agonist, as 
opposed to the endogenous ligand anandamide, as it was the only agonist to 
produce a clear response from which to derive curve parameters in all individual 
experiments. The RAi value for HU-210 ERK response was significantly greater 
than that for the HU-F$03UHVSRQVHZLWKDǻ5$i value of 12.8 (Figure 5.14; 
unpaired, two-tailed t-test; p<0.05), whereas there was no significant difference 
between the two values for the other agonists. 
 
 
Figure 5.14 Comparison of the RAi values of cannabinoid agonists modulating 
ERK and cAMP responses in Neuro 2a cells via CB1 receptors. The data shown 
represent mean ± SEM values from 5-6 individual experiments performed in 
triplicate. Statistical significance was determined using unpaired, two-tailed t-test; 
*p<0.05. 
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5.5. Discussion 
Neuro 2a cells are a murine neuroblastoma cell line which has been previously 
shown to express the CB1 cannabinoid receptor using both PCR analysis and 
immunocytochemistry, which in turn has been shown to couple to at least two 
distinct intracellular signalling pathways. This provides an attractive model to test 
the concept of functional selectivity at the CB1 receptor, by measuring CB1-
mediated responses to a range of cannabinoid agonists.  
 
The first intracellular mediators to be investigated were the extracellular signal-
regulated kinases or ERK, a family of mitogen-activated protein kinases which 
regulate numerous cellular responses, including gene expression, growth, cellular 
transformation and apoptosis (Pearson et al., 2001). Initial testing showed that 
HU-210 was clearly able to promote ERK phosphorylation after 5 minutes of 
stimulation with optimised conditions for cell number and primary phospho-ERK 
antibody dilution determined. These results are in keeping with previous reports 
which showed HU-210-mediated ERK phosphorylation in Neuro 2a cells (Graham 
et al., 2006; Zorina et al., 2010). It is of note that these results are the first 
published example of quantification of cannabinoid-mediated ERK signalling in 
Neuro 2a cells using the In-Cell Western technique, as most previously reported 
studies utilised Western blotting to measure phosphorylated protein levels. 
Subsequent time course experiments using HU-210 and the other cannabinoid 
agonists CP 55,940, WIN 55,212- ǻ9-THC, anandamide, methanandamide, 
ACEA and fenofibrate showed that all were able to promote ERK 
phosphorylation. The temporal profiles for all agonists tested were similar to each 
other, as well as generally consistent with those reported in other results chapters 
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for receptors expressed in CHO and HEK cell lines, i.e. phospho-ERK levels 
increased rapidly upon stimulation with agonist, reaching a peak between 5 ± 10 
mins, after which they steadily returned to near basal levels after 45 min. The 
results for HU-210 were also consistent with those reported by Graham et al. 
(2006), which showed a maximum response reached after 5 - 10 min and with 
subsequently decreased phospho-ERK levels at 20 and 40 min. However, in 
contrast to our findings, a report from Zorina et al. (2010) at Mount Sinai School 
of Medicine indicated an initial-phase maximum HU-210-mediated phospho-ERK 
response at 50 min. These differences may be due to different experimental 
technique, or use of different subclones of the Neuro 2a cell line.  
 
All agonist-mediated phospho-ERK responses were clearly shown to be 
concentration-dependent, with a rank order of potency consistent with previously 
reported findings at the murine receptor (Govaerts et al., 2004) and with that 
reported in previous results chapters in this thesis for human receptors expressed 
in other cell lines. It is noteworthy, however, that the absolute potency values were 
higher for the Neuro 2a receptor compared to the cannabinoid ERK responses at 
the transfected CHO human receptor. This is consistent with reports by Govaerts 
et al. (2004), which show the affinity of cannabinoid ligands HU-210, CP 55,940 
and WIN 55,212-2 at the murine CB1 receptors, as determined by [3H]-CP 55,940 
binding assay, to be around ten times greater than that reported for the human 
receptor determined using the same assay. Only one previous example of a HU-
210 concentration response curve for ERK phosphorylation in Neuro 2a cells has 
been reported in the literature (Rozenfeld et al., 2012), with a reported EC50 of 
0.43 ± 0.01 nM, which corresponds very closely to our calculated value of 0.40 ± 
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0.01 nM. The response curves for the other agonists are, as far as can be 
ascertained, the first ones reported in the literature for this cell line. No pattern of 
partial agonism could be clearly identified, with no significant difference between 
the agonist Rmax values, in contrast with the clear pattern of partial agonism 
SUHVHQWLQWKHWLPHFRXUVHH[SHULPHQWVSDUWLFXODUO\IRUǻ9-THC, anandamide and 
ACEA. This observation is most likely due to variance caused by using a 
relatively low concentration of phospho-ERK antibody (see In-cell western 
optimisation, 3.4.2.1), something which is unavoidable as this concentration of 
antibody is needed to obtain results with a useable signal: basal ratio. The CB1-
selective antagonist AM 251, was able to produce a significant rightwards shift of 
all agonist concentration/ response curves, clearly indicating that the responses are 
CB1-receptor mediated validating the cell line for use in our study of functional 
selectivity at an endogenously-expressed CB1 receptor population.  
 
The next signalling pathway to be investigated was the c-Jun N-terminal kinases 
or JNK, a second family of MAP kinases which typically responds to stress 
stimuli including inflammatory cytokines, UV radiation, heat shock and ROS. 
Addition of hydrogen peroxide, a noxious stimulant and ROS at high 
concentrations produced a clear phospho-JNK response, demonstrating that the 
activation of this signalling pathway is possible in the Neuro 2a cell line. All of 
the cannabinoid agonists tested failed to elicit a phospho-JNK response up to 90 
min stimulation, which is in agreement with Graham et al. (2006) who also 
reported no change in phospho-JNK levels upon stimulation with HU-210 over 5 ± 
40 min, determined using both immunocytochemistry and Western blotting. 
However, this is in stark contrast to reports by He et al. (2005) at Mount Sinai 
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School of Medicine (NY, USA), which reported a clear increase in phospho-
JNK1/2 levels after 30 min treatment with HU-210. As suggested in the 
introduction to this chapter, these differences in results may be due to the use of 
different subclones of the Neuro 2a cell line, leading to putative differences in 
protein expression and ability of the receptor to couple to the JNK signalling 
pathway. 
 
The final protein phosphorylation pathway measured was for signal transducer and 
activator of transcription 3 or STAT3, a transcription factor which regulates cell 
processes including growth and apoptosis (Qi & Yang, 2014). Treatment with 
foetal bovine serum (FBS) produced a rapid increase in phospho-STAT3 levels 
with a maximum response at 5 min, returning steadily to near basal levels from 60 
min onwards, demonstrating the activation of this signalling pathway in the Neuro 
2a cell line. HU-210 was unable to produce a clear phospho-STAT3 response up 
to 180 min. This is in contrast to several reports, again from Mount Sinai School 
of Medicine, which provide clear examples of HU-210-CB1-mediated STAT3 
phosphorylation in Neuro 2a cells (He et al., 2005; Rios et al., 2006; Zorina et al., 
2010). The most likely reason for this difference is the use of phenotypically 
divergent subclones of the Neuro 2a cell line. It is important to note the technical 
issues encountered when performing these assays. First, the optimised phospho-
STAT3 primary antibody dilution was 1:50, which is prohibitively high for use in 
multiple experiments. The antibody was chosen for use on the recommendation 
from colleagues at the University of Nottingham who are experienced in 
measuring STAT3 phosphorylation in other cell models (Palmer, personal 
communication, 2013). Also, as noted in Results (see 5.4), there was no clear 
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difference in the basal level of phospho-STAT3 and the non-specific binding of 
the relevant secondary antibody, which indicates that basal levels of phospho-
STAT3 are below the sensitivity range of the assay. So, while the FBS response 
clearly validates the use of the assay technique, any subsequent work would be 
better done using an alternative assay method, such as Western blotting or a 
STAT3 luciferase reporter. 
 
The CB1 receptor is well known to couple to Gi/o proteins which, among other 
functions, inhibit the activity of the enzyme adenylyl cyclase (AC), an effect 
which can be observed by measuring changes in intracellular cAMP levels. 
Examples in the literature of Gi/o-coupled receptor modulation of cAMP 
accumulation in Neuro 2a cells include transfected µ- (Chakrabarti et al., 1995b) 
anG į-opioid receptors (Zhang et al., 2006). Stimulation of Neuro 2a cells with 
forskolin, which directly activates AC, produced a concentration-dependent 
increase in intracellular cAMP accumulation. Treatment with the cannabinoid 
agonists HU-210, CP 55,940, WIN 55,212-2, anandamide and ACEA, but not the 
other agonists produced a clear inhibition of FSK-stimulated cAMP accumulation. 
This contrasts strongly with the results for ERK phosphorylation where all 
agonists were able to activate the signalling pathway. The rank order of potency of 
these agonists is generally consistent with previous reports, though for all agonists 
the absolute pEC50 values were markedly lower than those for ERK 
phosphorylation ranging from anandamide which was 10-fold less potent, to CP 
55,940 which was 80-fold les potent. In terms of efficacy, all of the agonists 
produced only modest effects, with WIN 55,212-2 being most efficacious with an 
Rmax value of 20 ± 4 % inhibition of cAMP accumulation, which was significantly 
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greater than those of all other agonists, except CP 55,940. This contrasts with the 
results for ERK phosphorylation for which there was no significant difference in 
the agonist Rmax values. These relatively modest responses also contrast with 
results from previous chapters looking at effects of the same agonists on 
transfected human CB receptors in different cell lines and with the examples of 
Gi/o-coupled receptor modulation of cAMP accumulation in Neuro 2a cells, 
mediated via transfected µ- DQG į-opioid receptors which both produced 
inhibitions of about 60 % (Chakrabarti et al., 1995b; Zhang et al., 2006). This is 
probably due to weak coupling of this endogenous receptor to AC and the 
expected smaller receptor population compared to that of transfected over-
expressed receptors. 
 
Finally, the effect of pertussis toxin on CB1 receptor modulation of cAMP 
accumulation was investigated. Several reports in the literature on both transfected 
(Felder et al., 1998), and endogenously expressing neuronal cells (Glass & Felder, 
1997), in addition to results in this thesis clearly demonstrate that CB1 receptor 
coupling can be switched to Gs protein by inhibiting Gi/o protein function with 
PTX. Gs protein activates AC, resulting in increases in intracellular cAMP levels. 
There is at least one example of endogenous receptor coupling to Gs protein in 
Neuro 2a cells, with treatment with prostaglandin E1 elevating cAMP levels, most 
likely via Gs-coupled EP2 or 4 receptors (Wu et al., 1996). Forskolin produced a 
concentration-dependent increase in intracellular cAMP levels in PTX-treated 
Neuro 2a cells; however none of the agonists produced a significant change in 
basal cAMP levels, demonstrating negligible CB1 receptor coupling to Gs protein. 
 
224 
 
$QDO\VLVRIWKHGDWDLQGLFDWHVWKDWǻ9-THC, methanandamide, and fenofibrate are 
biased towards ERK phosphorylation versus inhibition of cAMP accumulation as 
these compounds failed to elicit a response in the cAMP assay. It is difficult to 
ascertain whether this is due to a complete inability of the agonist-receptor 
complex to couple to the signalling pathway, or whether the agonists are partial to 
the point of being beyond the sensitivity of the detection assay, a phenomenon 
NQRZQ DV µREVHUYDWLRQDO ELDV¶ (Kenakin & Christopoulos, 2013a). For those 
agonists which gave measurable responses for both pathways, the bias can be 
quantified and statistically analysed by comparing the estimated intrinsic relative 
activity (RAi) for each agonist at each pathway. The significant differences 
between RAi IRUDVLQJOHDJRQLVW WHUPHGǻ5$i, demonstrate bias of that agonist 
for one pathway over anotherZKLOHGLIIHUHQFHVLQǻ5$i values between agonists 
demonstrate their functional selectivity relative to each other. HU-210, but not the 
other agonists, exhibited significant bias towards ERK versus cAMP signalling as 
indicated by its significantly greater ERK RAi value. 
 
5.6. Conclusions 
The results in this chapter clearly demonstrate that cannabinoid agonists are able 
to modulate ERK and AC in Neuro 2a cells via endogenously expressed CB1 
receptors. Furthermore, activation of these signalling pathways appears to exhibit 
clear agonist bias. 
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Chapter 6 
 
General Discussion 
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6.1. General discussion 
The main aim of this project was to identify any patterns of functional selectivity 
at the cannabinoid type 1 (CB1) receptor, expressed in a number of different cell 
types. While many examples of functionally selective signalling at the CB1 
receptor exist, prior to the initiation of this project no comprehensive studies 
existed looking at a variety of signal transduction pathways in a single cell type. 
 
Prior to the start of full scale characterisation of cannabinoid receptor signalling in 
the cells, advantage was taken of recent in-house observation that fenofibrate 
represented a novel structural family of cannabinoid ligands. Fenofibrate was 
shown to be a cannabinoid receptor agonist, being moderately (~25-fold) CB2 
receptor-selective. Further testing demonstrated that fenofibrate was able to inhibit 
electrically-evoked smooth muscle contraction in isolated guinea-pig ileum in an 
AM 251-sensitive manner, confirming that fenofibrate is indeed a functional CB1 
receptor agonist, albeit within a restricted concentration range. The 
characterisation of fenofibrate as an example of a new class of cannabinoid 
receptor ligands is of great importance to our understanding of CB1 receptor 
pharmacology as functional selectivity is most readily identified when comparing 
the responses to structurally distinct agonists. This is true of the CB1 receptor, 
where the aminoalkylindole WIN 55,212-2 exhibited bias towards Gs and Gq 
protein coupling, when compared to structurally unrelated agonists (Bonhaus et 
al., 1998; Lauckner et al., 2005), while the classical ligand HU-210, and the non-
classical ligand CP 55,940 exhibited reciprocal ERK and JNK activation in N1E-
115 cells (Bosier et al., 2008). Indeed, fenofibrate exhibited bias towards ERK 
signalling versus inhibition of cAMP accumulation in transfected HEK-hCB1 
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cells. As a commonly prescribed drug for the treatment of hyperlipidemia, 
fenofibrate has an extensively characterised tolerability profile. This point, in 
combination with our results, means fenofibrate represents a very real basis for the 
generation of new, functionally selective drug-like compounds targeting 
cannabinoid receptors. To this end, current and future research within the 
University of Nottingham will aim to generate homologous compound series 
based on fenofibrate in an effort to produce compounds of greater receptor and 
pathway selectivity. 
 
In addition to its action as an orthosteric agonist, as demonstrated by competitive 
inhibition with the orthosteric antagonist AM 251, fenofibrate appeared to act as a 
negative allosteric modulator of the CB1 receptor at high concentrations (above 3 
µM). These seemingly contradictory results can be explained by the theory of 
µELWRSLF OLJDQGV¶- molecules that exhibit concomitant interaction with the 
orthosteric and allosteric sites on a single GPCR (Lane et al., 2013). Important 
future work would be to perform a SAR study on fenofibrate, in an effort 
determine whether or not distinct pharmacophores are responsible for these 
distinct effects. 
 
Three cell lines were used in the investigation of functional selectivity at the CB1 
receptor - Chinese hamster ovary cells and human embryonic kidney cells, both 
transfected with the human CB1 receptor, and the murine neuroblastomal Neuro 2a 
cell line, which endogenously expressed the mouse variant of the CB1 receptor. 
All three cell lines have previously been used to study cannabinoid receptor 
signalling, including several reports of functionally selective agonist responses 
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(Bonhaus et al., 1998; He et al., 2005; Lauckner et al., 2005). All three cell lines 
exhibited CB1 receptor-mediated ERK activation, represented by an increase in 
phosphorylated ERK levels. This response has previously been observed in a 
number of cell types, including transfected CHO and HEK cells (Galve-Roperh et 
al., 2002; Daigle et al., 2008), and endogenously expressing U373MG human 
astrocytoma (Bouaboula et al., 1995), Neuro 2a and murine neuroblastomal N1E-
115 cells (Graham et al., 2006; Bosier et al., 2008), as well as in a number of cell 
and tissue types in vivo (Valjent et al., 2001). These reports, combined with our 
observations, indicate that CB1 receptor coupling to ERK is probably a ubiquitous 
signalling pathway. While the nature of the initial ERK response was generally 
consistent in all three cell lines i.e. a rapid, transient increase in phospho-ERK 
levels with a broadly similar pattern of potency and efficacy, there were some 
noticeable differences. First, temporally distinct Gi/o protein-dependent and 
independent ERK activation were observed in the HEK cells, while the ERK 
responses in the CHO cells were found to be wholly Gi/o protein-dependent. A 
hypertonic concentration of sucrose, which inhibits clathrin lattice formation 
inhibited Gi/o protein-independent ERK activation in HEK cells ± clathrin lattice 
IRUPDWLRQ LV D QHFHVVDU\ FRPSRQHQW RI ȕ-arrestin±mediated receptor 
internalisation, whLFK LQ WXUQ LV DQ LPSRUWDQW VWHS IRU ȕ-arrestin-mediated 
VLJQDOOLQJ:KLOHWKHVHUHVXOWVLQGLFDWHDSRWHQWLDOUROHIRUȕ-arrestin in this ERK 
response, other mechanisms could not be definitively excluded. Future 
experiments using siRNA, or dominant negativHYDULDQWVRIWKHȕ-arrestin protein 
to inhibit its normal function will allow us to unequivocally determine the role of 
ȕ-arrestin in CB1 UHFHSWRUVLJQDOOLQJLQWKLVPRGHO$FWLYDWLRQRI*SURWHLQDQGȕ-
arrestin-dependent signalling has previously been shown for a number of GPCRs, 
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and has real therapeutic implications. A good example is the mu-opioid receptor, 
where Gi SURWHLQ VLJQDOOLQJ LV UHTXLUHG IRU PRUSKLQH DQWLQRFLFHSWLRQ ZKLOH ȕ-
arrestin-2 blockade has been shown to improve morphine-mediated analgesia and 
inhibit the development of analgesic tolerance (Al-Hasani & Bruchas, 2011). Such 
a scenario may exist with the CB1 UHFHSWRUV ZLWK * SURWHLQ DQG ȕ-arrestin 
signalling having contrasting effects on receptor-mediated effects, such as 
analgesia. As an example, WIN 55,212-2 is moderately biased towards the Gi/o 
protein-independent signalling, meaning it may be unsuitable as a therapeutic if 
the aim to limit non-Gi/o SURWHLQGHSHQGHQWUHVSRQVHVVXFKDVȕ-arrestin signalling.  
 
Next, it was clear that all three cell lines exhibited CB1 receptor-dependent 
inhibition of cAMP accumulation, with again broadly similar patterns of potency 
and efficacy. However, only the HEK cells demonstrated an increase in cAMP 
levels in the presence of PTX, most likely mediated by receptor activation of Gs 
protein. At first glance these differences in signalling between the three cell lines 
seems counter-intuitive, given that the series of agonists being tested and the 
receptor-coupled signalling pathways are the same in all three. However each cell 
line has a distinct pattern of protein expression, with the stoichiometry between 
the receptor and the signal transduction mediators dependent on the cell type. This 
in turn determines the ability of the receptor to couple to a certain signalling 
pathway in a cell line. To illustrate this point, a study by Atwood et al. (2011), 
which used microarray analysis to compare the expression of GPCRs, and 
associated proteins, mRNA in a number of commonly used cell lines, including 
HEK cells, showed significant differences in the relative expression levels of 
YDULRXV*SURWHLQ$&SURWHLQNLQDVH*5.DQGȕ-arrestin subtypes between the 
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cell lines. Furthermore, the differences in signalling between the three cell lines 
can be seen as representative of the expected cell-dependent nature of receptor 
signalling in vivo. These points highlight the importance of choosing a cell model 
appropriate to the target tissue type, when investigating receptor pharmacology, 
particularly functional selectivity. 
 
These differences between the cell lines were also present when comparing the 
patterns of agonist bias, determined using the relative intrinsic activity values. 
Both WIN 55,212-2 and ACEA exhibited bias towards ERK activation after 5 min 
agonist stimulation, when compared to inhibition of cAMP accumulation. In 
addition, however, anandamide exhibited the same ERK bias in CHO cells only, 
ZKLOH ǻ9-THC, methanandamide and fenofibrate exhibited bias towards ERK 
activation in HEK cells only. The RAi values for the Neuro 2a cells were 
calculated with WIN 55,212-2 as the reference agonist, as opposed to HU-210, so 
direct comparison with the transfected cell lines is less useful; however only HU-
210 exhibited any agonist bias, again towards ERK versus cAMP, with neither 
anandamide nor ACEA showing any bias. Visual observation of the results for 
Neuro 2a indicate that WIN 55,212-2 may also exhibit some bias, this time 
towards cAMP signalling however this was not definitively quantified. 
 
This thesis has provided several examples of both novel, and more established 
patterns of agonist bias at the CB1 receptor, particularly towards activation of 
ERK, which plays a fundamental role in regulating synaptic plasticity, and away 
from inhibition of cAMP accumulation, which is linked to inhibition of neuronal 
cell function and altered gene expression. The possibility therefore exists to use 
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these biased compounds as the basis for new agonists with improved positive 
and/or negative signalling selectivities. Such compound could have great 
therapeutic potential by maximising activation of beneficial, and/or minimising 
activation of unwanted signalling pathways, providing drugs with increased 
therapeutic benefit and reduced side effects. 
 
As with ERK activation, CB1 receptor coupling to JNK and p38 MAP kinase has 
been reported in a number of cell types, including CHO cells (Rueda et al., 2000) 
and in human primary coronary artery endothelial cells (Rajesh et al., 2010). In 
addition there are many reports in which the activation of one MAP kinase, but not 
the other, is described, including activation of JNK in Neuro 2a and N1E-155 cells 
(Graham et al., 2006; Bosier et al., 2008) and activation of p38 in rat and mouse 
hippocampal slices (Derkinderen et al., 2001), and human platelets (Signorello et 
al., 2011). None of the three cell lines investigated in this thesis showed any CB1 
receptor coupling to either JNK or p38, despite the inclusion of positive controls 
showing these signalling pathways to be present. The most likely explanation for 
this is that the particular cell line subclones used in the experiments described in 
this thesis either lack or weakly express the cellular machinery necessary to couple 
the receptor to the signalling pathways. CB1 receptor-mediated activation of JNK 
has been shown to involve Gi/o protein-dependent signalling via PI3K/Ras in CHO 
cells (Rueda et al., 2000), and Src/Rac in Neuro 2a cells (He et al., 2005). The 
pathway by which the receptor activates p38 MAP kinase is less well understood, 
but has been shown to be independent of Src in rodent hippocampal neurons. As 
we have shown the CB1 receptor is able to couple to Gi/o protein in all three cell 
lines, it is likely downstream mediator such as those described which is limiting 
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effective coupling. A precedent for this already exists with the Neuro 2a cells, in 
which one research group clearly demonstrated CB1 receptor-mediated JNK 
activation, while another unequivocally stated the absence of this response in a 
different subclone of the cell line. However, given more time, it would have been 
useful to assay JNK and p38 MAP kinase activation in these cells using 
immunoblotting techniques to allow for more direct comparison with the findings 
in the literature. 
 
Transfected model cell lines are well suited to investigating functional selectivity, 
as high numbers of cells can be cultured, and the relatively high level of receptor 
expression allows large responses, which aid in identifying the often subtle 
differences in efficacy and potency between agonists at different signalling 
pathways. However, to ascertain whether functionally selective signalling has any 
physiological relevance to native systems, it is necessary to investigate it in cells 
which endogenously express the receptor of interest (Seifert, 2013), which in this 
case was the Neuro 2a cell line. While the use of more physiologically relevant 
cells, such as primary cell cultures would have been a more appropriate model to 
investigate functional selectivity, the difficultly in acquiring and culturing enough 
cells to perform full concentration-response experiments on numerous agonists 
was beyond the means of this study. Generally, the issues limiting the usefulness 
of native cells are the converse of those that make recombinant cell lines so 
advantageous ± cell culture is often more restrictive, providing fewer cells for 
experimentation (Seifert, 2013). Also, the responses are often small compared to 
transfected cell lines (i.e. a small signal-to-basal window), which increases 
variance and allows much less scope for distinguishing between full and partial 
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agonism (Seifert, 2013). This was partly the case with the Neuro 2a cells, in which 
the phospho-ERK responses were lower than those in the CHO and HEK cells, 
and the maximum inhibition of cAMP accumulation was only 20 %, compared to 
48 % in the CHO cells, and even greater in the HEK cells. Despite this, responses 
were obtained in endogenously expressing cells, and with steps to increase assay 
sensitivity and increased experimental numbers, future research should be able to 
effectively utilise native cells. 
 
6.2. Future directions and points to consider 
Many of the findings in this thesis have raised additional questions, and 
highlighted a number of areas of further work which would greatly contribute to 
our understanding of cannabinoid receptor signalling. In addition to those already 
mentioned, some areas where future work is warranted are outlined below. 
 
Stimulation of HEK cells with concentrations of WIN 55,212-2 above 100 nM for 
20 min produced Gi/o-dependent sub-maximal levels of ERK activation, an effect 
which was also indicated in the sub-basal phospho-ERK levels in the 6 hour time-
course experiments in the CHO cells. One potential explanation for this is the 
involvement of distinct Gi and Go protein subtypes. Future research to determine 
the G protein subtypes involved would help explain this novel functionally 
selective response. 
 
Next, while this thesis has focused on receptor-coupled intracellular signalling 
pathways, investigation of a whole-cell measure of receptor activation and/or 
downstream physiological changes mediated by effectors such as ERK and PKA 
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would be useful to determining the physiological impact of functionally selective 
signalling. As described in Chapter 5, treatment of Neuro 2a cells with HU-210 
has been shown to promote cell differentiation and neurite outgrowth (He et al., 
2005). Future work would aim to fully characterise concentration-responses for all 
the agonists tested in this thesis and then compare these results with the pattern of 
intracellular signalling. A series of preliminary concentration-response 
experiments were performed on CHO cells using the xCELLigence system (Roche 
Applied Science and ACEA Biosystems). This label-free whole-cell assay, detects 
changes in adherent cell morphology by measuring the impedance of a very weak 
current along the bottom of a 96-well assay plate (Scott et Peters. 2010). 
Measurement is dynamic giving both kinetic and concentration-dependent data 
and the consequence of GPCR activation over several hours can be easily 
investigated if desired. While these preliminary experiments yielded interesting 
results, complete data sets were not available for inclusion in this thesis. 
 
Finally, given more time, the next step in this project would have been to 
investigate functional selectivity in other native systems, particularly primary cell 
and tissue cultures, and human native cells, where possible. Such models have yet 
to be widely used for research into functional selectivity at GPCRs; however some 
examples include the use of primary culture of rat neurons and human neutrophils 
(Seifert. 2013). The use of these native cells will be necessary to determining the 
true therapeutic relevance of bias compounds as drugs.  
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6.3. Conclusion 
The thesis demonstrates functional selectivity at the cannabinoid type 1 receptor in 
a number of cell lines, expressing both native and transfected recombinant 
receptor. These findings contribute to our increased understand of the complexity 
of GPCR signalling, and potentially allow for the development of more targeted 
drug which are coupled to selected, beneficial signal transduction pathways. 
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